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ABSTRACT 
Despite 30 years of intensive research，an effective human immunodeficiency 
virus  (HIV) vaccine still remains elusive. The desirable immune response capable of 
providing protection against HIV acquisition is still not clear. The accumulating evidence 
learned from a recent vaccine efficacy correlate study not only confirmed the importance 
of antibody responses, but also highlighted potential protective functions of antibodies 
with a broad repertoire of HIV-1 epitope specificities and a wide range of different 
antiviral mechanisms. This necessitates a deep understanding of the complexity and 
diversity of antibody responses elicited by HIV-1 vaccines. My dissertation characterizes 
antibody response profiles of HIV-1 Env antibodies elicited by several novel 
immunogens or different immunization regimens, in terms of magnitude, persistence, 
epitope specificity, binding affinity, and biological function.  
First, to overcome the challenge of studying polyclonal sera without established 
assays, we expanded a novel platform to isolate Env-specific Rabbit mAbs (RmAb) 
elicited by DNA prime-protein boost immunization. These RmAbs revealed diverse 
epitope specificity and cross-reactivity against multiple gp120 antigens from more than 
one subtype, and several had potent and broad neutralizing activities against sensitive 
Tier 1 viruses. Further, structural analysis of two V3 mAbs demonstrated that a slight 
shift of the V3 epitope might have a dramatic impact on their neutralization activity. All 
of these observations provide a useful tool to study the induction of a desired type of 
antibody by different immunogens or different immunization regimens.  
Since heavily glycosylated HIV Env protein is a critical component of an HIV 
vaccine, we wanted to determine the impact of the HIV Env-associated glycan shield on 
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antibody responses. We were able to produce Env proteins with a selective and 
homogeneous pattern of N-glycosylation using a glycoengineered yeast cell line. 
Antigenicity of these novel Env proteins was examined by well-characterized human 
mAbs. Immunogenicity studies showed that they were immunogenic and elicited gp120-
specific antibody responses. More significantly, sera elicited by glycan-modified gp120 
protein immunogens revealed better neutralizing activities and increased diversity of 
epitopes compared to sera elicited by traditional gp120 produced in Chinese Hamster 
Ovary (CHO) cells.  
Further, we examined the impact of the delivery order of DNA and protein 
immunization on antibody responses. We found that DNA prime-protein boost induced a 
comparable level of Env-specific binding Abs at the peak immunogenicity point to co-
delivery of DNA. However, antibody responses from DNA prime-protein boost had high 
avidity and diverse specificities, which improved potency and breadth of neutralizing Abs 
against Tier 1 viruses. Our data indicate that DNA vaccine priming of the immune system 
is essential for generation of high-quality antibodies.  
Additionally, we determined the relative immunogenicity of gp120 and gp160 
Env in the context of DNA prime-protein boost vaccination to induce high-quality 
antibody responses. Immunized sera from gp120 DNA primed animals, but not those 
primed with gp160 DNA, presented with distinct antibody repertoire specificities, a high 
magnitude of CD4 binding site-directed binding capabilities as well as neutralizing 
activities. We confirmed the importance of using the gp120 Env form at the DNA 
priming phase, which directly determined the quality of antibody response. 
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CHAPTER I 
 
Introduction 
1. HIV pandemic and HIV virus 
1.1 HIV pandemic  
              Entering the fourth decade of the AIDS epidemic, death caused by HIV-1 remains a 
leading cause of mortality worldwide. By the end of 2013, reports from the World Health 
Organization (WHO) show about 35 million people are living with HIV. In the year 2013, 
2.1 million people are newly infected with HIV globally, and 1.5 million people die of HIV 
caused illness (1), with sub-Saharan Africa being the most affected region, followed by 
eastern Europe and the Caribbean. HIV-related deaths have steadily declined since 2010 and 
new HIV infections have declined by 38% since 2001, mostly due to widely available free 
drug treatment in sub-Saharan Africa.  
             Several interventions have contributed to this unprecedented progress in HIV 
prevention, especially in South Africa. First, combination antiretroviral treatment not only 
helps reduce the viral load in HIV infected patients but also greatly reduces the risk of 
transmission to their HIV-negative partners. Second, behavioral interventions, including the 
introduction of condoms, regular HIV testing, needle syringe exchange programs for 
injecting drug users, and male circumcision, have also, at least partially, reduced the risk of 
infection (2-4). Third, pre-exposure antiretroviral prophylaxis (PrEP) with 1% tenofovir gel 
also reduces the risk of HIV acquisition by 39% in HIV-negative women (5), and daily use 
of oral combination prophylaxis with tenofovir and emtricitabine reduced HIV acquisition 
by 44% among homosexual men and transgender women (6-8), although one trial did not 
show any reduction of HIV infection rate using antiviral prophylaxis treatment (9). 
Nonetheless, PrEP intervention is expensive and requires persistent adherence to topical or 
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oral antiretrovirals. Moreover, mathematical modeling analysis has predicted that, on a large 
scale, a combination of these various interventions may be able to dramatically reduce HIV 
incidence, but may not diminish HIV infection (9, 10). Therefore, developing an effective 
vaccine for HIV infection is a still global priority.  
1.2 HIV subtypes and genome 
   HIV is a member of lentivirus genus, a part of the Retroviridae family. Its life 
cycle involves reverse transcription of the viral RNA genome to DNA and subsequent 
insertion into the host genome. Due to error prone replication and retroviral 
recombination events, the HIV-1 viral sequence has daunting genetic diversity. HIV is 
divided into two types, HIV-1 and HIV-2 and both of them cause AIDS; however, HIV-1 
causes the majority of HIV infection throughout the world. HIV-1 can be further 
categorized into four viral groups: the “major” group M, the “outliner” group O, and two 
new groups, N and P. Group M is the predominant circulating HIV-1 group，which is 
further divided into nine subtypes, A-D, F-H, J and K.  Intersubtype combinations are 
very common and at least 55 circulating recombinant forms (CRFs), such as AE, and 
unique recombinant forms (URFs) have been identified.  
  Three major genes in the HIV-1 genome, gag, pol and env, encode polyproteins 
that are subsequently cleaved into multiple short functional proteins. The gag gene 
encodes the Gag protein, which is sufficient to drive the assembly and release of virus-
like particles from the host cell. The pol gene encodes reverse transcriptase and does not 
have proofreading activity, therefore, the replication process is error-prone and point 
mutations are introduced into each new copy of the viral genome. The Env gp160 protein 
expressed by the env gene forms a trimer and is then cleaved by a furin protease into 
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gp120 and gp41, which are involved in receptor binding and membrane fusion, 
respectively. In addition, the HIV genome contains genes encoding regulatory factors 
including tat and rev and accessory genes nef, vpr, vpu, and vif. Genetic variation 
between subtypes within group M can be as high as 35%, with the env gene having the 
most significant genetic diversity. 
Since HIV exhibits such daunting global genetic diversity and has the mutation 
capacity to escape adaptive immune responses and the early establishment of latent viral 
reservoirs, development of a prophylactic HIV-1 vaccine is urgently needed but it is clear 
that such development is not without major challenges and obstacles.  
1.3 Env structure 
A critical HIV-1 vaccine target protein is the Env spike. It is the only protein on 
the HIV virus particle and mediates virus entry. The mature HIV-1 envelope spike is 
composed of three copies of non-covalently associated gp120 and gp41. Once gp120 
protein binds to the primary receptor, CD4, conformational changes expose the binding 
site for chemokine co-receptors (CCR5 and CXCR4). CD4 binding induces 
conformational changes within the Env trimer that result in the transition of the gp41 
ectodomain into prehairpin intermediates. Upon chemokine receptor binding, heptad 
repeat regions, HR1 and HR2, form a six-helical bundle, promoting the fusion of viral 
and target cell membranes(11, 12). 
The gp120 subunit protein is composed of five conserved regions (C1-C5) that are 
interspersed with five variable regions (V1-V5). Due to intrinsic heterogeneity, the 
presence of a complex glycan shield, and the conformational flexibility of Env, gp120 
structure characterization has been a great challenge. To visualize HIV-1 gp120 Env at an 
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atomic level, early crystallization studies stabilized Envs in their CD4-bound 
conformation with V1/V2/V3 truncated and N-glycans removed (13, 14). These structural 
studies revealed that gp120 core protein consists of an inner domain and an outer domain, 
referring to parts of gp120 that are close to inner and outer regions of the trimer spike, 
respectively. Through these studies, it was determined that the outer domain is 
structurally constant, whereas the inner domain displays extraordinary structural 
diversity(15). CD4 makes initial contact with the outer domain of gp120, a surface 
constitutively exposed on the envelope spike. Soon after this interaction between CD4 
and the outer domain of gp120, the inner domain rearranges in a highly coordinated 
manner to form a four-stranded bridging sheet mini-domain, which holds the CD4 
molecule in place. The initial CD4 attachment site is identified as a critical site of 
vulnerability and is a most desirable neutralizing epitope for vaccine targets (16).  
In addition to conserved regions, the five variable regions are also highly 
glycosylated and project surface-exposed loops, protecting the core from potentially 
neutralizing antibodies. Electron tomography and cryo-electron microscope studies 
showed V1/V2 of the viral spike is a membrane distal ‘cap’, suggesting that the V1/V2 
region is accessible in the context of trimer (17-20). Although V1/V2 is not necessary for 
viral entry, deletion of this region makes viruses sensitive to antibody neutralization. 
α4β7 integrin receptor, which is highly expressed in gut-associated lymphoid tissue 
(GLAT), was suggested to bind to the Env spike via a conserved integrin binding motif, 
LDI/V, within the V2 region (21, 22). This accumulating evidence is compatible with a 
critical role of V2-specific antibody responses in inhibiting HIV infection as observed in 
immune-correlate analysis of samples from the RV144 trial (23). The V3 loop forms an 
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extended structure whose tip protrudes ~30Å from the main portion of the gp120 core 
(24, 25). It is localized directly beneath the V1/V2 hairpin with the tip pointing toward 
the trimer axis and interacts with the V2 base from the adjacent promoter. The V3 region 
mediates direct binding with entry co-receptor and determines whether CCR5 or CXCR4 
will be used for HIV-1 entry. Its protruding loop-like structure makes the V3 region 
highly immunogenic and accordingly has been named the ‘principle neutralizing 
determinant’ of HIV-1. At a sequence level, V3 is the most conserved region in 
comparison with the other variable regions, as it is almost always 35 residues long and its 
tip harbors a highly conserved motif, Gly-Prop-Gly-Arg/Gln (GPGR/Q), a key 
neutralizing epitope (26). The V4-V5 regions are highly disordered in most crystal 
structures (27), as to be expected based on both their location and the variability in 
sequence within these regions. Overall, V1-V5 loop residues have adopted multiple 
conformations, depending on which antibody is bound with Envs.  
While gp120 on Env mediates virus attachment to target cells, the transmembrane 
region gp41 subunit is responsible for membrane fusion between virus and target cells. It 
consists of two long prominent helices; heptad repeat 1 forms a three-helix bundle with 
neighboring protomers in the trimer core and heptad repeat 2 wraps around the outer 
periphery of the trimer base, angling downward with its C terminal proximal to viral 
membrane. Once CD4 and co-receptor are bound to Env, the gp120 promoters is rotated 
outwards and gp41 is exposed, which undergoes a structural rearrangement and finally 
forms a six-helix bundle structure, perpendicular to the viral membrane, as a post-fusion 
conformation.  
The high resolution architecture of the Env trimer has remained elusive until a 
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recent major breakthrough. Results from a recent study identified a trimer from a clade A 
HIV-1 isolate (BG505) as a naturally stable trimer, which was further engineered to 
remove the hydrophobic transmembrane anchor and the MPER region (19, 20). In 
addition, a disulfide bond was introduced to increase trimer stability, and cleavage 
efficiency of the precursor into a mature trimer was further optimized. Crystal structure 
and cryo-electron microscopy of this so-called SOSIP.664 trimer provided unprecedented 
insight regarding spatial arrangements for HIV-1 Env. It has a tightly packed mushroom 
shape with the gp120 trimer as its cap and the transmembrane gp41 trimer as its stem. 
There is a small opening between the Env apex and the top of the central gp41 helices. 
gp120 subunits are held together, partially associated with V1/V2/V3 regions at the top of 
trimer. For the CD4 binding site, only a narrow range of approach angles are available for 
this area to engage with trimer. This comprehensive quaternary nature of CD4bs epitopes 
on trimer might not be identical with that from monomer. Indeed, thorough antigenicity 
analysis of this trimer showed high reactivity with all Env-specific broadly neutralizing 
antibodies  (bNAb) but no detectable binding with non-NAb against CD4bs, CD4i, or the 
gp41 region (28). V3-specific non-NAb only recognizes trimer by enzyme-linked 
immunosorbent assay but not at all by surface plasmon resonance and only a limited 
extent by electron microscopy. 
The structural characterization of the SOSIP trimer revealed a fundamental 
antigenic difference between the SOSIP trimer and traditional gp120 protein (19, 20). 
Only broadly neutralizing epitopes are accessible on the SOSIP trimer. However, 
immunogenicity data from both rabbits and macaques (29) showed that the SOSIP trimer 
does not improve neutralization activities; the trimers induced strong but transient NAb 
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response against autologous, neutralization-resistant (Tier 2) BG505. For heterologous 
viruses, the immune sera also can neutralize Tier 1 viruses, but not Tier 2 viruses. 
Epitope mapping analysis showed antibody responses targeted at the conformational 
epitope on gp120 and linear V3 region, but this activity was without linear V1/V2-
specific or CD4bs antibody-specific responses. This suggests that a trimer-based 
immunogen alone might not be the most useful tool for development of an effective 
vaccine. 
One important feature of the Env protein is that it is heavily coated with potential 
N-glycosylation sites (PNGS); nearly 50% of its molecular weight is made up of a 
heterogeneous population of N-glycans. There are three different types, including high 
mannose, hybrid, and complex. Different Env strains have different numbers of PNGS; 
different glycoforms could present at the same glycosylation site and not all glycosylation 
sites are utilized (30, 31). Furthermore, glycosylation patterns from different cell types or 
even the same cell type under different metabolic conditions are distinct (32). For 
example, the recombinant gp120 protein produced from traditional mammalian CHO 
cells has more than 70% complex-type glycans, whereas the native Env amplified from 
peripheral blood mononuclear cells (PBMC) shows mostly a high mannose population 
(Man5GlcNAc2) (33), adding an additional layer of microheterogenity on the glycan 
shield on Env proteins.  
The contribution of these Env protein glycan shields to immune evasion and 
recognition were still only partially understood. It was shown that a lack of complex N-
glycans on HIV-1 Env preserves protein conformation and virus entry function (34). 
Even a partial enzymatic deglycosylation can preserve the structure of cleaved Env 
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trimers (35). However, the antennae of complex N-glycan serves to protect the V3 loop 
and CD4 binding site, while N-glycan stems regulate the native trimer conformation. 
Removal of these N-glycans causes neutralization sensitivity change and failure to 
complete the conformational rearrangement necessary for infection (36). Although 
carbohydrates were considered the “glycan shield” used to protect Env, it recently was 
found that both high mannoses and complex carbohydrates are targeted by the humoral 
immune system at an early stage of infection, thus glycan-dependent broadly 
neutralization activities were commonly observed among infected animals and human (37, 
38).  
2. Immunization approaches for HIV vaccine 
2.1 Protein-based HIV vaccine 
Despite the triumph of recombinant protein-based hepatitis B vaccines (HBV) in 
the 1980s, the first two large-scale HIV vaccine trials using a similar strategy did not 
have such fortune. Between 1998 and 2003, two phase III HIV vaccine efficacy trials 
were performed by VaxGen among HIV-1 seronegative volunteers (39-41). The VAX004 
trial was held in North America and the Netherlands, using AIDSVAX B/B vaccine, 
consisting of bivalent recombinant HIV Env gp120 proteins (MN and GNE8) from Clade 
B. VAX003 was conducted in Thailand, evaluating the immunogenicity of AIDSVAX 
B/E, incorporating Env gp120 antigens from the predominant circulating viruses in 
Thailand. Neither trial prevented virus acquisition or reduced viremia in those later 
infected with HIV. The immunized sera showed Env-specific binding antibody and NAb 
responses against vaccine strains; however, there was no strong heterologous NAb 
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response against primary isolates. It was determined that the protein-based immunization 
alone was ineffective to generate a comprehensive immune response against HIV.  
2.2 Viral vector-based vaccine  
In early HIV research, vaccines consisting of live attenuated SIV viruses with 
deletion of nef genes demonstrated nearly full protection from either homologous or 
heterologous SIV challenge (42-45). However, the attenuated SIV strain was able to 
revert to virulence by repairing the engineered deleted genes via their error-prone reverse 
transcriptase, which poses a serious safety risk for administration of such attenuated virus 
in humans. However, these studies reassured the field that it may be feasible for a vaccine 
to elicit specific enough immune responses to fight against the HIV virus.  
Following the failure of the VaxGen trial to elicit protective antibodies, Merck 
Research Laboratories specifically designed an adenovirus 5 (Ad5) vector-based strategy 
to induce only T cell-mediated immunity. The Ad5 vector is a non-replicating vector 
resulting from deletion of the early region 1 (E1) gene, which is necessary for virus 
replication. Two phase IIb vaccine trials, STEP and Phambili in the United States and 
South Africa, respectively, studied the efficacy of the rAd5 vector vaccine expressing 
HIV gene, gag, pol, and nef to prevent HIV infection (46). The vaccine proved to be safe 
and strongly immunogenic, demonstrated by antigen-specific IFN-γ responses in 77% of 
immunized subjects, poly-functional CD4+ T cell response among 41% of vaccinees, and 
antigen-specific CD8+ T cell responses from 73% of immunized volunteers (47). 
Unfortunately, such strong T cell immunity did not confer prevention against virus 
acquisition or reduce the viremia in those who later became infected with HIV. Both 
trials were halted since this vaccine appeared to increase the risk of HIV-1 infection 
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among those vaccinees previously exposed to Ad5 adenovirus (48). It was hypothesized 
that activation of pre-existing Ad5 vector-specific CD4 T cells at mucosal surfaces 
following Ad5 vaccination might have resulted in an elevated number of target cells for 
HIV infection (49). However, this hypothesis was later challenged by a new observation 
that Ad5-seropositive volunteers in the STEP trial did not develop higher vector-specific 
cellular immune responses when compared to Ad5-seronegative subjects (50). The 
mechanism of higher HIV susceptibility for the vaccine group in the STEP trial remains 
to be resolved.  
Given the safety concerns of the rAd5 viral vector, there have been ongoing 
efforts to develop alternative rAd vector serotypes for HIV-1 vaccines, to overcome this 
problem of pre-existing anti-Ad5 immunity and facilitate the development of adenovirus 
vector-based regimens. In preclinical studies, some of these serotypes have demonstrated 
an ability to induce strong cellular responses despite of pre-existing Ad5 immunity (51-
53). Some promising vectors, including rAd26, rAd35, and rAd5HVR48, which are 
biologically different from Ad5, are being evaluated in phase 1 clinical trials. An initial 
analysis showed that Ad26-Env immunization induced HIV-specific mucosal humoral 
and cellular immune response without a detectable vector-specific response (54).  
Furthermore, pox viral vectors also have been widely used for vaccine 
development since the success of the vaccinia virus-vectored vaccine for the eradication 
of smallpox. Poxvirus has large genome, which is able to accommodate more than 10 kb 
of foreign DNA.  Furthermore, inserted transgene products can be expressed at high 
levels, resulting in potent cellular responses. Based on efficiency of expression and safety 
record, the three most promising non-replicating poxviral vectors are ALVAC, attenuated 
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modified vaccinia virus Ankara (MVA), and the modified Copenhagen vaccinia strain 
(NYVAC); other pox vectors in development include Tiantan pox vector (55) and 
fowlpox vector (56, 57). 
ALVAC is a naturally-attenuated canarypox construct that effectively induces an 
HIV-specific CD8+ cytotoxic T lymphocyte (CTL) response, as it can process expressed 
antigen through the major histocompatibility (MHC) class I pathway.  
A phase II clinical trial showed poor immunogenicity of ALVAC expressing gp120 
antigen (58). Low titer neutralizing antibodies were detected in 56% of recipients, 30% of 
vaccine subjects showed a CD8+ CTL response, and 28% of volunteers showed 
lymphocyte proliferation. This suggested that ALVAC alone vaccination could not elicit 
optimal T cell or antibody responses.  
Both MVA and NYVAC vectors had a highly attenuated phenotype and high 
expression of heterologous antigens and in previous studies they both showed good safety 
profiles and triggered broad and durable immune response to HIV antigens. MVA has 
been shown to preferentially drive CD4+ T cell response, while NYVAC focuses on 
activation of CD8+ T cell response (59). However, similar to the ALVAC vector, 
administration of MVA or NYVAC vector expressing HIV antigen alone showed only 
modest immune responses. In the MVA study, MVA immunization lead to a IFN-γ 
response among 25% of the low dose group and 62% of the high dose group (59) whereas 
in the NYVAC study, two doses of NYVAC resulted in induction of T cell immune 
responses in 40% of volunteers but this response disappeared by 48 weeks after 
immunization (60). 
An attenuated cytomegalovirus (CMV) vector has also drawn substantial attention 
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as a T cell vaccine delivery vector. It can induce persistent, systemic, high frequency, 
circulating and tissue-resident effector memory T cells, which have unprecedented 
breadth and can recognize promiscuous epitopes that are restricted both by MHC class I 
and II molecules (61). A challenge study in rhesus monkey has shown that these virus-
specific, effector memory T cells could be maintained by a persistent rhesus CMV 
(RhCMV) vector. Although they could not protect the host against acquisition of 
infection, they can shut down productive SIV infection, maintain immune surveillance 
over time, or functionally cure and possibly eradicate SIV infection (62). To use this 
promising CMV platform for HIV vaccine development, several concerns must be 
addressed. First, it will need to be determined whether the human CMV vector has 
similar properties to RhCMV and if such substantial efficacy of protection observed in an 
animal model can be translated into humans. Second, although CMV infection is 
nonpathogenic in the majority of individuals, it is still considered a potential risk for 
pregnant women and immunocompromised individuals. Nevertheless, the substantial 
efficacy of CMV vectors in an animal model, combined with identification of human 
homologs to RhCMV genes, make a promising CMV vector platform for HIV vaccine 
development. Clinical trials are currently planned for CMV vectors.  
In addition, live-attenuated vesicular stomatitis virus (VSV) (63), alphavirus 
vector (64, 65), and Semliki Forest virus (SFV) have also been adopted for HIV pre-
clinical vaccine studies.  
2.3 DNA vaccines 
The introduction of DNA vaccine in HIV field started at early nineties when a 
DNA plasmid encoding HIV-1 Env was able to raise both humoral and cellular response 
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in small animals. The first human DNA vaccine study was done in HIV-1 infected 
patients as a Phase I clinical trial for safety analysis, followed by studies in healthy, HIV-
1 negative volunteers (66, 67). These studies confirmed the overall safety profile for 
DNA vaccines but the immunogenicity results were disappointing.  The magnitude and 
frequency of T cell immune responses were low and HIV-1 antigen-specific antibody 
responses were generally low or below detection.  
 In an attempt to improve the immunogenicity of DNA vaccine, several technical 
improvements to the design of DNA vaccine vectors have contributed to improved 
antigen expression and immunogenicity of HIV-1 DNA vaccines in both animal and 
human. First, codon-optimization of immunogen genes was found highly effective in 
elevating immunogen protein expression in vitro and enhancing T cell and antibody 
response in vivo (68-71). Second, replacement of HIV-1 Env leader sequence with signal 
peptides from other mammalian proteins, such as human tissue plasminogen activator 
(tPA), was able to greatly improve the protein expression of Env-based HIV-1 DNA 
vaccine (72, 73). Third, the viral promoter efficiency improved greatly gene transcription 
of HIV DNA vaccine. Intermediate-early gene 1 promoter adopted from human 
cytomegalovirus (HCMV), a non-carcinogenic virus, has been widely used with high 
efficiency in most DNA vaccine design (74).  Furthermore, adding an intron A sequence 
from HCMV to an immediate downstream region of the HCMV promoter was able to 
further enhance the immunogenicity of HIV-1 DNA vaccines (72). With such 
modification, HIV DNA vaccine was able to effectively elicit both T cell response and 
antibody response in small animal and non-human primate models; however, the 
immunogenicity of DNA vaccines was still poor when used alone in humans.  
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2.4 Heterologous prime boost immunization 
 Each novel immunization approach mentioned above has been tested in clinical 
trials; however, each appears to have their shortcomings. The VaxGen trial showed that 
the traditional recombinant subunit protein was immunogenic but failed to generate high 
quality antibody against HIV-1 virus and limited T cell immune responses; whereas viral 
vector vaccines and DNA vaccines alone were not immunogenic enough to elicit robust T 
cell and antibody response in humans. A landmark study adopted a heterologous prime-
boost strategy that used vaccinia vector encoding SIV Env glycoprotein, boosted with 
recombinant gp160 protein (75, 76). Animals primed with vaccinia vector vaccines 
showed robust Env-specific T cell responses, with weak antibody responses. Remarkably, 
soon after the boost immunization, the animals showed a substantial increase in Env-
specific antibody titers as well as broad neutralizing activities against homologous and 
heterologous viral antigens. Further, these immunized animals showed complete 
protection against intravenous challenge of homologous viral challenge. Since then, the 
heterologous prime-boost strategy has been widely investigated and optimized to 
combine different immunization modalities to reach the optimal immune response.  
2.4.1 DNA prime viral vector boost 
The idea of DNA prime Ad5 vector boost to elicit HIV-specific T cell response 
was most recently tested in a phase IIb clinical trial, HVTN505 (77). Study participants 
were primed with DNA vaccines and boosted with Ad5 vectors expressing Env, Gag, and 
Pol. During this HVTN505 trial conducted in the United States, the volunteers were fully 
circumcised and did not have pre-existing anti-Ad5 neutralizing antibodies. However, the 
use of the Ad5 vector is being challenged following this clinical trial. This trial was 
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discontinued since it showed a lack of protection in terms of reduction of the rate of virus 
acquisition or viral load set point among vaccinees. Both humoral and cellular immune 
responses were observed in the majority of recipients. While 61.5% of CD4+ T cells and 
64.1% of CD8+ T cells showed HIV-1 specific response demonstrated by intracellular 
cytokine staining, antibody response including neutralizing antibody, non-neutralizing 
antibody, and V2-sepecific antibody levels were low. More detailed analysis is currently 
under investigation. 
To generate robust T cell responses, several combined immunization approaches 
using DNA prime followed by MVA or NYVAC boost has been demonstrated to 
synergistically improve vaccines-specific cell mediated immunity. Researchers from 
Oxford University (Oxford, UK) used a DNA vaccine, composed of several T cell 
epitopes for HIV-1 including a fragment encoding the gag antigen as a prime followed by 
a MVA vaccine boost expressing the matched antigen. However, only low level T cell 
responses were generated, which may be due to limitations of epitope vaccines delivered 
by DNA vaccines (78-82). The HVTN065 trial later tested a DNA vaccine containing 
several HIV-1 antigens as the priming immunization, followed by boost with a 
recombinant MVA expressing HIV-1 antigens. This DNA prime-MVA boost vaccine 
was well tolerated and produced detectable and reproducible HIV-1-specific cellular 
immunity in humans (83, 84). In this regimen, DNA priming was responsible for the 
induction of HIV-1-specific T cell immune responses following the boost of MVA. The T 
cell responses were poly-functional; about 50% of the HIV-specific CD4
 
and CD8
 
T cells 
induced in vaccinated subjects produced more than three cytokines. Furthermore, strong 
T cell proliferation, as well as robust production of the T cell growth factor IL-2 by HIV-
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1-specific CD4
 
and CD8
 
cells, was observed. A phase II clinical trial (HVTN205) using a 
similar DNA prime-MVA boost regimen has been completed and the immune responses 
are currently under analysis. 
Data from the EuroVacc 02 trial using DNA prime-NYVAC boost demonstrated 
the safety and high immunogenicity of this platform (60). Both the DNA and NYVAC 
expressed fused Gag-Pol-Nef and Clade C isolate CN54 gp120 Env. T cell responses 
were detected in 90% of DNA prime-NYVAC boost vaccinees, which was superior to 
responses induced by NYVAC alone (33% of responders). However, T cell responses 
were predominantly mediated by CD4+ T cells, while only a modest level of CD8+
 
T cells 
specific for HIV-1 antigens Gag, Pol, and Nef were detected. 
2.4.2 Viral vector prime protein boost 
In an attempt to elicit balanced T cell and antibody-mediated immune responses,  
the phase III RV144 trial combined two HIV vaccine components that focused on a 
distinct mechanism. The prime, a canarypox vector (ALVAC-HIV), encodes HIV-1 
gp120, gag and pol protein, and several CTL epitopes from nef and pol, which focus on T 
cell responses; whereas two vaccinations with recombinant gp120 protein from isolate 
A244 (Clade AE) and MN (Clade B) (AIDSVAX B/E) was used as the boost, which is 
responsible for high antibody responses. Although these two vaccine components failed 
to show any efficacy, this combined regimen, for the first time in history, showed 31% of 
vaccine efficacy at preventing HIV infection.  
         The immunogenicity of this vaccination was analyzed; a modest T cell-mediated 
immune response was observed. Among 19.7% of vaccines at 6 months post-vaccination, 
Env- or gag-specific T cell immune response were observed as determined by IFN-γ 
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ELISPOT assay. Furthermore, CD4+ Env-specific intracellular cytokine staining was 
observed more in the vaccine group compared to the control group. One interesting 
finding was that T cells preferentially targeted the V2 region (85). Almost all volunteers 
(99%) developed Env-specific binding antibody response, however, these responses 
waned considerably after 6 months (86). In terms of epitope specificity, strong antibody 
responses against C1, V2, V3, and C5 regions of gp120 were observed by overlapping 
peptide microarray (23). There was a low level of neutralizing antibodies against Tier 1 
viruses, but not Tier 2 viruses demonstrated by TZM-bl assay. Interestingly, overall NAb 
responses from RV144 were even lower compared to those elicited by VAX003 (87).  
To determine a potential immune correlate of decreased infection risk by 
vaccination, six primary variables were included into a statistical analysis, including 1) 
IgA Abs binding to Env, 2) avidity of IgG antibodies for Env, 3) antibody-dependent cell 
mediated cytotoxicity (ADCC), 4) neutralizing antibodies, 5) gp70-V1V2 binding, 6) 
CD4+ T cells (88). It turns out that gp70-V1V2 binding antibody inversely correlates 
with infection, while plasma IgA directly correlates with infection. To further confirm 
this finding, sieve analysis was performed to identify if vaccine efficacy would vary with 
different genotypic HIV viruses. Indeed, the estimated vaccine efficacy against viruses 
matching the vaccine at the position 169 (K169) was 48%, whereas vaccine efficacy 
versus position-181-mismatched  (I181) viruses was 78%, and vaccine protection against 
viruses both matched with K169 and mismatched with I181 was 80%, suggesting a V2 
antibody response specifically targets the K169 position (89). Furthermore, four mAbs 
isolated from RV144 vaccinees mediated ADCC activity, which was dependent upon 
position 169 in breakthrough Envs (90). All of this evidence suggests that the V2-specific 
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antibody response is critical to prevent infection with viruses matching the vaccine at the 
V2 K169 residue. An independent analysis of plasma IgG responses against linear 
epitopes as potential correlates of risk of infection also confirmed the importance of V2 
antibody (23).  Overlapping linear peptide microarray showed dominant responses 
against the C1, V2, V3, and C5 regions of gp120 in the RV144 trial. Statistical analysis 
further confirmed that V2-specific IgG significantly inversely correlated with infection 
risk; meanwhile, V3-specific IgG showed a similar trend but only in vaccine recipients 
who had lower levels of other antibodies, especially Env-specific plasma IgA and 
neutralizing antibodies (23). Of note, the antibody response waned quickly after 12 
months post final immunization, which contributed to decreased protection efficacy over 
time. This vaccine trial provided valuable information about immune correlates for an 
HIV vaccine. This study also further suggested that dissecting antibody quality is critical 
in evaluating a vaccine regimen. Meanwhile, more potent vaccine candidates will 
presumably be desirable.  
In addition, adenovirus vector prime protein boost is also a promising candidate 
since it can generate balanced immunity. It has been demonstrated that this strategy can 
induce a high level neutralizing response when Ad26 prime gp140 protein boost was 
adopted (91).  
2.4.3 DNA prime protein boost 
Similar to canarypox prime protein boost approach, DNA prime protein boost 
strategy is also aimed to elicit a balanced antibody and cellular mediated response against 
HIV-1, which has been extensively studied by our group as well as other groups. 
Although DNA vaccine alone or gp120 protein alone failed to generate effective antibody 
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response which is able to neutralize against JR-FL viruses, either rabbit sera from gp120 
or gp140 DNA vaccines delivered by gene gun followed by gp120 protein boosting was 
capable of neutralizing JR-FL virus strain (92). Further, DNA priming plus recombinant 
protein boosting approach delivering polyvalent primary Env from representative A, B, 
C, D, and AE was able to compromise the diverse genetic sequence variance, and such 
vaccine strategy can further expand the neutralized viruses from subtype A, B, C, D and 
AE (93). Indeed, in a NHP study, DNA vaccines encoding four Env antigens from 
subtype A, B, C, and AE and HIV-1 Gag antigen from Clade B induced binding 
antibodies to Envs from multiple HIV-1 isolates that were markedly enhanced following 
boosting with homologous gp120 proteins. These sera neutralized homologous and, to a 
lesser degree, heterologous HIV-1 isolates. 75% immunized animals had sterile immunity 
following rectal challenge with a SHIV encoding Env from HIV-1Ba-L, whereas reduced 
virus load was observed in the infected animals compared to naïve controls (94). 
Dissection of polyclonal sera showed that the improved neutralization activities might be 
result from higher antibody avidity, a more diverse and conformational epitope profile 
(95). Interestingly, antibody responses targeting several peptides that overlap with known 
CD4 binding area were detected only in DNA-primed sera (96).  Further, recent evidence 
showed that DNA immunization was able to induce higher level of germinal center B cell 
via T follicular helper cells, which is critical to produce optimally affinity-matured 
antibody responses(97). 
Among a few DNA prime-protein boost studies conducted in healthy human 
volunteers, the DP6-001 study provided the most comprehensive and promising 
immunogenicity data (98). In this study, participants received three times priming 
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immunizations with a polyvalent HIV-1 DNA vaccine, including six DNA plasmids (five 
expressing different primary gp120 antigens from clades A, B, C, D and E and one 
expressing a clade C Gag antigen), followed by two times boost with a polyvalent 
recombinant gp120 protein vaccine (five gp120 proteins matching those used in the DNA 
prime). Although the DNA vaccine components were administered via intramuscular or 
intradermal needle injection without using an adjuvant or a physical delivery device (such 
as gene gun or EP), positive gp120-specific CD4+
 
T cell responses were detected in all 
volunteers at the end of three DNA immunizations, and were further boosted by the 
gp120 protein boost. It was also important to note that these effector memory CD4+
 
T 
cells were multifunctional, secreting IFN-γ, IL-2, and TNF-α. The subpopulation positive 
for CD154 maintained proliferative potential and could rapidly develop into mature 
effector CD4+
 
T cells (99). Interestingly, this phenotype was also seen in long-term non-
progressors or aviremic HIV-1 infected patients on highly active antiretroviral therapy 
(HAART). In the higher dose group (1.2 mg for Gag-expressing DNA vaccine 
component), positive Gag-specific CD4+
 
T cell responses were also detected at the end of 
three DNA immunizations, a response that was rare in previous DNA vaccine studies 
when no adjuvant or EP device was used. Antigen-specific CD8+
 
T cells were also 
observed in vaccinated participants (99). 
However, the most significant finding was that high-titer gp120-specific antibody 
responses (end titration titers of 1:105, equivalent to Env-specific antibody titers in 
chronically infected HIV-1 positive patients) were detected in immune sera of 100% of 
the DP6-001 trial participants following one or two gp120 protein boosts (98). All of 
these immune sera had a broad reactivity recognizing gp120 antigens from HIV-1 
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subtypes A to E. High level neutralizing activities were easily detected against 
pseudotyped viruses expressing Env from the sensitive viruses (TCLA isolates and 
SF162), activities that were better than observed in a previously reported DNA prime-
Ad5 vector boost vaccine trial (100), in which no neutralizing activities were detected 
even against these sensitive viruses. There are good levels of ADCC activities in 
vaccinees’ sera (95). When DP6-001 trial volunteer immune sera were tested against the 
more difficult to neutralize pseudotyped viruses from clades A to E and positive NAb 
was determined as greater than 50% inhibition, sera from approximately 1/3 of the 
volunteers were able to neutralize 80%–100% of this pseudotyped virus panel; the other 
1/3 of the immune sera was able to neutralize 50%–79% tested viruses, and the remaining 
1/3 of the immune sera neutralized 25%–49% of the tested viruses; serum from only one 
volunteer could neutralize only one pseudotyped virus (98). In addition, a neutralization 
assay was conducted against the most difficult to neutralize Tier 2 viruses, but the 
neutralizing activities were very low. In summary, the DP6-001 trial raised high level 
binding antibody and broad neutralizing antibody responses. Additional assays have been 
done to show high level anti-V2 antibodies in DP6-001 volunteers (unpublished data), 
similar to RV144 trial results. 
The finding of high titer and high quality antibody responses in the DP6-001 trial 
was supported by another phase I DNA prime-Env protein boost clinical trial. A two-
valent DNA vaccine prime, including one expressing an HIV-1 Gag and one expressing a 
V2-deleted gp140, were formulated in polylactice-coglycolides and delivered by 
intramuscular needle injection, followed by boost immunization using the recombinant 
gp140 protein matching that used in DNA prime. Compared to volunteers who received 
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gp140 protein alone immunizations, DNA priming generated skewed Th1 phenotype 
polyfunctional Env-specific CD4+
 
T cells, a higher frequency of Env-specific memory B 
cells, and a higher titer of neutralizing antibodies and ADCC (101). However, the breadth 
of neutralizing activities in this trial was limited, presumably due to limited valency of 
Env immunogens included in the formulation and/or a potential negative impact of V2 
deletion to the quality of antibody responses. 
In summary, heterologous prime-boost strategy has been demonstrated to not only 
effectively augment the quantity level of immune response elicited by individual vaccine 
component alone, but also improve the quality of antibody and T cell responses. It has 
been a promising approach to combine distinct vaccine components to achieve balanced 
immune response for HIV-1 vaccine.  
3. Env-specific monoclonal antibodies 
3.1 Important role for antibodies in HIV prevention 
The critical role of antibody in HIV prevention was initially demonstrated by 
passive immunization studies, during which, administration of single NAbs or a 
combination of NAbs prior to challenge in non-human primates were both able to prevent 
viral acquisition or, at least, lower the viral load (102-105). While antibody monotherapy 
might result in a transient reduction in viral load followed by rebounded viremia, a 
combination of new generation bNAbs that target different epitopes was able to fully 
control infection and suppress viral load to an undetectable level (106). In addition to 
direct antibody administration, vector-mediated gene transfer expressing several new 
generation bNAbs was also able to fully protect humanized mice from HIV infection 
(107). This protection was conferred by broad and potent neutralization activities against 
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viruses, as passive transfer of polyclonal non-NAbs with ADCC function failed to 
prevent HIV-1 infection (108). Meanwhile, Fc effector domain is also required for in vivo 
capacity for blockage of viral entry and suppression of viremia. For example, binding 
NAbs with activating Fcγ receptor (FcγR), but not inhibitory FcγR, were able to augment 
in vivo anti-HIV protective activity (109). All of this previous research suggests a pivotal 
role of both the antigen binding site and the Fc domain in in vivo anti-viral protection.  
3.2 bNAbs from infected patients 
For a long time, only 4 mAbs (b12 (110), 2G12 (111, 112), 2F5 (113, 114)and 
4E10 (113, 115)) that could neutralize ~40% of HIV-1 viruses circulating throughout the 
world were available. Sera from elite neutralizers and new biotechnologies allowing for 
Env-specific B cell identification and isolation (116-120), have allowed for a 
considerable amount of bNAb to be isolated in the past 4 years (Table 1.1). Epitopes of 
novel bNAbs can be categorized into four groups: 1) CD4 binding site on gp120, 
including VRC01-VRC03 (116), HJ16 (121), VRC-PGV04 (122), CH30-CH34 (119), the 
HADD motif antibodies (117), CH103 (123). Crystal structure analysis along with deep 
sequencing of VRC01-like heavy chain variable (VH) region and light chain variable 
(VL) region showed a convergent mode of epitope recognition despite divergent 
sequences. Compared to b12, these mAbs can approach its cognate epitope on the 
functional spike with less steric hindrance. Indeed, it seemed that a restricted set of VH 
gene families (VH1-46 and VH1-2) was used to generate VRC01-like antibodies. 
Further, they all have an extraordinarily high number of somatic mutation (~30% for VH 
gene, ~18% for VL gene) whereas, the average human VH mutation is 5% elicited by 
immunization; 2) a quaternary epitope dependent upon N160 at V1/V2 region including 
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PG9, PG16 (124), CH01-CH04 (125) and PGT141-PGT145 (118). These antibodies were 
isolated through recognition of the conformational V1V2 epitope and shown to have a 
high degree of somatic mutation, ranging from 11.5% to 16%.  Their long CDR3 regions 
are rich in tyrosines that are frequently sulfated; 3) N332 glycan-dependent V3 epitopes, 
including PGT121-123 (126), PGT135-PGT137 (118), PGT125-PGT1 (127), and 
PGT130-PGT131 (37). In contrast to CD4bs mAbs, this group of mAbs can approach 
Env from several different angles. PGT121-PGT123 bind to the V3 base, N332, and a 
glycan attached to V1/V2. Using long CDR H1 and CDR H3, PGT135 binds to glycans 
attached to N332, N392, and N386 as well as to peptide residues at adjacent beta strands 
between V3 and V4 loops. PGT128, PGT130, and PGT131 recognizes an epitope that 
includes the C terminal of V3 as well as N-glycan at N332 and N301 positions by 
adopting a long CDR3 and CDR2 from heavy chain. These antibodies are quite potent, 
but not as broad as CD4bs antibodies, since they could not neutralize some clade A and 
clade C viruses; 4) transmembrane protein gp41, including 10E8 and PGT151-PGT152 
(128, 129). 10E8 is specific for a linear epitope on the gp41 MPER region (128). 
Different from previously isolated 2F5 and 4E10, 10E8 is not polyreactive and does not 
non-specifically bind to lipids but it was able to neutralize 98% of test viruses at IC50 
below 50ug/ml.  PGT151-PGT158 recognize a complex glycan dependent epitope on the 
both gp120 and gp41, and only recognize a properly formed, cleaved Env trimer(130). 
PGT151-PGT152 were able to neutralize two thirds of viral isolates at a median IC80 
24ng/ml (129).  
Newly discovered bNAbs provide valuable information regarding vulnerable 
regions on the Env spike, which could be used as a guideline for immunogen design.  
  
25 
Table 1.1 Class of broadly neutralizing Env-specific antibodies isolated from 
infected individuals 
 
 
 
N/A: not available in the literature 
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However, one caveat concerning these bnAbs is that they were isolated from 
chronically infected individuals. The host environment is very different in HIV-infected 
patients from that in healthy, uninfected people who are the target population of 
prophylactic HIV vaccines. First, in a vaccine setting, much lower immunogen dosing 
and a shorter exposure time are used for healthy populations than for those with chronic 
HIV-1 infection. Second, the unique features of Env-specific B cells observed in HIV-1-
infected patients, such as hyper-activation of B cells and continuously elevated 
immunoglobin levels (131), which are responsible for the high degree of somatic 
mutation, long CDR3, and high autoreactivity of Env specific antibodies, are lacking in 
healthy humans. Therefore, it is not clear whether findings from how HIV and antibodies 
act in infected humans can be directly translated into developing vaccine-elicited 
antibodies for non-HIV infected individuals. 
3.3. Env-specific animal mAbs from immunization  
In order to better understand gp120 structure and function, a large panel of mouse 
mAbs derived from monomeric gp120 protein immunization has been reported in 
literature. Mouse mAbs epitopes include neutralizing epitopes against CD4bs, CD4i, C4, 
V3, V2 as well as non-neutralizing epitopes against C1 and C5 region (132). 
Rhesus macaques are often used in the evaluation of immune responses to 
infection and vaccination. Phylogenetic tree analysis shows that rhesus and human heavy 
chain Ig loci are highly homologous (133); therefore, rhesus monkey is a desirable animal 
model to study antibody evolution elicited by vaccination. CD4bs monoclonal antibodies 
(mAbs) from gp140-F trimer-immunized monkeys have a lower degree of somatic 
hypermutation and neutralization activity against Tier1 but not Tier 2 viruses (133).  Fine 
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epitope mapping showed these CD4bs epitopes elicited by vaccines overlapped with 
those of non-broadly neutralizing CD4bs mAbs but remarkably less so with VRC01. 
Recent developments in deep sequencing will further facilitate an understanding of the B 
cell repertoire as elicited by immunization.   
The llama is also an important animal model for vaccine study as it has only one 
heavy chain. These unique llama mAbs have a long CDR3 and an additional disulfide 
bridge between CDR1 and CDR3. A panel of llama CD4bs or CD4i mAbs resulting from 
gp120 or trimeric gp140 Env immunization has been generated (134-136). Among them, 
at least three llama mAbs were able to potently neutralize ~96% of HIV-1 strains tested, 
equivalent to that of the new generation of mAbs from infected patients. This is the first 
time we have observed such potent and broad mAb induced by experimental 
immunization. However, the applicability of research in llamas to other animal models or 
humans is unclear due to the uniqueness of the llama heavy chain only antibody.  
Rabbit is also an attractive animal model to study vaccine-elicited antibody 
response because rabbit is highly immunogenic in responding to various immunization 
regimens to produce high titer antibody responses. We will present original data from 
isolated rabbit mAbs using DNA prime protein boost vaccine in Chapter II.  
3.4. Env-specific human mAbs from HIV vaccine trials 
The first panel of human antibody clonal lineages was derived from HIV vaccine 
trial, GSK PRO HIV-002; in that trial, gp120 protein immunization was used (137). 
During affinity maturation, the epitope of one Ab (3491) shifted from the linear C2 
region to a conformational epitope. This panel of mAbs showed only sporadic 
neutralization against one or two Tier 1 sensitive viruses. As expected, protein 
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immunization induced low level affinity maturation, with only ~3.8% mutation frequency 
observed.   
Several unique mAbs were isolated from the RV144 trial. These antibodies have 
been critical in dissecting immune-correlate and biological functions of antibody 
responses. First, two V2-specific mAbs CH58 and CH59 were isolated and considered 
the immune-correlates in the RV144 trial (90). The antigen-contacting residues of CH59 
include four residues (K169, H173, F176 and Y177), while CH58 has larger footprint 
also around K169 area. Although they bind at or near the site in V2 at which HIV-1 V1-
V2 bNAbs (PG9 and CH01) also bind, CH58 and CH59 mAbs recognize a structurally 
heterogenous site. Increased vaccine efficacy against a virus with a V2 K169 residue was 
observed among vaccinees, suggesting that the immune pressure observed in the RV144 
trial might be mediated by CH58- and CH59-like antibody responses. In addition, four 
mAbs, CH54, CH57, CH81, and CH91, were also isolated and shown to target at a 
conformational C1 epitope. Similar to A32, a conformational C1-specific mAb isolated 
from infected individuals(138), these mAbs also mediated ADCC responses (139). 
Furthermore, IgA mAb CH38 and CH29 were found to block ADCC activity mediated by 
C1-specific mAbs (139). This confirmed the previous finding showing that IgA responses 
correlate with infection risk.  
In summary, pursuing vaccine-elicited monoclonal mAbs will not only help 
understand the antibody development pathway, but will also help us dissect out the most 
desirable antibody epitopes that have anti-viral activity.  
4. Research Framework and Objectives 
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Use of information regarding the quality of vaccine-elicited humoral responses 
has helped lay a foundation for future vaccine design. Several lines of research including 
the RV144 trial and animal challenge studies, have provided more evidence suggesting 
that the coordinated activities of multiple antibody functions, including high affinity 
binding, neutralizing, and functional non-neutralizing antibodies, may be correlated with 
protection against acquisition of infection. The goal of the original work described here is 
to characterize the antibody profiles resulting from several major Env immunogens and 
regimens.  
 In first part of dissertation, I aim to determine the quality of antibody response 
elicited by HIV vaccination by isolating rabbit monoclonal antibodies (mAbs). To meet 
this goal, first, I expanded a novel rabbit monoclonal antibody platform to isolate 
antigen-specific mAbs. Second, I determined the binding, cross-reactivity, the degree of 
affinity maturation, binding specificity, and neutralization activity of these rabbit mAbs. 
Third, in collaboration with Dr. Xiang-peng Kong from New York University, we studied 
several representative rabbit mAbs with unique antigen specificities to understand 
structure-function relationship.  
In addition, I evaluated the impact of unique N-glycan patterns on the antigenicity 
and immunogenicity of gp120 Env proteins. By using genetically engineered yeast cells 
in collaboration with GlycoFi, a division of Merck, six recombinant HIV-1 gp120 protein 
immunogens with unique glycan patterns were expressed and purified with high 
homogeneity. Their antigenic properties have been thoroughly analyzed and their 
immunogeneity has been determined in rabbits. These novel Envs are promising 
immunogens capable of inducing high quality antibody profiles. 
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Moreover, to advance beyond our current gp120 DNA prime gp120 protein boost 
vaccine strategy, I compared antibody profiles elicited by vaccination using different 
immunization schedules and immunogen forms. To do this, I compared simultaneous 
delivery of DNA and protein-based vaccination versus DNA prime protein boost 
vaccination, and examined the influence of gp120 monomeric Env versus gp160 trimeric 
Env (generously provided by Dr. Shiu-lok Hu from University of Washington) in the 
context of Env DNA prime protein boost vaccination. The distinct antibody profiles 
elicited by such vaccination studies will serve as important guidelines for future vaccine 
design.  
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Chapter II Section I 
A novel rabbit monoclonal antibody platform to dissect the diverse repertoire of 
antibody epitopes for HIV-1 Env immunogen design 
Introduction 
Antibody research in the HIV-1 vaccine field has focused for a long time on the 
study of neutralizing human monoclonal antibodies (HmAbs) generated from HIV-1-
infected patients.  While these studies have provided remarkable information on the 
structural requirements for HmAb, in terms of the breadth and potency of their 
neutralizing activities, such unusually broad neutralizing HmAbs can only be identified in 
2-4% of the infected population and only after two or three years’ infection (140-143).  In 
contrast, the role of non-neutralizing antibodies targeting other areas of Env was virtually 
unknown prior to the study of antibody responses in RV144 volunteers.  RV144 provided 
a rare opportunity to study the quality of antibody responses in immunized individuals 
and it was shown that antibodies against the V2 region correlated with protection (88).  
Furthermore, several HmAbs from the RV144 trial that target the V2 region have been 
produced (90).  Since it is a lengthy process to advance a candidate vaccine to human 
trials, most studies on the diversity and quality of antibody responses will be first 
conducted in experimental animals during the pre-clinical phase of HIV-1 vaccine 
development. 
            Previously, we reported the elicitation of cross-clade neutralizing antibody 
responses when a DNA prime-protein boost immunization approach was adopted to 
deliver a polyvalent Env immunogen formulation in animal and human studies (92, 95, 
98).  Further epitope mapping and antibody competition analyses identified quality 
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differences between immune sera elicited by the DNA prime-protein boost approach and 
the protein alone approach (96, 144).  However, these studies were conducted using 
polyclonal sera and results from these studies were unable to link the observed antibody 
activities with a particular antibody component in a polyclonal serum. 
Here we report the development of a recombinant rabbit monoclonal antibody 
(RmAbs) technology to monitor the specificity and neutralizing activities of antibodies 
elicited by a candidate HIV-1 Env immunogen.  Historically, rabbit has been an attractive 
animal model for antibody studies and has been used more recently in HIV vaccine 
research because rabbit is highly immunogenic in responding to various immunization 
regimens to produce high titer antibody responses.  It was shown that only RmAbs were 
able to provide high quality detection against certain difficult epitopes, such as those in 
tissue section samples and HIV viral particles (145-147).  Rabbit antibodies usually carry 
limited background reactivity against testing antigens.   Rabbits provide a large volume 
of immune sera for a wide range of antibody assays while the other common 
experimental animal species, such as mouse or rat, can only provide limited volume of 
immune sera, usually with high background in functional antibody assays.  Moreover, 
rabbit immune system, but not that from mouse, is able to generate long CDR3 regions, 
which is important for many neutralizing antibodies against HIV-1 (148, 149). 
In the current pilot study, a panel of 12 HIV-1 Env-specific rabbit hybridoma cell 
lines were produced that can recognize a wide range of Env epitopes.  Furthermore, their 
heavy chain and light chain genes were cloned and their genetic features were analyzed.  
Recombinant RmAbs were produced from these rabbit Ig clones and their epitope 
specificity, binding affinity, and neutralization activities were determined. 
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Results 
Generation of HIV-1 Env-specific hybridoma cell lines from a rabbit immunized 
with the DNA prime-protein boost JR-FL gp120 vaccine 
In this pilot study to explore the feasibility of producing recombinant rabbit mAb 
specific for HIV-1 Env, one NZW rabbit from a previously published immunogenicity 
study (95) was used for MAb isolation and characterization. During the initial 
immunogenicity study, this rabbit received three DNA inoculations followed by two 
inoculations with gp120 protein from HIV-1 JR-FL (Fig. 2.1).  By the time we decided to 
produce RmAb from this rabbit, it had been 16 weeks since the last immunization.  
Therefore, this rabbit was boosted further with a one-time JR-FL gp120 DNA 
immunization and a one-time recombinant JR-FL gp120 protein immunization separated 
by 4 weeks.   Four days after the final protein boost, the rabbit spleen was harvested and 
sent to a subcontractor for production of hybridoma cells (Fig. 2.1). 
A total of 57 multi-clonal stage hybridoma cells were screened for their 
supernatant reactivity against the JR-FL gp120 antigen (Fig. 2.2).  Among them, 36 
(63%) tested positive by ELISA, including two (R39 and R47) that were considered 
weakly positive (Fig. 2.2A).  Western blot analysis further confirmed that a smaller 
fraction (17 hybridoma cells, 30%) had various levels of positivity against denatured JR-
FL gp120 antigen (Fig. 2.2B). Based on the above screening results, a panel of 12 
hybridoma cell lines (13, 15, 20, 27, 28, 31, 35, 41, 43, 52, 53, and 56) was selected for 
further production of stable monoclonal stage of hybridoma cells. 
Diverse epitope profiles of gp120-specific RmAbs elicited by JR-FL gp120 
immunogen 
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Figure 2.1. Schematic representation of the rabbit immunization schedule. The 
rabbit was given three times HIV Env encoding DNA at two-week intervals and followed 
by twice matched protein boost, monthly. After a 16-week resting period, this rabbit was 
further boosted with 1x DNA and 1x protein boost. The rabbit spleen was harvested 4 
days after the final protein boost to generate hybridoma cell lines. 
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Figure 2.2. Initial screen of 36 multi-clonal stage of hybridoma cell lines by their 
binding to HIV-1 JR-FL gp120 protein. (A) Binding of rabbit hybridoma supernatants 
to HIV-1 JR-FL gp120 protein was tested by ELISA. The rabbit sera samples prior to 
immunization and at week 14 served as the negative control (“-“) and positive (“+”) 
control, respectively.  (B) Testing hybridoma supernatants against JR-FL gp120 protein 
by Western blot. The positive and negative controls were same as (A).  
  
36 
The epitope specificity of these RmAbs was determined by an ELISA against linear 
peptides (15 amino acid (aa) residues each with 11 aa overlapping) spanning the entire 
length of consensus gp120 from M group of HIV-1. These 12 rabbit hybridoma cell lines 
could be divided into 5 groups based on their antigen epitope specificity (Fig. 2.3). 
(1) V3 specific hybridomas – R20, R43, and R56 (Fig. 2.3A).  These hybridomas 
recognized two different epitopes within V3 region.  One hybridoma, R56, recognized 
the V3 crown, the principal target for most anti-V3 mAbs isolated from patients 
chronically infected with HIV-1. The other hybridomas R20 and R43 recognized the C 
terminal portion of the V3 region, an epitope not commonly seen by human mAbs but 
recently described as part of a key neutralizing epitope for several highly potent human 
mAbs, such as PGT128 (127). 
(2) C4 specific hybridoma – R53 (Fig. 2.3B).  Based on the epitope peptide 
sequence, R53 binds to the bridging sheet of gp120, a rare epitope only reported in a 
mouse study in early days of HIV-1 research (150, 151).  One unique feature of R53 is 
that it can bind to two discontinuous linear epitopes in the C1 and C4 regions although 
there is limited sequence homology between these two peptides. 
(3) C5 specific hybridoma - R13 (Fig. 2.3C).  This hybridoma binds to the far C-
terminus of gp120, a region known to be immunodominant (152). 
(4) C1 specific hybridomas – R15, R35, and R41 (Fig. 2.3D).  Supernatants from 
these three hybridoma cell lines were able to bind to the same three constitutive peptides 
in the first constant region of HIV-1 Env. 
(5) Hybridoma with unknown epitope - R27, R28, R31, and R52 (Fig. 2.3E).  
These RmAbs did not bind to any of the peptides included in the overlapping M-group  
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Figure 2.3. Diverse repertoire of gp120-specific rabbit monoclonal hybridoma 
supernatants revealed by ELISA with plates coated with individual consensus B 
gp120 overlapping peptides. RmAbs were grouped into the following five groups: (A) 
V3-specific (R20, R43, and R56); (B) C4-specific (R53); (C) C5-specific (R13); (D) C1-
specific (R15, R35, and R41); (E) unknown epitopes (R27, R31, R52, and R28);  (F) List 
of identified epitope sequences for selected rabbit hybridoma cell lines.  
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Env peptide pool.  R27, R31, and R52 may recognize conformational epitopes as they 
showed positive ELISA binding against ConA-captured JR-FL gp120 (Fig. 2.2A) but no 
binding as observed by Western blot to the same but denatured gp120 antigen (Fig. 2.2B).    
For R28, because it showed positive binding by both ELISA and Western blot against JR-
FL gp120, it is possible that R28 can only recognize a JR-FL-specific linear peptide that 
may be different from the sequences of the consensus clade B overlapping peptides. 
Crystal structures have been produced for several RmAbs described in the current 
study.  In particular, three RmAbs (R20, R56, and R53) have been co-crystalized with 
their respective targeted peptides, as described in the above epitope mapping analysis, 
confirming the accuracy of epitopes mapped by ELISA (153). 
Broad binding profile and high affinity of RmAbs against gp120 proteins from 
different clades of HIV-1 
The gene transcripts of the full length IgG heavy chains and light chains from the 
above RmAbs were cloned from these hybridoma cells by RT-PCR and further subcloned 
into a mammalian protein expression vector.  Individual recombinant RmAbs were 
produced from 293T cells transiently transfected with these RmAb-expressing molecular 
clones. 
Recombinant RmAbs were individually characterized for their ability to bind to a 
panel of five recombinant gp120 proteins (92UG037, JR-FL, 93MV965, 92UG021, and 
consensus AE Env, representing clades A, B, C, D, and E, respectively) (Fig. 2.4).  All 
isolated rabbit mAbs were able to bind well to JR-FL gp120 by ELISA but had different 
levels of binding against other gp120 antigens.  Among the V3-specific RmAbs, R56  
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Figure 2.4. The reactivity of 12 RmAbs with a panel of representative gp120 
proteins revealed by ELISA. HIV-1 Env gp120 proteins were derived from the 
following isolates 92UG037, JR-FL, 93MW965, 92UG021, and consensus AE.  
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binds to four gp120 proteins but not that from the clade D isolate, 92UG021.  The tip of 
V3 loop for clade D gp120, 92UG021, has a very different sequence GVGR vs. the more 
common GPGR or GPGQ sequences seen with other clades, in addition to unique 
sequences immediately upstream of the V3 tip (Fig. 2.8).  The other two V3 RmAbs, R20 
and R43, bind gp120 proteins from JR-FL and clade A isolate, 92UG037, better than 
other three gp120 proteins from clades C, D, and E isolates.  This is also consistent with 
overlapping peptide ELISA (Fig. 2.3) and phylogenic lineage (Fig. 2.7) results, which 
showed that R20 and R43 are grouped together in both analyses. 
R53 is one RmAb that was broadly reactive with all five gp120 proteins from 
different clades.   In contrast, C1-targeted RmAbs (R15, R41, and R35) uniformly bind to 
two gp120 proteins from clade B (JR-FL) and clade A (92UG037) with high efficiency. 
Three RmAbs recognizing conformational epitopes, R52, R31, and R27, appeared 
to be highly specific to JR-FL gp120, whereas low to no detectable binding was observed 
for the other four gp120 proteins tested.  R28, which targeted at unknown linear epitope, 
was broadly reactive to all five gp120 proteins, but the overall binding affinity was low, 
especially to gp120 protein from clade A isolate, 92UG037. 
More detailed binding kinetics, including the binding affinity of these 
recombinant RmAbs, was further measured using a ForteBio instrument based on 
recently developed Bio-Layer Interferometry (BLI) technology.   This system is similar 
to the traditional Biacore technology but is more user-friendly and can process a large 
number of samples simultaneously.  Actual measurements for three RmAbs (R15, R53, 
and R56) are shown in Fig. 2.5.  All RmAbs exhibited a considerably high binding 
affinity to JR-FL gp120 with KD ranging from 0.02 nM to 4.47 nM (Fig. 2.5). 
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Gene sequence analysis of HIV-1 gp120-specific RmAbs 
The full-length IgG heavy chain and light chain genes of the RmAbs were 
sequenced.  Germline family usage, mutation frequency, and CDR3 length in heavy chain 
and light chain were determined using IMGT and V-QUEST (Fig. 2.6 and Table 2.1).  
Consistent with a recent report (154), most of the isolated RmAb heavy chain genes 
preferentially utilized IGHV1S40*01 (IMGT numbering system) or a3-VH1 (Kabat 
numbering system) as the germline family gene while only R13 and R31 used 
IGHV1S45*01 (IMGT numbering system) or a3-VH4 (Kabat numbering system).  For 
light chain, diverse germline gene families were utilized to generate gp120-specific 
mAbs. 
Somatic hypermutation (SHM) is a key parameter in evaluating antibody affinity 
maturation.  In the most studied influenza immunization, the mean VH mutation 
frequency of human antibodies induced by repeated vaccination is ~5% (155, 156). 
Among 12 gp120-specific RmAbs identified in the current study, heavy chain V genes 
exhibited an average SHM of 14.6 ± 9.2% (ranging 5 to 27%) at the amino acid level, 
while light chain V genes exhibited an average of SHM of 9.25 ± 1.5% (ranging 7 to 
12%), indicating that the immunization regimen used in this study was effective in 
stimulating a high SHM rate of gp120 antigen-specific Ab genes (Table 2.1). The 
mutated amino acids for heavy chains were mainly distributed in CDR1 and CDR2 
region, while SHM occurred across the light chain kappa gene (Fig. 2.6). Examination of 
the heavy chain CDR3 region revealed an average length of 10.9 ± 6.5 aa (ranging 6 to 
23 aa) and the light chain CDR3 region contained an average of 11.5±1.7 aa (ranging 
from 8 to14 aa) (Table 2.1), compatible with rabbit mAbs elicited from immunization, as  
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Figure 2.5. Binding affinity of rabbit mAbs to JR-FL Env gp120 protein determined 
by a ForteBio Octet QKe  system.  Rabbit mAbs were immobilized on the chip surface 
and the JR-FL gp120 proteins were added in the testing solution. (A) The rate constants, 
Ka, Kd and KD, for rabbit mAbs binding to JR -FL gp120, which were obtained by global 
fitting the curves to 1:1 binding model. (B) The binding kinetics of three selected 
RmAbs, R56, R53, and R15, to three-fold serial dilution of JR-FL gp120 protein. 
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Figure 2.6. Protein sequences of heavy and light chain variable regions of gp120-
specific rabbit mAbs. The sequences are aligned to their corresponding putative 
germline genes. Framework region (FR) and CDRs are indicated based on IMGT 
(http://www.imgt.org/) nomenclature. Somatic mutated amino acids compared to the 
putative germline are in red and CDR3 regions in blue.
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Figure 2.7. Phylogenetic tree of heavy chains and light chains gene sequences 
constructed using maximum likelihood method.  V3-specific RmAbs were highlighted 
in red, C1-specific mAbs in orange, C4-specific mAbs in cyan, C5-specific mAbs in blue, 
and conformational/unknown RmAbs in black. 
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Table 2.1 Characteristics of the variable region of heavy chains and light chains of 
the vaccine-elicited rabbit mAbs. 
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previously reported (157). 
 
To define the genetic relationship of these RmAbs, phylogenetic trees were 
constructed based on heavy chain and light chain gene sequences using the maximum 
likelihood method (Fig. 2.7).  Interestingly, RmAbs targeting at the same region of gp120 
tend to cluster together to form an independent subtree.  For example, heavy chains and 
light chains from R15, R35, and R41 (all targeting the C1 region) formed independent 
subtrees.   Similarly, the heavy chain from three V3-specific RmAbs, R56, R20, and R43, 
grouped into another subtree, whereas the light chain genes of R43 and R20 clustered in a 
subtree but not with R56. This demonstrates a process of clonally-related B cell lineage 
development and affinity maturation.  At the same time, building a phylogenetic tree may 
help determine the biological relevance of Env-specific RmAbs. 
The breadth and potency of neutralizing activities with individual gp120-specific 
RmAbs 
A screening neutralization assay was conducted using an in-house assay at the 
University of Massachusetts Medical School to first identify those RmAbs with possible 
neutralizing activities (Table 2).  Because this particular rabbit was immunized with a 
clade B gp120 antigen, a standardized in-house TZM-bl assay was used with a small 
panel of pseudotyped viruses expressing HIV-1 Env antigens from clade B viruses 
representing both neutralization-sensitive (Tier 1) and neutralization-resistant (Tier 2) 
primary isolates. Among 12 isolated RmAbs, 3 showed positive neutralizing activities in 
this initial screening assay.  V3-specific R56 displayed potent neutralizing activity 
against SF162 (IC50=0.02 µg/ml) and to a lesser degree against another sensitive Tier 1  
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Figure 2.8.  V3 region protein sequences from isolates JR-FL, 92UG037, 93MW965, 
92UG021, and consensus AE. The residue position refers to the HXB2 strain.  The R56 
epitope is highlighted in orange and the R20 epitope is in blue. The amino acids within 
V3 region that differed from the JR-FL strain are highlighted in red.  
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Table 2.2 Neutralization IC50 (µg/ml) of rabbit MAbs by in-house TZM-bl assay
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Table 2.3 Neutralization IC50 (µg/ml) of rabbit MAbs by PhenoSense assay at 
Monogram Biosciences 
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Table 2.4 Neutralization IC50 (µg/ml) of rabbit MAbs by TZM-bl assay at CAVIMC
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virus SS1196 (IC50=4.0 µg/ml) and a Tier 2 virus QH0692 (IC50=8.6 µg/ml).  C4-specific 
R53 had potent neutralizing activity against SF162 (IC50=0.5 µg/ml) but much less so 
against SS1196 (IC50= 31.9 µg/ml).   It is interesting to see that R15, a C1-specific 
RmAb, was also able to neutralize SF162 and SS1196, suggesting a novel neutralizing 
epitope within the C1 region, at least to certain sensitive viruses. 
To further map the breadth of neutralizing activities of RmAbs, a high throughput 
neutralizing assay was conducted at Monogram, Inc. using its PhenoSenseTM assay 
system.  R53 and R56 were tested against three highly sensitive viruses in addition to 13 
primary isolates covering clades A to AE (Table 2.3).  V3-specific R56 showed 
neutralizing activities against SF162 and QH0692, confirming the screening assay results, 
but was unable to neutralize other pseudotyped viruses.  Interestingly, C4-specific R53 
neutralized all three sensitive viruses with high potency (IC50 < 1.9 µg/ml) and a wide 
range of primary isolates from various clades although at a low potency. 
Because a number of the primary viral isolates used in Monogram’s assay were 
not characterized as either Tier 1 or Tier 2 viruses, final neutralization assays were 
conducted by the Comprehensive Antibody Vaccine Immune Monitoring Consortium 
(CAVIMC) of the Collaboration for AIDS Vaccine Discovery (CAVD) program 
supported by the Bill & Melinda Gates Foundation.  RmAb R56, R53, and R15 were 
tested against a panel of well characterized pseudotyped viruses expressing Env from a 
wide range of primary HIV-1 isolates, including 19 Tier 1 viruses (2 clade A, 7 clade B, 6 
clade C, 1 clade AE, and 3 clade AG) and 25 Tier 2 viruses (3 clade A, 6 clade B, 3 clade 
C, 3 clade AE, 3 clade AG, 2 clade BC, and 2 clade G) (Table 2.4). V3-specific R56 
showed potent neutralizing activities (IC50 titer<1 µg/ml) against Tier 1 Clade B viruses 
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SF162.LS, Clade C viruses MW965.26, and Clade AG viruses DJ263.8; while exhibited 
moderate to low neutralizing activities against three Tier 1 Clade B viruses (SS1196.1, 
Bal.26, and Bx.08.16), one Tier 1 Clade C virus (TV1.21), one Clade AE virus (Th023.6) 
and one Clade AG virus (T271-11).  C4-specific R53 was also able to neutralize 3 Tier 1 
viruses (SF162.LS, MW965.26 and Bx08.16) and 1 Tier 2 virus (Thro4156.18) at low 
potency.  No other viruses on this panel were neutralized by R53. C1-specific R15 was 
able to neutralize seven Tier 1 viruses, including SF162.LS, SS1196.1 and Bx.08.16 
(Clade B), MW965.26 and TV1.21 (both are Clade C), TH023 (Clade AE), 242-14 
(Clade AG) and 1 clade C Tier 2 virus, ZM135M.PL10a. 
Discussion 
In the past few years, experience in producing high quality HIV-1 Env specific 
mAb from animal models is limited.  Recently, a panel of CD4bs-directed macaque 
mAbs elicited by an Env vaccine was identified (133) but the high cost of NHP studies 
prevents the wide adoption of this system.  Historically, murine mAbs were unable to 
achieve good neutralizing activities, partially due to the poor efficacy in generating long 
CDR3 for mouse mAbs (148, 149). Transgenic mouse systems expressing human 
antibodies are well established; however, many of these systems are under the control of 
major pharmaceutical companies, preventing scientists not affiliated with these 
companies to have easy access to these models due to intellectual property barriers. 
Newly developed humanized mice models are making progress in HIV infection studies, 
including the analysis of T cell responses, but their use for B cell and antibody 
development has not been fully developed (95, 96). 
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Results presented in this report established the feasibility of producing high 
quality Env-specific and potentially functional rabbit mAbs. Rabbit is an attractive model 
to study antibody responses against a wide range of emerging infectious diseases 
vaccines including HIV-1 (92, 95, 96, 144, 158, 159).  Rabbits share common features in 
B cell development similar to those in mice and human and those of gut-associated 
lymphoid tissues (GALT) species, such as chickens, sheep, and cows (160). B 
lymphopoiesis in rabbit occurs similar to that in the human and mice classical pathway in 
the bone marrow; however, as a member of the GALT species, rabbit B lymphopoiesis 
terminates during early development (161). The exogenous antigen will further expand 
and diversify B cell in GALT through somatic hypermutation and gene conversion.  
Furthermore, phylogenetic analysis showed that human heavy chain variable (VH) genes 
can be divided into three major groups, A, B, and C; and all rabbit VH genes are closely 
related to one another and form one monophyletic group, which is included in VH group 
C (162). Among those VH genes, most rabbit B lineage cells rearranged the same VH 
gene, VH1, which encodes the VHa allotypic sequence and rabbits preferentially use it to 
produce functional antibodies (163). The rabbit humoral system can serve as a simplified 
testing platform to study the evolution pathway of antibody genes, since the rabbit 
adopted a much less complicated germline usage compared to mouse and human. On the 
other hand, it was speculated that no VRC01-like antibody will be raised in rabbits due to 
the lack of an optimal germline VH segment (164). 
The phylogenetic analysis suggests that the human and rabbit Ig genes evolved at 
nearly the same rate.  In contrast, most mouse genes evolved considerably faster than 
human and rabbit genes (162). Gene conversion and somatic hypermutation occur not 
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only in the germinal center (GC) of the young rabbit appendix, but are also used for 
diversification during the immune response in secondary lymphoid tissues, such as the 
spleen (165).  Rabbit B cells see antigen in a similar manner as does the human immune 
system (166).  A rabbit hybridoma fusion partner was developed previously (167) and 
optimization of the traditional rabbit fusion partner cells and fusion methods greatly 
facilitated the generation of monoclonal antigen-specific rabbit hybrdioma cell lines (US 
patent No.: US 7,575,896 B2 and US 7,732,168 B2), allowing for relatively efficient 
production of RmAbs and use in our current study as a contracted service. 
In this first report of HIV-1 Env-specific rabbit mAb, a wide diversity of epitopes 
was identified from a single immunized rabbit, which showed high levels of serum 
polyclonal antibodies against the autologous JR-FL gp120 antigen.  Besides the common 
V3 loop-specific rabbit mAbs, other rabbit mAbs were produced against both linear 
epitopes at either N-terminal or C-terminal regions of gp120 and conformational 
epitopes.  Several epitopes were not previously known.  At the time of this study, the role 
of V2-specific antibodies was not known therefore, efforts were not devoted to cloning 
V2-specific RmAbs in this study.  However, serum from this rabbit did show positive 
antibody responses, recognizing gp70-V1V2 antigen, indicating the presence of V2-
specific antibodies. 
Three of twelve RmAbs cloned in this pilot study showed positive neutralizing 
activities.  R15 indicated a previously unknown neutralizing epitope in the C1 region of 
Env as it was able to neutralize several viral isolates across subtypes B, C, AE and AG, 
although these viruses are from Tier 1 groups and the potency of R15 was low. V3-
specific R56 demonstrated high potency against those viral isolates that were sensitive to 
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V3 neutralization, but the breadth of R56 was limited as would be expected from mAbs 
recognizing the tip of V3 loop. 
The third neutralizing mAb R53 is the only one in this pilot study that was able to 
bind all five gp120 antigens from subtypes A to E and also showed broad neutralizing 
activities in Monogram assays despite low potency.  Interestingly, previous studies 
reported that several murine mAb (151), as well as rat mAbs (150), isolated from gp120 
protein immunization, were able to prevent gp120 binding to CD4.  They mainly bound 
to a region on aa 430-447 of C4 region which is now known as part of the Env bridging 
sheet.  Crystal structure analysis showed that R53 actually binds to the beta strand 21 
region within the bridging sheet (153).  R53 was also able to compete with b12, a CD4bs-
directed mAb.  The bridging sheet, along with the interface of outer domain and inter 
domain of Env compose the CD4 binding site. Upon CD4 binding, the bridging sheet 
undergoes a conformational change and enables the formation and exposure of the co-
receptor binding site.  Given the broad reactivity of R53 against a wide range of primary 
gp120 proteins across different subtypes and its ability to neutralize multiple Tier 1 
pseudoviruses from different clades, future Env vaccine studies should further investigate 
the protection potential of this class of bridging sheet targeting antibodies. 
In this pilot study, RmAbs were first screened by conventional ELISA against 
recombinant monomer gp120 antigens.  Screening based on recognition of viral particles 
or positive neutralizing antibody activities will improve the chance of identifying more 
functionally relevant mAbs.  Furthermore, limited by the cost restraints associated with 
the contracted service used, not all gp120-positive hybridomas from the initial screening 
were further cloned which reduced the understanding on the full spectrum of gp120-
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specific RmAb elicited by immunization.  Alternative technologies that can isolate 
individual gp120-positive B cells, similar to those developed for human mAbs, should be 
applied to RmAbs production in future studies. 
Studies of HIV-1-specific human mAbs have suggested that somatic 
hypermutation and unusually long heavy chain CDR3, as two key indicators for affinity 
maturation, are usually required for broad and potent neutralizing activities of human 
mAbs (128, 168-170).  Rabbit mAbs identified in the current study showed various levels 
of hypermutation and length of CDR3, suggesting HIV-1 vaccines delivered in the 
current prime-boost format were able to initiate the antibody maturation process.  It is not 
known whether the low potency observed in several neutralizing RmAbs could be 
improved if the affinity maturation process is further enhanced, such as by a different 
adjuvant.  Also, the current study only examined the status of affinity maturation at the 
end of a full vaccination schedule.  Observing the induction of gp120-specific antibody 
responses throughout the entire process starting from time points before immunization or 
early in immunization, by using the new RmAb platform, will provide more insight on 
this process. 
As learned from studies following the RV144 trial, antibody activities detected in 
vitro can link to correlates of immune protection, and identifying the effector mAbs 
would be helpful to evaluate vaccine-elicited humoral immune response. Isolation of 
mAbs from preclinical vaccine studies using small animal or non-human primate models 
will help us understand the antibody response and B cell development driven by 
immunization.  The RmAb platform described in the current report will provide a useful 
tool to achieve such goals. 
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Chapter II section II 
Rabbit Anti-HIV-1 Monoclonal Antibodies Raised by Immunization Can Mimic the 
Antigen-Binding Modes of Antibodies Derived from HIV-1-Infected Humans 
Abstract 
Here we present structural analyses of two rabbit monoclonal antibodies (mAbs), 
R56 and R20, against the third variable region (V3) of HIV-1 gp120. R56 recognizes the 
well-studied immunogenic region in the V3 crown, while R20 targets a less-studied 
region at the C terminus of V3. By comparison of the Fab/epitope complex structures of 
these two antibodies raised by immunization with that of the corresponding human 
antibodies derived from patients chronically infected with HIV-1, we found that rabbit 
antibodies can recognize immunogenic regions of gp120 and mimic the binding modes of 
human antibodies. This result can provide new insight into the use of the rabbit as an 
animal model in AIDS vaccine development. 
The rabbit mAb structural analysis was conducted by Dr. Xiangpeng Kong from 
New York University School of Medicine. We provided the reagents R56 and R20. The 
full illustration of this work is in Appendix I.  
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Chapter II section III 
Masking of an immunogenic epitope region in HIV-1 gp120 C4 critical 
for receptor and co-receptor binding 
Introduction 
            HIV-1 surface envelope glycoprotein gp120 initiates the virus entry into host cells 
by engaging its receptor CD4 and co-receptor CCR5/CXCR4, and it is the major target 
for the AIDS vaccine development. However, gp120 uses many decoys to dodge human 
immune surveillance, making the development of a protective vaccine very challenging. 
Conformational masking is one of the decoys gp120 uses to evade the immune responses 
(171). The variable loops can often adopt different conformations, so that antibodies 
recognize one conformation will not be able to effectively target another conformation 
(90, 172, 173). Conformational masking can also protect functionally conserved sites of 
gp120. For example, the CD4 receptor-binding site is protected by entropy masking (171), 
and the co-receptor-binding site in the pre-fusion complex is completely buried under the 
variable loops (19, 20, 24). CD4 receptor binding will expose the co-receptor binding site, 
which is comprised of various conserved regions including the fourth conserved region 
(C4). The conformational masking of C4 is the subject of investigation for this 
manuscript. The C4 region of gp120, consisting of residues 419-448 (numbering in HxB2 
scheme (174)), play many important functional roles: it directly involves receptor binding, 
co-receptor binding and co-receptor selection (tropism) (175, 176). Crystal structures of 
gp120 complex have revealed that residues Asn425, Met426 and Trp427 in the C4 region 
have direct contacts with CD4 (13). The C4 region, together in spatial proximity with the 
base of the third variable loop (V3), also involves co-receptor binding. Early mutagenesis 
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studies indicated that residues Pro438 and Gly441 in the C4 region are important for CCR5 
binding (177), and later a structural study of gp120 in complex with CD4 and mAb 412d 
showed that residues Ile439, Arg440 and Gly441 in the C4 region involve in the binding with 
the N-terminus of CCR5 (24). A slight conformational change of the C4 region can 
influence the structure of V3, and even a single amino acid mutation change in the C4 
region could increase the neutralization sensitivities of anti-V3 antibodies (178, 179). The 
C4 region, as well as the V3, also involves in co-receptor selection and mutations of 
residue 440 in the C4 region can alter co-receptor specificity (180). 
                 The C4 region is highly immunogenic. It can induce T-cell immune response 
in HIV-1 infected patients and in immunized animal models (181, 182). For example, 
monomeric gp120 could elicit mouse helper T cell immune responses reactive with a C4 
peptide, named T1 (a 16-mer peptide containing the region of residues 428-443), and, 
vise versa, the T1 peptide could elicit helper T cell immune response reactive with gp120 
as well (181). Moreover, recombinant vaccinia virus expressing gp160 gene can elicit 
human T cell immune response reactive with the T1 peptide. After boosted with the 
recombinant fragment of gp120 containing the T1 site, the T cell immune response to T1 
significant increased (182). The C4 region is thus an antigenic site to T cell immunity. 
                  The C4 region can also induce antibody response (183, 184). A number of 
animal immune sera and mAbs have been described to target the C4 region. One of the 
characteristics of these antibody responses is that they can block the binding of CD4 with 
gp120, thus they were collectively named as CD4-blocking antibodies (185). In fact the 
CD4 binding region of gp120 was first identified by an anti-C4 mAb 5C2E5, which was 
raised by immunizing mice with recombinant gp120 and identified by competition with 
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CD4 binding (175). Since then many antibodies targeting the C4 region have been 
generated from animal models, including rabbit polyclonal R10-12 and R19-21 raised 
with poliovirus chimaera S1/env/4 (186), mouse mAbs G3-42, G3-299, G3-508, G3-536 
raised with recombinant BH10 gp120 (187, 188), rat mAbs ICR 38.8f and ICR38.1a 
raised with recombinant BH10 gp120 (150). These reports suggested that the anti-C4 Ab 
responses can be readily elicited by gp120. 
                 Structurally the C4 region was initially suggested to form amphipathic helices 
(182), but crystal structures of CD4-bound gp120 showed that the C4 region forms two 
beta strands, numbered 20 and 21, of the bridging sheet and the following loop F (13). 
Beta strand 20 involves in CD4 binding while beta strand 21 involves in co-receptor 
binding. Recent crystal structures of gp120 in complex with various mAbs showed that 
the C4 region, a sequence-conserved region, could display distinct conformations among 
the unliganded, CD4-bound and different antibody-bound states (13, 16, 20, 189, 190). 
                 Here we present functional and structural characterizations of a recently 
generated rabbit anti-C4 mAb R53, which was elicited by JR-FL gp120 using a DNA 
prime - protein boost regimen (191). We show that R53 has broad cross-clade binding 
activities against gp120 proteins from clade A, B, C, D and E. It could neutralize 
sensitive viruses quite potently but was unable to any neutralize Tier 2 viruses. We have 
determined crystal structures of Fab/epitope complex and Fab alone of R53, and 
structurally defined R53 epitope and found that this epitope harbors a conserved motif 
AMYAPPI (residues 433-439) located at the C-terminus of the bridging sheet and loop F. 
Our data provide a structural understanding of this immunogenic but functionally critical 
region and how it is protected by conformational masking. 
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Results 
Immunological characterization of rabbit mAb R53 
                Rabbit mAb R53 is one of the mAbs we generated recently from a New 
Zealand white rabbit immunized with JR-FL DNA prime followed by a homologous 
protein boost as previously reported (191). The location of its epitope was mapped to the 
C4 region of gp120 using a 15-aa overlapping peptide array, and a capture assay was 
used to identify whether the epitope of R53 overlaps functionally with those of CD4 
binding site (CD4bs) mAbs (Table 2.5). CD4bs mAb b12, V3-specific mAb 3074, and 
glycan specific antibody 2G12 were used as competitive targets. The supernatant of R53 
hybridoma was able to prevent 56% virus binding to mAb b12, suggesting that R53 
indeed targets the CD4bs region. In contrast, it could not compete against either V3 mAb 
3074 or glycan mAb 2G12, further supporting its specific competition against b12. Since 
previously described mAbs targeting at this C4 region were found to block CD4 binding 
of gp120 (175, 185), we determined the binding specificity of R53 by competition ELISA 
(Fig.2.9A). R53, sCD4 and R56 were used to compete with Ig-CD4 for binding to JR-FL 
gp120. As expected, R53 could inhibit Ig-CD4 binding (IC50=9.8ug/ml), although it is 
not as effective as the positive control sCD4 (IC50=0.22ug/ml). As a negative control, 
R56 did not have any impact on Ig-CD4 binding of gp120. These results confirmed that 
R53 can block CD4 to bind gp120. 
                To determine the binding breadth of R53 for HIV-1 gp120 from different 
clades, eight representative gp120s were chosen: 92UG037.8 from clade A; 92US715, 
BaL, and JR-FL from clade B; 96ZM651 and 93MW965 from clade C; 92US021 from 
clade D, 93TH976.17 and AE consensus from clade AE. A Western blot analysis showed 
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Table 2.5 Ability of hybridoma supernatants to outcompete binding to mAbs with 
known specificities 
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Figure 2.9. R53 broadly reacts with gp120s of diverse clades. (A) R53 competition 
with Ig-CD4 assay. Data from the soluble CD4 (sCD4) and anti-V3 mAb R56 were used 
as controls. (B) Western blots showed that five selected gp120 proteins from different 
clades were recognized by R53. (C) R53 binds 10 gp120s from clades A, B, C, D and AE, 
revealed by ELISA. (D) Protein sequence alignment of R53 epitope region for the 10 
gp120s used in panel (C). The R53 epitope is underlined in the JR-FL sequence.  
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 that five representative gp120s from different clades were recognized by R53 in 
denatured conditions (Fig.2.9B). In addition, R53 was able to recognize all these Env 
demonstrated by ELISA (Fig. 2.9C). Binding kinetics of R53 with selective five gp120s 
were further determined using a ForteBio instrument. R53 is shown to have high binding 
affinities to all five gp120s tested, with KD ranging from 1.79 nM to 3.98 nM (Table 2.6). 
A sequence alignment of R53 epitope region revealed that it is highly conserved among 
clades A, B, C, D and AE (Fig. 2.9D). 
Crystal structure of Fab/epitope complex of rabbit mAb R53  
          We determined the crystal structure of R53 antigen-binding fragment (Fab) in 
complex with a peptide (VGKAMYAPPIRGQIR, residues 430 to 444 in HXB2 
numbering). The complex structure of R53 Fab/epitope was solved by molecular 
replacement and refined to 2.3 Å resolution with Rwork/Rfree of 18.4%/23.0% (Fig. 2.10 
and Table 2.7). The crystals grew in the orthorhombic space group P212121 with two 
Fab/epitope complexes in the asymmetric unit. The two complexes are highly similar 
(RMSD = 0.551 Å), we thus chose only one for description here. We numbered the 
residues following the Kabat and Wu convention (192), with the light and heavy chains 
preceded by “L” and “H”, respectively, and the residues of the epitope by a “P”. 
Although a 15-mer peptide was used in the crystallization, only 11 residues, i.e., 
GKAMYAPPIRG (residues 431 to 441), were observed in the electron density map. We 
also determined the structure of Fab alone (Table 2.7); superposition of the two Fab 
structures showed that R53 Fab appears to have minimal conformational change upon 
epitope binding (RMSD = 0.772 Å). R53 has a typical rabbit antibody inter-domain 
disulfide bond between residues 80 and 170 of the light chain, which places a constraint   
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Table 2.6 R53 binding kinetics to 5 representative Env proteins 
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 on its elbow angle (193).  
                The epitope of R53 (431GKAMYAPPIRG441) is shaped like a stretched spring, 
lying across on the top of the light and heavy chains (Fig. 2.10). Its N-terminus sits in a 
groove formed by the heavy chain while the C-terminus straddles on a saddle formed by 
R53 light chain residue AspL30, on one side hanging the side chain of ArgP440 and on the 
other side the side chain of IleP439. The electrostatic potential analysis shows that the 
antigen-binding site of R53 is negatively charged (Fig. 2.10D), complementing the 
positively charged epitope that harbors two positively charged residues, LysP432 and 
ArgP440. All complementarity determining regions (CDRs) involve in antigen binding 
except for the second CDR loop of the light chain (CDR L2). 
Antigen-antibody interaction of R53 
             The antigen-antibody interaction of R53 involves extensive hydrophobic contacts, 
with ~730 Å2 buried surface areas and multiple potential hydrogen bonds between the 
antibody and the epitope. The epitope of R53 is comprised of six hydrophobic residues, 
including AlaP433, MetP434, AlaP436, ProP437, ProP438 and IleP439, and they involve in several 
hydrophobic interactions (Fig.2.11). (1) A small pocket, formed by the phenyl ring of 
PheH31 and the side chains of ValH51 and ThrL96, accommodates the epitope residue 
AlaP433. (2) Another small pocket, formed by the phenyl rings of three tyrosines, TyrL32, 
TyrL92, TyrH97, and the backbone of residue ValL93, buries the Cb of AlaP436. (3) The third 
pocket, formed by the phenyl ring of TyrL92 and a hydrophobic residue AlaL28, buries the 
side chain of the epitope residue IleP439. (4) The side chain of TyrH97 of heavy chain 
stacks against ProP437 of the epitope. Interestingly, the second proline residue in the 
epitope, ProP438, has barely any contact with R53 (less than 5 Å2 of calculated contact 
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Figure 2.10. Structure of Fab R53/epitope complex. (A) A ribbon representation of the 
Fab R53 in complex with its epitope in a front view. The light, heavy chains, and the V3 
epitope were colored cyan, green and magenta, respectively (a coloring scheme kept 
throughout the manuscript, except where indicated otherwise). (B) A side view of the 
complex. (C) A top view of the R53/epitope complex looking at the antigen-binding site. 
The CDR regions are labeled and colored differently from the rest of Fab. Note that the 
epitope lies across on top of the light and heavy chains with its N-terminus of the epitope 
at the heavy chain side and its C-terminus at the light chain side. (D) A surface 
representation of Fab R53 colored according to its electrostatic surface potentials with red 
as the negatively charged and blue positively charged regions. The inset is the sequence 
of the peptide used in crystallization and the magenta region indicates the residues 
visualized in the crystal structure. 
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 areas). (5) The epitope residue TyrP435 has the largest contact with the antibody; its side 
chain stacks in parallel with the backbone of SerL95A of CDR L3. There are also hydrogen 
bonds between the epitope backbone and the antibody: for example, TyrL32 and TyrL92 of 
light chain with the backbone of the epitope residues ProP437 and IleP439, respectively; the 
backbone amide of AlaP433 with the side chain of heavy chain residue AspH51B; the 
backbone O of MetP434 with the amide of TyrH97; The OH group of epitope residue 
TyrP435 with the side chain of heavy chain GluH55 (Fig. 2.11).  
              The epitope of R53 harbors no acidic residues but two basic residues, LysP432 
and ArgP440. The side chain of LysP432 is located in an acidic environment formed by 
AspH51b and GluH55, while the side chain of ArgP440 forms salt bridges with two heavy 
chain residues AspL30 and GluL31 of R53 (Fig. 2.11). The R53 contacting residues, 
AM/IYAPPI, are highly conserved among clades A, B, C, D and AE (Fig. 2.10C).  
Spatial location of the R53 epitope in gp120 structures  
Examining all currently available gp120 structures in the RCSB Protein Data 
Bank (PDB), we found that the region of R53 epitope can form four distinct 
conformations (Fig. 2.12): i) the CD4-bound (represented by the first gp120 core 
structure; PDB ID 1GC1. The majority of the gp120 structures, including the unbound 
core structures, belong to this group), ii) the mAb b12-bound (PDB ID 2NY7), iii) the 
mAb F105-bound (PDB ID 3HI1), and iv) the mAb b13-bound conformations (PDB ID 
3IDX) (13, 16, 189, 190). In the CD4-bound conformation, this region extends from 
strand 21 of the bridging sheet to loop F. In the b12-bound gp120, the conformation of 
this region is similar to that of the CD4-bound gp120. But the bridging sheet is not 
completely formed due to the dislocation of the two strands (strands 2 and 3) from the 
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Figure 2.11. Details of the epitope binding in the Fab R53/epitope complex. (A) A stereo 
view of the antigen-binding site. The side chains of the key residues involved in the 
hydrogen bonding and van der Waals interactions (with contact areas greater than 10 Å2) 
are shown in sticks. Note that (1) three tyrosines and four negatively charged residues on 
R53 play a key role on binding the epitope, (2) C4 residue ArgP440 interacts with two 
acidic residues AspL30 and GluL31 from the light chain, and (3) the side chain of C4 
residue TyrP435 has a Van der Waals stacking with the antibody backbone, and its 
hydroxyl group forms a hydrogen bond with the side chain of GluH56 of the heavy chain. 
(B) A schematic of the antigen-antibody interaction. Hydrogen-binding interactions are 
indicated by dashed lines between the residues, while van der Waals contacts by 
eyelashes. Residues in solid ovals contribute to the interactions by their main chain atoms, 
and those in dashed ovals by their side chain atoms. 
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Figure 2.12 Location of the R53 epitope in the gp120 structures. The structure of R53 
epitope, together with Fab R53 (only the Fv region is shown), was superimposed onto the 
epitope region of gp120 structures with distinct C4 conformations, including the CD4-
bound (A), b12-bound (B), F105-bound (C) and b13-bound (D) gp120s (11, 25-27). The 
R53 epitope is colored in magenta, the gp120 is colored grey. Clashes between the 
antibody R53 and gp120 are indicated. The R53 epitope is accessible (without clashes 
between the antibody and gp120) only in the b13-bound conformation of gp120. (E) The 
location of the R53 epitope in the recent BG505 SOSIP.664 trimer. The R53 epitope 
region, located underneath V1V2/V3, was colored magenta while the rest of the three 
gp120s were colored grey, yellow, and orange, respectively. 
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inner domain. In the b13-bound and F105-bound gp120s, this region, as well as the 
region of strand 20, form coils. Superimposing the R53 epitope with the C4 region in 
these gp120 structures showed that the epitope is only available in the b13-bound 
conformation, i.e., R53 binding of the epitope does not cause any clashes with the rest of 
gp120 molecule. In recently appeared structures of the stabilized BG505 SOSIP.664 
trimer (19, 20, 194), the epitope region of R53 is covered under the variable loops V1V2 
and V3, thus completely buried in the interior of the trimer (Fig. 2.12E). 
Discussion  
               We have structurally defined for the first time a linear C4 epitope, 
representative of the epitopes of many CD4 blocking mAbs identified throughout the 
years. The epitope is located at the C-terminus of the bridging sheet and loop F. This 
gp120 region plays critical roles in gp120 functions, thus is highly conserved. Residues 
TyrP435, ProP438, IleP439, ArgP440 and GlyP441 in the R53 epitope region are critical for co-
receptor binding (24, 195). However, this region is also highly immunogenic, as indicated 
by many mAbs reported in the literature. On the other hand, most of antibodies targeting 
this region are not neutralizing or have only weak neutralization activities (150, 187, 191, 
196, 197), suggesting that this region is masked on gp120 trimer. Our data presented here 
provide a mechanistic understanding of a conformational masking of this region. In the 
prefusion complex, this region is buried by V1V2 and V3 loops that lay on top of it; thus 
this region is sequestered from access of any antibodies. In the CD4 bound state, this 
region is located on the surface of gp120 and is exposed (not shown). However, in this 
conformation the epitope of R53 is not available for the mAb to binding (Fig. 2.12), as 
the side chains of amino acids, such as TyrP435, that bind to R53 are buried and facing the 
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core of the molecule. Thus the high immunogenicity of this region may be derived from 
the side chains that are not accessible in the CD4 bound state, and these side chains are 
available in gp120 monomer as shown in the b13 bound conformation (Fig. 2.12).  
               The structure of R53 epitope can explain the mechanism of how this family of 
mAbs blocks the CD4 binding, i.e., as illustrated in Fig 2.14A, the CD4 bound 
conformation of gp120 is not compatible with R53 binding. In the other words, the 
binding of the CD4-blocking mAbs will prevent the correct formation of CD4 binding 
site, thus preventing CD4 binding to gp120. Structural understanding of R53 epitope also 
provides a way to design immunogens targeting this highly conserved functionally 
important epitope region. If an immunogen can induce antibody responses targeting the 
R53 epitope region from the side available in CD4 bound conformation, it will likely be 
more effective in neutralization against HIV-1. One way to design such an immunogen is 
to embed the R53 epitope region by a suitable protein scaffold that can structurally 
constrain this region in the CD4 bound conformation so that the right side can be 
presented to the immune system.  
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Chapter II, Section IV 
Structure basis to differentiate a broadly cross-neutralizing V3 mAb  
and other V3 mAbs targeting at overlapping epitopes 
Introduction 
The V3 region is the most immunodominant region on the Env protein. This 
region was identified in the early stages of HIV research as the “principle neutralizing 
domain” (PND) of HIV-1 (198). However, this idea was challenged by evidence of 
extreme sequence diversity within the V3 region. The V3 region usually has 35 residues, 
and is more conserved in comparison with other variable regions of gp120 (199). A 
highly conserved motif, Gly-Pro-Gly-Arg/Gln (GPGR/Q), is present at the tip of the V3 
region. Structural analysis of V3 in the context of gp120 core showed that it has three 
regions, including a base, stem, and crown (25).  
The V3 crown is around 13 amino acids in the middle of the V3 sequence and 
adopts a beta-conformation at the distal apex. Detailed structural analysis revealed that 
the V3 crown has four conserved structural regions, including an arch, a band, a 
hydrophobic core, and the peptide backbone (172). Interestingly, the majority of human 
V3 mAbs target the crown, and several of them have shown a 24%-39% breadth of 
neutralization against a panel of 41 tier 1 and tier 2 pseudoviruses from clades A, B, and 
C (200). This is quite similar to the breadth of some well-known broadly neutralizing 
antibodies, such as b12 and 2G12.  
Notably, in the RV144 trial, high-level anti-V3 IgG showed a significant inverse 
correlation with infection risk but only in vaccines that had lower level IgA and 
neutralizing antibodies (23). Neutralization responses in the RV144 trial were partly 
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mediated by V3 responses; two V3 crown-specific antibodies, CH22 and CH23, isolated 
from this trial, showed very potent but limited neutralization activity against tier 1 viruses 
(87). This new evidence suggests that V3 could also be an appropriate target for HIV 
vaccine development.  
 Here we present a panel of V3 crown-specific mAbs, mostly from one immunized 
rabbit. This panel shows a varying degree of neutralization capabilities, which will be an 
interesting study template for examining antibody affinity maturation.  
Results 
Rabbit immunization and generation of rabbit monoclonal antibodies  
One New Zealand White rabbit was immunized with three DNA expressing 
gp120AE through gene gun delivery, followed by a 5-valent protein intramuscular 
injection, that included UG21-9 from clade A, MW959 from Clade A, JR-FL from Clade 
B, 92US715 from Clade B, and Th14-12 from Clade B. Eight weeks later, just before 
termination for mAb production, the rabbit received an additional boost by one-time 
DNA immunization via gene gun and one-time protein immunization intravenously. The 
rabbit spleen was harvested at four days post final boost, and sent to a subcontractor for 
generation of hybridoma cells. 151 hybridoma cell lines were generated, and 11 
hybridoma cell lines were further selected to produce a stable monoclonal stage of 
hybridoma cell lines. Among these 11, we found four that targeted the V3 crown region.  
Different binding sites on V3 determined by peptide array 
The binding specificities of hybridoma cells were determined by ELISA using 
overlapping peptides from consensus M as coating antigens. Interestingly, four anti-V3 
mAbs were identified, named as R16, R73, R28, and R64 (Table 2.7). Two mAbs, R16 
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Table 2.7. Linear V3 peptide binding (OD450) with V3-specific mAbs determined by 
ELISA. The positive binding peptides were highlighted. 
  
  
76 
 
 
 
 
Figure 2.13. The cross reactivity of V3-specific rabbit mAbs with a panel of 
representative gp120 proteins. (A) ELISA showed RmAbs recognized most of selected 
Env gp120 proteins, including Clade A 92UG037, Clade B JR-FL, Clade C 93MW965, 
and consensus AE, but not Clade D 92UG021. (B) Binding affinity of rabbit mAbs to 
five selected Env protein determined by ForteBio Octet Qke system. Rabbit mAbs were 
immobilized on the chip surface, and the JR-FL gp120 protein was added in the testing 
solution. Rate constants Ka (equilibrium association constant), Kd (dissociation constant), 
and KD for rabbit mAbs binding to Env proteins were obtained by global fitting of the 
curves to the 1:1 binding model.  
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and R73, recognized three consecutive peptides, from #74 to #76. R28 recognized 
peptides #75 and #76, but bound  #76 stronger than #75. Interestingly, R64 recognized 
both #75 and #76, albeit in a weak manner, but strongly bound to gp120 Env, suggesting 
that conformational dependent epitopes may be involved. R56, another RmAb targeting 
the V3 crown, was isolated from another rabbit immunized with JR-FL DNA prime 
followed by JR-FL protein boost. R56 equally bound to both #75 and #76 peptides (191).  
Distinct binding profiles of V3 mAbs against cross-clade Envs proteins  
We cloned out the full-length heavy chain and light chain genes of the above four anti-V3 
mAbs and subcloned them into a mammalian protein expression vector. Individual 
RmAbs were expressed in 293T cells transiently transfected with these RmAb-expressing 
molecular clones. The distinct binding capabilities of RmAbs with cross clade Envs were 
observed by ELISA (Fig. 2.13A), although their footprints on the V3 region overlapped 
with each other. Both R16 and R73 bound to 92UG037 Env from Clade A, JR-FL Env 
from Clade B, 93MW965 Env from Clade C, and AE consensus Env from Clade AE 
equally well, but not to 92UG021 from Clade D. R64 showed strong recognition for Envs 
from JR-FL and AE consensus, with less recognition for 92UG037 and 93MW965 Envs, 
and a failure to recognize 92UG021 Env from clade D. Similarly, R28 recognized both 
Clade B and Clade AE Envs quite well but less so for Clade A 92UG037 Envs, and had 
no recognition for consensus AE.  However, different from the R64 binding profile, R28 
recognized Clade C 93MW965 less compared to 92UG037. R56, resulting from JR-FL 
immunization, appeared to bind to all four Envs except 92UG021 (191).  
Moreover, a more detailed analysis of rabbit mAb binding kinetics with the above 
Envs was conducted using Fortebio. Rate constants Kon, Kdis, and KD for individual 
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Figure 2.14. Protein sequence alignment of heavy and light chain variable regions of 
gp120-specific rabbit mAbs. The sequences are aligned to their corresponding putative 
germline genes. Framework regions (FR) and CDRs are indicated based on IMGT 
database (http://www.imgt.org/) nomenclature. Somatic mutated amino acids compared 
to germline sequences are highlighted in red and CDR3 region in blue.  
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Table 2.8. Characteristics of V gene of heavy chain and light chain of anti-V3 rabbit 
mAbs elicited by vaccination  
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RmAbs with Envs were determined (Fig. 2.13B). Consistent with the ELISA data, R16 
had very high affinity for the four Envs proteins from Clade A, B, C and AE, with a KD 
ranging from 0.19nM to 0.001nM. Fortebio was more sensitive to detect the interactions 
of R16 and 92UG021 from clade D, and their affinity was 14.1nM. We also detected 
strong binding between R73, R64, and R28 with Envs from Clade A, B, C, and AE, with 
similar binding kinetics. There was no detectable association between these V3 mAbs 
and Clade D Env.  
Genetic analysis and phylogenetic tree analysis for anti-V3 RmAbs 
To understand the genetic features of these anti-V3 RmAbs, the full length IgG 
heavy chain and light chain genes were sequenced. Germline usage, mutation frequency, 
and CDR3 length of the heavy chain and light chain V genes were determined using 
IMGT. For the heavy chain V gene, R16, R73, R64, and R28 use S44*01 as their 
germline; R56 comes from another immunized rabbit, adopting S40*01 as its germline 
family. Somatic mutation frequency is also critical for antibody affinity maturation. All 
of these antibodies showed low mutation frequencies, ranging from 7% to 10%, and 
CDR3 lengths around 6 or 7 amino acids. Light chain germline usage for each mAb is 
more diverse; distinct germlines were used and the mutation frequencies were 10-12%, 
with a CDR3 length of 10 amino acids (Table 2.8 and Fig. 2.12).  
Neutralization activities of vaccine-elicited anti-V3 RmAbs 
We sought to determine the neutralization capabilities for anti-V3 antibodies, 
including R56, R16, R73, R28, and R64. The RmAbs were sent to the Comprehensive 
Antibody Vaccine Immune Monitoring Consortium (CAVIMC) of the Collaboration for 
AIDS Vaccine Discovery (CAVD) (Seaman Lab at Harvard Medical School).  A panel of 
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Table 2.9. Neutralization IC50 (µg/ml) of rabbit MAbs by TZM-l assay  
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23 well-characterized pseudotyped viruses expressing Env from a wide range of primary 
HIV-1 isolates, including 19 tier 1 viruses (2 Clade A, 7 Clade B, 6 Clade C, 1 Clade AE, 
and 3 Clade AG) and 4 tier 2 viruses (2 Clade B, 1 Clade C, 1 Clade BC). Surprisingly, 
R16 neutralized 91% of the tested viruses at high potency, at geometric IC50 of 2.99µg/ml, 
whereas R73 neutralized 48% of the selected HIV viruses at a geometric IC50 of 
20.2µg/ml, R28 neutralized 39% of viruses at geometric IC50 of 23.3µg/ml, and R64 
neutralized 35% of tested viruses at geometric IC50 of 27.5µg/ml. R56 neutralized 39% of 
viruses in the panel at a geometric IC50 of 29.8µg/ml. 
It is very rare for R16, an antibody resulting from immunization, to have such 
broad and potent neutralization activities. Further, although peptide mapping suggested 
these 4 mAbs (R16, R73, R28 and R64) were focused on the V3 crown region, dramatic 
differences between their neutralization activities were observed.  
Structural features of antigen-antibody interactions of mAb R16 
 To gain a structural understanding of why mAb R16 had such superior 
neutralization activity, a crystal structure of its Fab in complex with a V3 peptide 
(V3conA) was determined (Fig. 2.14) by our collaborator, Dr. Xiang-peng Kong. The 
structure revealed that the epitope of R16 consists of 11 residues from LysP305 to PheP317 
(305KSIRIGPGQAF317) of the V3 crown region (Fig. 2.14A). R16 binds the V3 crown in 
cradle binding mode (Fig. 2.14B), similar to what was observed for another rabbit mAb, 
R56 (193). The R16 epitope has seven highly conserved residues, two hydrophobic 
residue Ilep307 and Ilep309, Glyp312ProP313Glyp314 on the crown arch, and Phep317 at C 
terminus ends of epitope. Three residues, IleP307, IleP309 and PheP317 play a dominant role 
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Figure 2.15. Structure of Fab R16 in complex with V3conA peptide. (A) Ribbon 
representation of a top view looking at the antigen-binding site of R16. The insert peptide 
sequence was used for crystallization and the residues responsible for interaction with 
R16 are highlighted in magenta. (B) Surface representation of Fab R16 colored according 
to its electrostatic surface potentials, with negative charged region in red and the 
positively charged region in blue. V3 is shown as a ribbon. (C) A top view of looking at 
the antigen-binding site of R16, with the epitope shown as a sphere with the amino acids 
noted. The exact epitope sequence is shown in below. The height of the residues is 
proportional to the binding intensity with R16. (D) Stereo view of the antigen-binding 
site.  
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Figure 2.16. Structural comparison of epitopes of R16 and R56. (A) Superimposition 
of V3 epitope bound to R16 (magenta) with that bound to R56 (Red).  (B) Sequence 
alignment of epitopes for R16 and R56. The height of residues was proportional to the 
binding intensity with corresponding antibodies.   
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in antigen-antibody interactions of R16 through extensive hydrophobic contacts  
(Fig.2.14B), which are highly conserved residues. These data provide a structural 
explanation of the broad recognition of cross-clade of the Envs observed in Fig.2.13.  
Structural comparison of mAbs R16 and R56 
The superimposition of epitopes from R16 and R56 shows that the majority of 
epitopes between these two antibodies overlap (Fig. 2.15). Although both antigen-
antibody sites adopted a cradle-binding mode, there are two major differences between 
the complex structure of R16 and R56. First, R16 targets the middle of the V3 crown, 
spanning 11 residues, 305KSIRIGPGQAF317, while R56 interacts with 10 amino acids at 
the N-terminal of the V3 crown, with the sequence of 303TRKSIHIGPG314. Second, R16 
primarily contacts the V3 crown via hydrophobic interactions, mostly via three 
hydrophobic residues Ilep307, Ilep309, and Phep317. In contrast, in addition to hydrophobic 
binding of IleP307, IleP309, R56 also interacts with a side chain, specifically with Argp304 
through a salt bridge. Therefore, the dominant residue responsible for this major 
interaction shifted from Argp304 on epitope of R56 to the highly conserved Phep317 for 
R16, which explains the broad recognition of variant Envs by R16, and its broad and 
potent neutralization activities. 
Discussion 
Here we present four mAbs from one immunized rabbit that target the same V3 
crown region but with different Env subtype specificity, binding affinity and 
neutralization breadth, using another V3 RmAb R56 reported previously as the control 
(Chapter II Section I). A diverse repertoire of different subspecificities, even within just 
the V3 region, was observed from antibodies developed from one rabbit. R16 and R73 
  
86 
recognized the tip of the V3 crown, R28 recognized the C terminal of the V3 crown, 
whereas binding of R64 to Env protein might be more conformational dependent. Genetic 
analysis showed that all V3 RmAbs had an average degree of affinity maturation in terms 
of hypermutation and CDR3 length. They bound to cross-clade HIV-1 Envs protein, 
including Clade A, B, C, and AE, with variant for each mAb, indicating that V3 
antibodies tend to have broad recognition and strong binding to a wide range of Env 
proteins.  
Interestingly, R16 showed superior neutralization activity, not only against tier 1 
but also selected tier 2 viruses. At a IC50 less than 50µg/ml, R16 was able to neutralize 
91% of viruses at a concentration that is less than 50µg/ml, and can neutralize three out of 
four tier 2 viruses tested. In contrast, R56, another V3 crown-specific RmAb isolated 
from another rabbit, recognized only 39% of tested viruses and could not neutralize any 
tier 2 viruses. Furthermore, the geometric IC50 of R16 was 10-fold lower than that of 
R56. The structural comparison of R16 and R56 suggested that one amino acid change of 
their epitopes from charged Argp304 the highly conserved Phep317 might be responsible for 
this great improvement in neutralization potential. There are two common contacting 
residues, IleP307 and IleP309; however, R56 also recognized Argp304 through a salt bridge; 
in contrast, R16 binds to a highly conserved residue, Phep317 via hydrophobic interaction. 
This suggests that it is critical for V3-specific mAbs to recognize their cognate epitopes 
via optimal hydrophobic contacts. 
 For the first time, we isolated a vaccine-elicited V3-specific mAb that has broad 
and potent neutralization activities. This suggests that V3 is an appropriate target for an 
HIV vaccine and our vaccine strategy is effective in generating such high quality 
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antibodies. Our collaboration study with Zolla-Pazner also succeed in eliciting cross-
clade neutralizing responses against tier 1 and tier 2 viruses by a similar approach, 
namely gp120 DNA prime followed by V3-scaffold protein (201). Furthermore, V3 has 
become part of key neutralizing epitopes of recently isolated bNAbs. For example, 
PGT121-PGT123 binds to V3 base and N332 glycan (126); PGT128 recognizes an 
epitope, including the C terminal of V3 (127). Therefore, given optimal immunogen 
design and sufficient affinity maturation, elicitation of R16-like antibody responses to 
prevent HIV acquisition is achievable and potential promising.   
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Section V 
Diverse repertoire of rabbit monoclonal antibodies elicited 
 by a Clade AE gp120 immunogen 
 
Introduction 
 
HIV-1 subtype AE was initially isolated in Thailand and is currently the 
predominant circulating isolate in south and southeast Asia. In order to find an 
immunogen candidate from clade AE, we have screened a number of gp120AE Envs 
from primary immunogens; however, these Envs could barely induce neutralizing 
antibody responses. Instead, a consensus clade AE gp120 developed by our lab was 
found to induce potent neutralizing antibody responses against several tier 1 viruses 
(Table 2.10). More interestingly, we found that this PG9 was able to bind gp120AE. PG9 
is an antibody that preferentially binds to the trimer, suggesting that the quaternary 
epitope from a conserved region of V1/V2 and V3 presented on the trimer is accessible 
on this particular gp120AE. To understand the uniqueness of gp120AE and its induced 
antibody response, a rabbit was primed with a DNA vaccine expressing gp120AE antigen 
via gene gun and further boosted with a 5-valent gp120 proteins, including 92UG037, JR-
FL, 93MV965, 92UG021, and AE consensus. Twelve gp120AE-specific monoclonal 
antibodies were isolated from this immunized rabbit; four V3-specific mAbs were 
described in section IV. In this section, we will describe the other eight mAbs, including 
their binding epitopes, genetic features, binding cross-reactivity, and neutralizing 
activities.  
Results 
Different binding epitopes for gp120AE-elicited mAbs as determined through 
peptide array 
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  mAb binding specificities were determined by overlapping linear peptides ELISA 
using consensus M gp120 as the coating antigen (Table 2.11). We were able to categorize 
10 mAbs into four groups:  
1) Four mAbs, UMMS2-R16, UMMS2-R73, UMMS2-R64 and UMMS2-R28, targeted at 
the most immunogenic V3 crown, which has been discussed in section IV. 
2) Three mAbs, UMMS2-R80, UMMS2-R47, and UMMS2-R75, which are specific for 
the C terminal end of the C1 region. Both R80 and R47 target peptide #27, UMMS2-R80 
recognizes the C terminus end of C1, and UMMS2-R47 recognizes peptides spanning 
#25 to #27. UMMS2-R75 only recognize C1 peptides weakly.  
3) Two mAbs, UMMS2-R76 and UMMS2-R7, targeted the middle of the C5 region. The 
footprint of UMMS2-R7 is slightly larger compared to UMMS2-R76, as UMMS2-R75 
recognizes two peptides and UMMS2-R76 only recognize one peptide.  
4) There is no detectable positive peptide recognized by two mAbs, UMMS2-R31 and 
UMMS2-R9. Therefore, they could target conformational epitopes or some unknown 
linear sequence.  
ELISA binding shows broad cross-reactivity against Envs 
To determine the binding capacity of vaccine-elicited mAbs, five genetically 
distinct Envs from subtype A, B, C, D, and AE were used in an ELISA assay where 
gp120AE was the vaccine strain (Fig.2.17). For C1 mAbs, UMMS2-80 and UMMS2-47 
bound to all five Envs quite well, whereas R75 did not bind to all Envs well, especially 
not to 92UG021 (D). Interestingly, three C1 mAbs isolated from a JR-FL immunized 
rabbit could bind only to 92UG037(A) and JR-FL (B) (Fig. 2.4), suggesting C1 region 
from AE immunogen may induce antibody with broader reacting against this region (191).  
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Table 2.10 Neutralization activity of rabbit sera primed with DNA vaccine 
expressing gp120AE consensus followed by a five-valent gp120 protein boost  
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Table 2.11. Binding specificities of vaccine-elicited mAbs mapped by overlapping 
peptide ELISA. (A) OD450 value of C1-specific mAbs against a panel of C1 linear 
peptides. The positive peptides were highlighted.  (B) OD450 value of C5-specific mAbs 
against a panel of C5 linear peptides. The positive peptides were highlighted.   
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Figure 2.17. Cross reactivity of rabbit mAbs with a panel of representative gp120 
proteins. RmAbs recognized most of the selected Env gp120 proteins by ELISA, 
including Clade A 92UG037, Clade B JR-FL, Clade C 93MW965, and consensus AE, 
but not Clade D 92UG021.  
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              For C5 mAb, R76 not only strongly recognized gp120 consensus AE, but also 
bound with gp120 proteins from 92UG037 (A) and JR-FL (B). It could not recognize the 
other two gp120s of subtype C and D (Fig.2.17). In contrast, R13, another C5 mAb from 
a JR-FL immunized rabbit, was able to recognize all 4 Envs except Env from Clade C 
(Fig.2.4). Two conformational mAbs, UMMS2-31 and UMMS2-9, appeared to recognize 
all five Envs, but UMMS2-9 had lower binding affinity for all Envs compared to 
UMMS2-31. 
Binding kinetics of selective rabbit mAbs for representative Envs 
To quantify the binding affinity of rabbit mAbs for different subtype Envs, C1 
mAb UMMS2-80, C5 mAb UMMS2-R76, and conformational mAb UMMS2-R31 were 
selected to determine KD for five Envs using Fortebio (Table 2.12). Consistent with 
previous ELISA results, UMMS2-80 showed the highest affinity for JR-FL gp120 and 
consensus AE gp120, with KD values of 6.06nM and 5.69nM, respectively. Interestingly, 
UMMS2-76 had high binding affinity for all five Envs, with highest affinity for JR-FL 
gp120 (KD value beyond 0.001nM) and a KD value of 0.302nM for consensus AE gp120. 
Conformational mAb UMMS2-31 had high affinity (nM range) for gp120 from B, C, D 
and AE, while slightly lower binding affinity (16.3nM) for gp120A.  
Genetic features of heavy chain and light chain of vaccine-elicited RmAb 
To understand the genetic features of these RmAbs, full length IgG heavy chain 
and light chain genes were sequenced. Germline usage, mutation frequency, and CDR3 
length for heavy chain and light chain V genes were determined using IMGT (Table 
2.13). In contrast to the observation that S40*01 had mostly germline usage in a JR-FL-
immunized rabbit (191), here we see a variety of germlines adopted, including S69*01,  
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Table 2.12. Binding affinity (M) of rabbit mAbs to five selected Env proteins 
determined by ForteBio Octet Qke. 
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Table 2.13. Characteristics of V gene of heavy chain and light chain of anti-V3 
rabbit mAbs elicited by vaccine  
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S44*01, and S42*01. This pattern could be the germline preference in individual rabbits,  
or it could be because different immunization strategies induce activation of different 
germlines. Interestingly, antibodies with similar epitopes also used different germlines, 
including two C5 mAbs and three C1 mAbs. Mutation frequency and the length of CDR3 
region are important parameters to evaluate the degree of affinity maturation of antibody 
development. We observed that UMMS2-R76 has a 21% mutation frequency in the 
heavy chain variable region, indicating a high degree of affinity maturation. Indeed, the 
affinity of UMMS2-R76 binding with gp120AE reached as high as 0.302nM. Besides, 
UMMS2-R31 has a long CDR3 (22 residues), which also binds broad gp120s, whereas 
CDR3 length in other mAbs is typically below 15 residues.  
Sporadic neutralization activities measured by TZM-bl assay 
To determine the neutralization capabilities of these mAbs, we conducted an in-house 
TZM-bl neutralization assay using a mini-panel of tier 1 viruses, against which only two 
mAbs had sporadic neutralization activities. We sent these two mAbs out to the Seaman 
Lab from the CAVD. A panel of 23 well-characterized pseudotyped viruses expressing 
Env from a wide range of primary HIV-1 isolates was used, including 19 tier 1 viruses (2 
Clade A, 7 Clade B, 6 Clade C, 1 Clade AE, and 3 Clade AG) and 4 tier 2 viruses (2 
Clade B, 1 Clade C, 1 Clade BC) (Table 2.14). Similar to what we observed in our in-
house assay, C5 mAb R76 neutralized clade AE virus, TH023.6, at a concentration of 
8.224µg/ml, clade C virus, MW965.26, at a concentration of 10.071µg/ml, and clade B 
virus, SF162.LS, at 27.524µg/ml. C1 mAb R75 neutralized Clade AE virus at 0.594µg/ml, 
Clade B, SF162.LS, at 1.920µg/ml, and Clade C virus, MW965.26, at 23.616µg/ml. 
Moreover, R75 neutralized Clade B viruses, BaL.26 and Bx08.16, at concentrations of  
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Table 2.14. Neutralization IC50 (µg/ml) of rabbit mAbs by TZM-bl assay  
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36µg/ml (for both). Neither mAbs could neutralize any tier 2 viruses and, overall, they 
had low level neutralization activities.  
Discussion 
 In this study, we examined humoral responses elicited by a HIV gp120AE 
vaccine by dissecting the epitopes and biological function of Env-specific monoclonal 
antibodies. Through gp120 AE vaccination, a diverse array of antibodies targeting 
different specificities was found, including V3, C5, C1, and conformational epitopes. 
Other epitopes, such as those in the V2 region, may have been missed since the mAbs 
were selected based on their potential neutralization capabilities before we learned 
RV144 study result. These recombinant mAbs have broad cross-reactivity against 
representative Envs, which not only bind to gp120 Env of the vaccine strain, but also 
recognize other Envs. This was also confirmed by determining binding affinities using 
Fortebio. Interestingly, antibodies targeting at the same epitope shared the similar cross-
reactivity against representative Envs from different clades. Unfortunately, unlike V3 
mAbs, only two out of seven mAbs showed low level neutralization activities and there 
was no detected neutralization activities for the other five mAbs .  
Despite low neutralization activities observed from these mAbs, these rabbit 
mAbs might also have other important biological functions. First, IgG Fcγ receptor 
(FcγR)-mediated inhibition of Abs plays an important role in anti-viral function. Abs that 
recognize an infected target cell via its Fab domain and FcγR on the effector cell via its 
Fc domain leads to lysis of infected cells, called antibody-dependent cellular cytotoxicity 
(ADCC). The RV144 trial has shown that low-level IgA and high level ADCC activities 
inversely correlate with infection risk (88). In addition to ADCC, various antibody 
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inhibitory functions may also contribute to HIV prevention, including phagocytosis, 
complement-mediated lysis, and transcytosis inhibition. Further, antibodies also have 
indirect anti-viral functions. They may modulate inflammatory and immune responses by 
induction of antiviral cytokines and chemokines and internalization of immune 
complexes for T cell presentation. Such assay systems to test these other potential 
biological functions of rabbit mAbs are yet to be established. For example, our lab 
recently has established a chimeric rabbit Fab-human Fc technology platform which 
allow us to study above non-neutralizing protective antibody activities.  
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Chapter III 
Immunogenicity of HIV-1 Envelope proteins with 
unique N-glycan patterns 
Introduction 
    The modest protection elicited by vaccines in the RV144 trial suggests that Env 
protein is a key component for HIV vaccine development. Env protein is heavily 
glycosylated, and nearly 50% of its molecular weight consists of a heterogeneous 
population of N-glycans with diverse glycoforms. However, the impact of various 
glycans on Env conformation and on its immunogenicity is still unknown. In particular, 
the glycoform for optimal immunogenicity of the Env protein is yet to be elucidated. It is 
current practice to produce GMP-grade Env proteins in CHO cell lines, a process that 
yields a mixture of different glycoforms that is unknown whether they will be same as 
that found in humans.  
    GlycoFi, a biotech company fully owned by Merck & Co., developed a 
sophisticated glycol-engineering method to control the composition of carbohydrates. In 
human cells when N-glycans are modified from “high mannose” to the final “complex” 
pattern, each step is controlled by a unique enzyme. In contrast, in yeast, a different set of 
host enzymes produces dramatically different patterns of N-glycans. Production of 
“humanized” yeast cells includes elimination of some yeast endogenous glycosylation 
pathways by gene knockout and re-creation of the human glycosylation pathway via 
introduction of heterogeneous essential genes in ER and Golgi in the yeast (Pichia 
pastoris) (Fig.3.1) (202, 203).  Based on the specific sets of enzymes used in transfection  
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Figure 3.1. A flowchart overview of GlycoFi techonology. Glycoengineered yeast 
cell lines knocked out and introduced certain enzyme genes to control the glycosylation 
of protein expression.  
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with this system, mammalian recombinant proteins can be produced with well defined 
and more homogeneous patterns of N-linked glycans in yeast cells.  
       In the current study, we collaborated with scientists at GlycoFi, Inc. to produce 
and test the immunogenicity of HIV-1 JR-FL Env proteins with well-defined N-glycan 
patterns.  We produced Env protein from five “humanized” yeast cell lines with distinct 
glycoforms, including Man5, Man8/9, Man3, 2,6 sialic acid and terminal gal (Table 3.1). 
This will be the first time that the impact of N-glycans on the immunogenicity of HIV-1 
Env can be extensively analyzed.  Optimal modified N-glycan forms on Env will be 
identified for the induction of protective antibody responses in animal models.   
Results 
Glycan analysis of glycan modified Envs produced from glycoengineered yeast cells 
Mass spectrometry and high performance liquid chromatography (HPLC)-based 
quantitative N-glycan analysis for five GFI Envs was performed independently in both 
GlycoFi and lab of Dr. Lance Well and Dr. Michael Tiemeyer from University of 
Georgia. Both results are very consistent. GFI materials showed a dominant population of 
desirable glycoform modification (Fig. 3.2). Man3 Env had 66% of Man3, and 34% of 
Man4; Man5 Env had 98% of Man5; Man8-9 Env had 68% of Man8 and 27% of Man9; 
terminal gal Env had a 74% of galactose and 25% Man4-7; 2,6 sialic acid Env had 91% 
of sialic acid and 9% Man5-7. CHO-producing Env had a mixed population of glycans, 
which contains fractions of complex and various high mannose forms, none of which 
constitute more than 30% of the total N-glycan species. This suggested that highly 
homogenous pattern of N-glycosylation modified Envs have been successfully produced.  
Glycan modification may impact the conformation of gp120 protein 
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Table 3.1 The gp120 proteins expressed from GFI engineered yeast cell lines 
and their corresponding glycoforms. Symbols used for the structural formulae 
in this figure: green circle, mannose; blue square, GlcNAc; yellow square, 
galactose; red square, sialic acid. 
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Figure 3.2 MALDI-TOF mass spectrometry analysis of released N-glycans from 
glycoengineered Pichia and CHO. Symbols used for the structural formulae in this 
figure: green circle, mannose; blue square, GlcNAc; yellow square, galactose; purple 
square, sialic acid. 
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Figure 3.3. The exposure of key neutralizing epitopes on high mannose or complex 
Env protein. The binding capabilities of five Env modified with a homogenous 
population of single glycoforms with human mAbs were determined by ELISA. Five 
human mAbs were included, glycan-specific mAbs, 2G12 and PGT128, and CD4-related 
mAbs such as VRC01, b12, and Ig-CD4. CHO-producing Env protein was also included 
as control.  
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Figure 3.4. The exposure of linear epitopes on high mannose or complex Env protein. 
The binding capabilities of five Env modified with a homogenous population of single 
glycoforms with human mAbs were determined by ELISA. Four rabbit mAbs were used, 
targeting C1, V3 crown, C4 and C5 epitopes, respectively. CHO-producing Env protein 
was also included as control.  
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To determine the immunological features of novel Env antigens with modified N-  
glycosylations, both well-characterized human monoclonal antibodies (mAbs) and rabbit 
mAbs were utilized to evaluate their binding to Env protein. First, using ELISA, we 
showed that five N-glycan-modified immunogens have distinct binding profiles (Fig.3.3). 
Human mAb 2G12, a glycan-specific antibody (Ab), specific for terminal dimannose 
(Manα1,2Man), was able to bind to Man8/9 gp120, 2,6 sialic acid and terminal 
galactosylated Env, but failed to bind to Man5 Env. PGT128, the most potent broadly 
neutralizing antibodies (bNAb) in the PGT family, which specifically recognize the 
Man8/9 glycans on gp120, was also included into our analysis. As expected, PGT128 
only recognized Man8/9 and CHO-produced Env proteins but none of the other GlycoFi 
(GFI) materials. CD4bs-specific Ab VRC01, a potent neutralizing mAb, was able 
recognize all of the glycan-modified immunogens, although in a weaker manner 
compared to Env protein produced from CHO cells. Another CD4bs mAb, b12, which 
neutralizes 40% of HIV-1 viruses, was able to bind to sialylated and galactosylated Env, 
but not man5 or man8/9 Env proteins. These differences in binding may be related to the 
different ways VRC01 approaches the CD4bs. VRC01 can approach its cognate epitope 
on the functional spike with less steric hindrance than does b12 and, surprisingly, with 
less hindrance than the soluble form of the virus receptor CD4 itself; while b12 
approaches the CD4 contact region by more of a loop-proximal approach (204). Our data 
indicate that the CD4bs may only be partially conserved on these novel Envs.  However, 
the overall integrity of these novel gp120 proteins are well preserved based on assays 
using a larger panel of representative rabbit mAbs (discussed in Chapter III), specific for 
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C1, V3, C4, and C5 regions (Fig.3.4). The rabbit mAbs used in the current study bound to 
the glycan-modified Envs as effectively as they bind to CHO-producing Env proteins.  
To quantify the binding affinity of Env protein and mAbs, we used ForteBio, a powerful 
and user-friendly assay system; specifically, ForteBio Octet, was used for high 
throughput measurement of intermolecular interactions, including determination of 
association, dissociation, and KD values down to a picomolar range. ForteBio Octet uses 
the natural phenomenon of biolayer interferonmetry analysis; it is label free, and provides 
a rapid, real-time record of biomolecule interactions. This technology made it possible to 
further determine the binding kinetics of human mAbs and glycan-modified Envs (Fig. 
3.5). Glycan-specific mAb 2G12 showed higher affinity binding to Man8/9 Env protein 
(KD =0.0263nM), compared to CHO Env protein (KD =2.45nM), while its binding 
affinities to man5 and man3 Env protein were below detection. 2G12 bound to complex 
glycan (terminal gal and 2,6 sialic acid)-modified Env with ~10 fold lower affinity, 
compared to CHO protein. Consistent with our ELISA results, CD4bs-related mAb, 
VRC01, bound to all N-glycan-modified Env with slightly lower affinity, ranging from 2- 
to 20-fold, suggesting that the VRC01 epitope is preserved on these novel Envs.  b12, 
another CD4bs mAb, bound Man8/9 protein with 18-fold lower affinity compared to 
CHO protein, and it failed to bind to Man5 protein. For complex carbohydrate-modified 
Envs, such as terminal gal and sialic acid Envs, b12 could bind with 13-fold and 16-fold 
weaker affinity, respectively, compared to CHO protein. For Ig-CD4, the binding 
affinities of Ig-CD4 to Man5, Man8/9, and Man3 proteins were 60-fold, 80-fold and 12-
fold lower, respectively, compared to that of CHO (KD=2.64nM). For complex glycans,  
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Figure 3.5. Binding affinity for GFI Envs to key human Env-specific mAbs 
determined by ForteBio Octet QKe. Human mAbs were immobilized on the chip 
surface; GFI Env or CHO Env was added to the testing solution. (A) The binding kinetics 
of five human mAbs to serially diluted glycan-modified Env protein. (B) Summary of 
binding affinity KD for human mAbs binding to Envs, which were obtained by global 
fitting of the curves to 1:1 binding models. NB indicates “no binding”. 
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Ig-CD4 binds to terminal gal and sialic acid Env protein with 20-fold and 40-fold lower 
affinity, respectively, compared to CHO-Env protein.  
We further examined epitope exposure of CD4i antibody, 17b, on these novel  
Envs. To measure its affinity, first soluble CD4 (sCD4) was incubated with Env protein 
for 1 hour, and then 17b was used to test its ability to bind to Env protein after exposure 
to sCD4. We found that 17b binds to CHO, Man3, terminal gal, and 2,6-sialic acid Envs 
with similar affinities (KD=2.82nM, 5.42nM, 4.32nM, and 10nM, respectively). 
However, 17b recognizes Man5 and Man8/9 with 25- and 10-fold lower affinity, 
respectively, compared to CHO Envs. The lower affinity with Man5 and Man8/9 may be 
due to their poor binding ability toward sCD4.  
In summary, the data presented here indicates that the 2G12 epitope was 
preserved with Man 8/9, sialylated, and galactosylated Env, but not with Man5 or Man3 
Env. The CD4bs was partially preserved on glycan-modified Env proteins, but may not 
take the same conformation as CHO-produced gp120 protein.  
Evaluation of the quantity and quality of gp120-specific antibody responses elicited 
by different glycan modified gp120s 
           The immunogenicity of the above novel glycan-modified Envs was tested. In this 
study, only protein immunizations were used so that we could compare the 
immunogenicity of Env proteins directly without the interference of DNA priming. In 
pilot study, R-MK-01, Man5 formulated with alum was used to establish a baseline for 
our future study. Man5 Env and CHO-Env protein were formulated with adjuvant 
aluminum hydroxide and intramuscularly injected into rabbits four times, two weeks 
apart. Serum was collected at 2 weeks post the fourth immunization.  
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              The antibody profile of immune sera was carefully examined. First, all gp120 
protein immunogens elicited comparable levels of gp120-specific IgG antibody titer as 
detected by ELISA (Fig. 3.6). When CHO-Env was used as coating antigen, rabbit sera 
immunized with CHO-Env has slightly higher titer compared to Man5 immunized sera, 
while when using Man5 and deglysoylated Env as coating antigen, both groups had 
similar level of binding titer, suggesting that CHO-Env immune sera preferentially bind 
to homologous sugar modified Env protein. To determine the neutralization activities of 
immunized rabbit sera, a panel of tier 1 and tier 2 HIV-1 pseudoviruses produced from 
293T cells was tested in a standard TZM-bl assay. The rabbit sera were sent to the 
Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) of the 
Collaboration for AIDS Vaccine Discovery (CAVD) (Seaman Lab at Harvard Medical 
School).  A panel of eight Tier 1 and seven Tier 2 pseudovirus isolates covering different 
clades were chosen (Table 3.2). Data from the Seaman lab revealed that different 
neutralizing activities could be seen between sera elicited by Man5 gp120 protein and 
CHO-gp120 protein (Fig.3.7). Using alum as an adjuvant, Man5 gp120 protein was able 
to induce neutralizing antibodies against some sensitive isolates, but at a lower potency 
compared to CHO-gp120 protein-elicited sera. Tier 1B 6535.3 (Clade B), Tier 2 TRO.11 
(Clade B), AC10.0.29 (Clade B), Du422.1 (Clade C), ZM53M.PB12 (Clade C), 
0260.v5.c36 (Clade A), Q259.d22.17 (Clade A) and vaccine strain JRFL.JB (Clade B) 
were also included in the analysis but without neutralization any activity. 
          However, the above data could not rule out the possibility that all pseudoviruses 
were produced from 293T cells, in which the N-glycosylation pattern is more similar to 
that from a CHO cell expression system. The following studies were designed to  
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Figure 3.6. Env-specific binding titer in rabbits immunized with either Man5 Env or 
CHO Env. Total gp120-specific IgG was measured by ELISA in sera collected 14 days 
after the final protein boost, using CHO Envs, Man5 Env, and deglycosylated Env as 
coating antigens. There is no statistical significance between groups by student’s t-test.  
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Table 3.2. A representative panel of 15 pseudoviruses used for evaluating 
neutralization activities of immune sera. The viruses included two tier 1A, six tier 1B, 
and seven tier 2 viruses. The corresponding subtype of each pseudovirus is noted, ranging 
from subtype A to subtype C.  
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Figure 3.7. Neutralization activity of sera elicited by either Man5 or CHO-Env 
protein formulated with alum-based immunization against sensitive HIV isolates. 
Rabbit sera collected at two weeks post final protein immunization was tested for its 
ability to neutralize HIV isolates in a TZM-bl assay system, performed by CAVD 
Seaman laboratory. There is no statistical significance between groups by student’s t-test. 
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Figure 3.8. Neutralization activity of immune sera elicited by either Man5 or CHO 
Env protein formulated with alum-based immunization against glycan-modified 
HIV isolates. Rabbit sera collected two weeks post final protein immunization were 
tested for their ability to neutralize HIV isolates in TZM-bl assay system. The 
pseudoviruses SF162 and ss1196 were produced from 293T cells, and Man5 SF162 and 
Man5 ss1196 viruses were produced from GnTI-293S cells. *:  p<0.05 by Student’s t-
test.  
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investigate this possibility.  To determine whether pseudoviruses containing modified N-
glycosylation may be more sensitive to neutralization by rabbit sera elicited from high 
mannose gp120 proteins, we produced a series of pseudoviruses expressing only 
modified Man5, which are produced from GnTI-/- 293S cells. For the SF162 isolate, a 
significant reduction in NAb titer against Man5 SF162 relative to SF162 was seen with 
rabbit sera from the CHO-gp120; while the neutralizing potency of sera from the Man5-
gp120 group was similar for N-glycan-processed SF162 as observed for the normal 
293T-producing SF162 virus. More dramatically, sera from the Man5-gp120 group 
showed significantly increased NAb titers against GnTI-ss1196, compared to 293T-
ss1196; whereas sera from CHO-gp120 immunized rabbits exhibited similar NAb titers 
against GnTI-ss1196 as it did against 293T-ss1196 (Fig. 3.8). Similar results were 
observed with the NL4-3 isolate. These observations suggest that Man5-gp120 protein 
immunogens may preferentially induce NAb against high mannose-modified viruses. 
Epitope mapping with overlapping peptides for R-MK-01 rabbit immune sera 
           Distinct epitope specificities were observed between Man5-Env and CHO-Env 
proteins by using JPT high throughput peptide microarray technology, conducted by Dr. 
Tomaras’s Lab, which is part of the CAVIMC in the CAVD (23). Binding specificity of 
rabbit sera was tested against seven types of consensus HIV Env peptide pools and 
against six vaccine strains. Figure 3.9A shows the maximum binding of each region of 
Env protein, indicating the highest binding intensity to a single peptide within a specific 
epitope region. First, all rabbits developed strong cross-clade anti-V3 responses. Second, 
distinct antibody repertoire were identified between the Man5 protein groups and the 
CHO protein group. In particular, Man5 Env protein generated strong antibody responses  
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Figure 3.10. Neutralization activity of sera against sensitive HIV isolates elicited by 
either Man5 or CHO Env protein formulated with ISCOMATRIXTM based 
immunization. Rabbit sera collected at two weeks post final protein immunization were 
tested for their ability to neutralize HIV isolates in TZM-bl assay, performed by CAVD 
Seaman laboratory (* : p<0.05 by student’s t-test). 
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against C1.3, C1-V1 and C2.3 epitopes, responses that were weak in CHO-Env 
immunized rabbit sera; whereas CHO-Env was able to elicit a higher level of C4-specific 
antibody responses compared to the Man5-Env group.  
             We also detected low level V1V2 positive responses on peptide microarray, 
likely due to the fact that V2-specific recognition is conformational dependent. To further 
confirm whether we elicited a V1V2-specific response, scaffold protein gp70 derived 
from Feline leukemia virus envelope fused with V1V2 was used as a coating antigen in 
an ELISA assay. Man5 gp120 elicited higher JRFL V1V2-specific antibody responses, 
compared to CHO cell-derived gp120 (Fig. 3.9B).  
ISCOMATRIXTM enhanced GFI Env protein for induction of higher neutralizing 
antibody responses 
  For this study, we sought to determine whether an alternative adjuvant, 
ISCOMATRIXTM, could further improve the immunogenicity of Man5 Env protein. 
ISCOMATRIXTM adjuvant is by nature both a particulate and a saponin, which has been 
observed in vivo to induce IL-1B responses (205, 206). This adjuvant was also selected 
for our next generation HIV-1 polyvalent vaccine due to its ability to elicit higher titer 
bNAb with improved breadth against more primary HIV-1 viruses. Therefore, in our 
second animal study, we gave rabbits four immunizations of Man5 Env protein 
formulated with ISCOMATRIXTM to see whether this adjuvant might be optimal for 
glycan-modified materials. For Env-specific binding titers, we found that immune sera 
was more preferentially bound to each homologous N-glycan modified antigen. 
(Fig.3.10A). Similar to R-MK-01, CHO-Env immune sera had a higher binding titer 
against CHO-Env compared to Man5 Env immune sera. In addition, different from our  
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observation from R-MK-01, Man5 immune sera also had a higher binding titer against 
Man5 Env compared to CHO-Env immune sera, suggesting that this adjuvant did 
improve the immunogenicity of Man5 Env. Furthermore, there was a clear improvement  
in NAb activities with the rabbit sera that were elicited by Man5 gp120 proteins 
(Fig.3.10B).  
Rabbit sera elicited by Man5 JRFL gp120 elicited higher titer NAb against tier 1 
viruses (SF162, ss1196, and NL4-3) compared to the CHO-Env protein group. 
Meanwhile, one rabbit from Man5 gp120 generated NAb against tier 2 virus, SC422.8, at 
low titer, while rabbit sera from the CHO-gp120 group failed to elicit any neutralization 
activities against tier 2 viruses.  Our data confirmed that the glycan-modified gp120 
proteins produced in yeast cells are equal or more immunogenic than the original gp120 
protein produced in CHO cells, especially with the help of an optimal adjuvant such as 
ISCOMATRIXTM.  
 Fig. 3.11A shows the maximum binding intensity for each epitope from the R-
MK-02 study using JPT technology. First, similar to the R-MK-01 study, we observed 
that all animals developed strong cross-clade anti-V3 responses. Second, using 
ISCOMATRIXTM adjuvant, Man5-Env protein elicited higher IgG responses against 
additional regions compared to the CHO Env group, including C1.1, C1.2 and C2.3,. 
Moreover, Man5 protein elicited a higher level of V1V2-specific Ab responses than sera 
from the CHO-gp120 group (Fig.3.11). 
Man8/9 Env protein-induced glycan-specific humoral responses  
 
                In this set of studies, we further explored the immunogenicity of other high 
mannose Env proteins. Man8/9 Env proteins formulated with ISCOMATRIXTM were  
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Figure 3.12. Env-specific binding titer in rabbits immunized with either Man8/9 Env 
or CHO Env. Total gp120-specific IgG was measured by ELISA in sera collected 14 
days after the final protein boost, using CHO Envs and Man8/9 Env as coating antigen. *: 
p<0.05 and **: p<0.005 by Student’s t-test.   
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Figure 3.14. Neutralization activity of sera elicited by either Man8/9 or CHO Env 
protein immunization against sensitive HIV isolates. (A) Rabbit sera collected two 
weeks post final protein immunization were tested for their ability to neutralize HIV 
isolates in TZM-bl assay system, performed by CAVD Seaman laboratory. * : p<0.05 by 
Student’s t-test. (B) Neutralization activities of immune sera against either 293T-
producing viruses or with treatment with sugar inhibitor kifunensine.  
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injected into rabbits four times, one month apart. All proteins elicited comparable levels 
of gp120-specific IgG antibody titer as detected by ELISA (Fig. 3.12). Interestingly, 
gp120 protein with Man8/9 Env protein induced the highest binding titer in rabbit sera 
against the Man8/9 Env, while CHO-Env immunized rabbit sera had the highest binding 
titer against the CHO-Env protein. This suggests that N-glycan modification on Env may 
influence glycan-specific antibody responses.  
           To determine whether any specific Man8/9 humoral responses were generated, a 
Man8GlcNAc2 heavily glycosylated protein, Pst1, was used as the coating antigen in an 
ELISA binding assay (207). Pst1 is a non-HIV related yeast membrane protein that shows 
high affinity for 2G12(208). More importantly, although it cannot neutralize 
pseudoviruses produced from regular 293T cells, it is able to generate antibody that can 
neutralize Man8/9-modified pseudoviruses in rabbit. Fig. 3.13 shows that Man8/9 Env 
protein generated pst1-specific IgG responses, whereas hardly any detectable pst1-
specific Ab responses could be observed with CHO-Env immunized rabbits. 
Deglycosylation of pst1 abrogated binding of rabbit sera immunized with Man8/9 
proteins were used as a control.            
To determine the neutralization activities of immunized rabbit sera, a panel of tier 
1 HIV-1 pseudoviruses produced from 293T cells was tested in a standard TZM-bl assay, 
conducted by the CAVD Seaman Lab (Fig. 3.14A). The sera of rabbits immunized with 
Man8/9 Env had the higher titer against sensitive viruses SF162 (Clade B) and 
MW965.26 (Clade C) when compared to rabbit sera induced by CHO-Env. Man8/9 also 
elicited decent levels of neutralizing activities against Tier 1b viruses, including Bx08.16 
(Clade B), BaL.26 (Clade B), ss11961.1 (Clade B), but reduced level of neutralizing  
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Figure 3.15. Epitope specificity of immune sera elicited by either Man8/9 or CHO 
Env protein.  Rabbit sera collected two weeks post final protein immunizations were 
tested for their epitope specificity, especially against linear epitope and V1V2 region. (A) 
Maximal binding intensity of immune sera, Man8/9 Env (black) and CHO Env (white) 
against gp120 linear overlapping peptides. *: p<0.05 and **: p<0.005 by Student’s t-test. 
(B) V1V2-specific IgG response for immune sera from Man8/9 Env and CHO Env group 
(p<0.05).  
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antibodies was observed in CHO-Env induced rabbit group. Man8/9 was even able to 
neutralize Clade AG DJ263.8 at very low level while the other groups failed to do so.  
To further determine whether rabbit sera could become more sensitive to 
neutralize Man8/9 glycan-modified pseudoviruses, the above pseudoviruses were 
produced from 293T cells treated with α-mannosidase inhibitor Kifunensine (Kif). Kif 
inhibits Man9GlcNAc2 into Man5GlcNAc2, so that all pseudoviruses have only 
Man9GlcNAc2 at all utilized N-linked glycosylation sites (209). All rabbit sera showed 
increased neutralizing titers against both Kif-treated SF162 and ss1196 when compared 
to those from 293T cells (Fig. 3.14). This suggests that key neutralizing epitopes might 
be easily accessible due to a decreased presence of protective sugars. 
                Peptide microarray data performed by the CAVD showed a wide range of 
cross-clade responses against gp120 epitopes including C1, C2, V3, C4, and C5. In 
particular, strong N-terminal C1 region- and C terminal of C2 region-specific responses 
occurred in the Man8/9 Env group compared to the CHO-group. Man8/9 also induced 
higher N-terminal C5-specific responses compared to CHO-Env groups (Fig. 3.12A). 
Further, Man8/9 immunized sera showed strong IgG responses against the V1V2 region 
compared to CHO-Env protein (Fig. 3.15B). 
Complex glycan-modified Env induced higher neutralizing activities 
 In addition to high mannose, complex and hybrid sugar is also a target of bNAbs 
(129). In this set of studies, we determined the immunogenicity of the remaining GFI Env 
proteins, including Man3, terminal gal, and 2,6-sialic acid Env protein. Using CHO-Env 
and three other GFI Envs in ELISA, I was able to detect the binding titer of Envs (Fig. 
3.16). Either CHO-Env or GFI Envs produced overall comparable levels of binding titer  
  
128 
 
 
Figure 3.16. Env-specific binding titer in rabbits immunized with terminal gal, 2,6 
sialic acid, Man3, and CHO Env. Total gp120-specific IgG was measured by ELISA in 
sera collected 14 days after the final protein boost, using each immunogen as a coating 
antigen (**: p<0.005 by Student’s t-test).
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Figure 3.17. Neutralization activity of sera elicited by terminal gal, 2,6 sialic acid, 
Man3, and CHO Env protein immunization against sensitive HIV isolates. Rabbit 
sera collected two weeks post final protein immunization were tested for their ability to 
neutralize HIV isolates in TZM-bl assay system, performed by the CAVD Seaman 
laboratory. * : p<0.05 and ** : p<0.005 by Student’s t-test. 
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(no statistical difference), using either CHO-Env or GFI Env as coating antigen. CHO-
Env induced significantly higher binding titer compared to that from 2,6 sialic acid Envs, 
if using CHO-Env as coating antigen (p=0.001).  
Further, we determined the neutralization activities of immunized rabbit sera. All  
groups showed a high level of neutralizing responses against Tier 1a viruses SF162.LS 
and MW965.26 (Fig. 3.17). Three GFI Env proteins induced significantly higher 
neutralizing titers against four tier 1b viruses, including Bx08.16, BaL.26, ss11961.1, and 
DJ263.8 compared to the CHO-Env group. Only the 2,6 sialic acid Env group was able to 
neutralize the BZ167.12 virus. Interestingly, complex glycan-modified Envs (2,6 sialic 
acid and terminal gal) induced the highest level of NAb responses compared to other GFI 
cell line modified Envs, despite a lack of statistical significance. All immunized groups 
failed to neutralize tier 2 viruses, indicating that protein alone immunization still is not an 
effective approach to induce potent neutralization activities.  
 Similar to previous observations from Man5 and Man8/9 Envs, Man3, terminal 
gal, and 2,6 sialic acid Envs also induced antibody repertoire with diverse specificities, 
especially higher level of antibody against N terminal of C1, C terminal of C2, and V3 
region. Moreover, higher level of V1V2-specific antibody responses was also generated 
compared to CHO produced Envs (Fig. 3.18).   
Discussion 
      Given the significant demand for recombinant Env proteins for HIV vaccine 
development, a solid understanding of the quality of Env proteins with an optimal 
glycosylation pattern will guide the production of Env immunogens. In this study, we 
established a yeast-based expression system for functional Env proteins with humanized 
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N-glycosylation, which provide a highly efficient and less costly expression system for 
the production of more affordable HIV vaccines. 
      In this study, five different glycoform-modified Env proteins were evaluated for 
their antigenicity and immunogenicity. Three high mannose carbohydrates were included. 
The first, Man5GlcNAc2 (Man5), is a biosynthetic intermediate in the N-link 
glycosylation pathway. HIV-1 Env-derived infected PBMCs are almost entirely 
oligomannose (Man5-9GlcNAc2) with a predominant population of Man5GlcNAc2 (33), 
indicating a lack of processing by GnTI or any of the subsequent Golgi-resident glycan 
processing enzymes. Therefore, Man5 is the native glycoform when viruses are 
propagated in infected PBMC (210). The second glycoform is Man8/9, composed of the 
epitope of a few glycan-dependent broadly NAbs. 2G12 binds terminal Manα1,2 Man-
linked sugars moieties of high-mannose (Man8-9 GlcNAc2) with high affinity. PG9 and 
PG16 also depend on Man8/9 oligomannose, due to the fact that they show decreased 
neutralization sensitivity against pseudoviruses produced from GnTI-deficient 293S cells 
while showing enhanced neutralization with Kifunesine treatment (209). Further, PGT 
family antibodies (PGT125-128 and 130-131) bind specifically to Man8/9 glycans on 
gp120 and potently neutralize cross clade viruses.  The third glycoform, Man3, is the 
simplest glycan and has the minimal core structure for oligomannose. With a 
homogenous population of Man3, Envs have lower glycan “layer” compared to hybrid or 
complex glycan-modified Envs, which may allow for potential exposure sites for broadly 
NAb epitopes. 
       Two complex N-glycan types were also included. The first is a complex human 
biantennary structure with terminal galactose. One study showed increased neutralization 
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activity and T cell responses elicited by gp120 by enzymatic replacement of sialic acid on 
these carbohydrate chains with alpha-gal epitopes (211, 212). Anti-gal epitopes can bind 
the natural anti-Gal antibody (present in all humans as 1% of IgG), and thus form 
immune complexes, when injected as a vaccine into humans. It was considered that 
gp120 expressing alpha-gal epitopes lead to enhanced effective antigen uptake by 
antigen-presenting cells, due to the interaction between the Fc portion of the antibody and 
Fcγ receptor on antigen presentation cells (APC). The other is α-linked 2,6 sialic acid, 
which is a human type N-glycan and is negatively charged with a relative large size. 
These two N-glycans are the end products during N-glycosylation biosynthesis; CHO-
produced Env protein has a dominant population of these complex N-glycans.  
          Antigenicity results from current studies suggest that CD4bs might not be exposed 
on glycan-modified Envs or if they are present, that may take on an alternative 
conformation since GFI Envs do not typically have high affinity for either Ig-CD4 or b12, 
especially when compared to CHO-derived Envs. However, this did not necessarily 
translate to poor immunogenicity for the CD4bs. For example, L40 and B33 are Env 
isolated from a single patient; they have low affinity for CD4 and high affinity for CD4, 
respectively. Surprisingly, L40 elicited broader NAb responses than B33 due to the 
recognition of CD4bs of Env (213). Indeed, all GFI Envs showed broader and more 
potent NAb responses compared to CHO-Envs. Epitope mapping indicated that GFI Envs 
tend to have a diverse range of linear epitope specificities, whereas there is a dominant 
population of V3-specific antibody responses from the CHO-Env protein immunized 
group. Further, GFI Envs also induced glycan-specific antibody responses, which might 
also enhance neutralization activities.  
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 Interestingly, the majority of GFI Envs induced higher V1V2-specific antibody 
responses than those induced by CHO-Env. This is also consistent with epitope 
microarray data, which showed comprehensive humoral responses generated against 
diverse linear epitopes. In particular, high mannose Envs (Man5 and Man8/9 Env) 
elicited the highest level of V1V2-specific response, which might be due to a decreased 
sugar lattice on the Env protein, leading to increased exposure of the V2 region. The 
V1V2 region gained much attention lately due to its correlation with vaccine efficacy in 
the RV144 trial (85). 
Another exciting finding was that carbohydrate-specific responses were also 
detected from GFI immunized sera. Carbohydrate is often considered poorly 
immunogenic (214). However, recent evidence shows that the human immune system can 
target either the glycan shield or specific N-glycan sites, followed by further affinity 
maturation and refinement to bNAbs, such as 2G12, PGT128, and PGT121 (37, 126, 127, 
215). In our study, we also found carbohydrate-specific antibody responses from Man8/9 
Env immunized sera, demonstrated by a strong recognition for pst1, an exclusively 
Man8/9 coated yeast cell membrane protein. Meanwhile, the deglycosylation of pst1 
leads to a loss of recognition by immune sera. Moreover, Man8/9-modified psedoviruses 
were more sensitive to Man8/9 Env immunized sera, but not to CHO-Env-induced sera. 
Evidence has showed that HIV-1 viruses produced from infected PBMC are high  
mannose (33). All of these studies indicate that glycoforms play a critical role in vaccine 
design, and an optimal N-glycan form would be able to induce strong carbohydrate-
specific antibody responses, which might further enhance neutralization activities in vitro 
and in vivo.  
  
135 
 Several glycoforms of interest have been identified. We showed that Envs with a 
homogenous population of certain glycoforms are immunogenic and can even elicit high 
NAb responses and V1V2 responses. In particular, Man8/9 Envs is capable of inducing 
glycan-specific IgG responses, which was shown to play an important role in virus 
defense. Further, complex glycans, such as 2,6 sialic acid and terminal gal, have superior 
neutralization activities and induce V1V2 responses better than CHO-producing Envs. It 
will be of great interest to explore the immunogenicity of a polyvalent vaccine that 
combines Envs with several distinct glycoforms in non-human primate models.  
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Chapter IV 
Sequential versus concomitant delivery of DNA and protein vaccines 
Introduction 
Initial work in our lab has shown that DNA prime-protein boost was more 
effective to elicit cross-clade neutralizing antibody responses compared to protein alone 
or DNA alone approaches (95, 96). Heterologous DNA prime-protein boost delivery not 
only may induce higher quantity antigen-specific humoral responses, but also generated 
an improved humoral response with broad neutralizing activity and higher avidity. 
Moreover, sera specificity against the CD4 binding domain of Env was more prevalent in 
the DNA prime-protein boost group whereas little was seen in the protein alone group. 
This result suggested that different immunization modalities lead to distinct antibody 
repertoires, allowing us to design new immunization delivery strategies to maximize the 
protective immune response.  
           Given our previous findings, in the current set of studies we sought to determine 
whether there is any beneficial impact to delivery both DNA and protein components at 
the same time throughout the entire immunization course, Recent studies from the 
Pavlakis group suggest that, compared to DNA prime-protein boost, co-immunization of 
DNA and viral particles might be more beneficial in generating a protective immune 
response against HIV acquisition (216). Further, they showed that co-immunization of 
DNA and protein induced similar cellular responses, but that these humoral immune 
reponses were of higher magnitude and greater longevity compared to those induced by 
DNA prime-protein boost in both mice and macaques (217, 218). However, there is a 
potential caveat in their study: their comparison was not based on equal amount of 
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immunogens throughout the immunization, as the co-delivery group received double dose 
of DNA and protein compared to those receiving sequential DNA prime-protein boost.  
In this study, we attempted to address these caveats by making a more stringent 
comparison of humoral responses elicited by different delivery regimens in both mouse 
and rabbit. To complete our questions about the impact of immunization order on the 
humoral response, in addition to a co-immunization DNA-protein group and DNA prime-
protein boost group, we also included a protein prime-DNA boost immunization regimen 
and also simultaneous delivery of vector DNA and protein. The primary outcomes of 
these studies were binding antibody titer at immunogenicity peak time point, long-term 
immunity, epitope specificity, and neutralization capability of immunized sera. These 
analyses indicated that the DNA prime-protein boost strategy was able to induce superior 
antibody responses with unique protective epitopes and better neutralizing activities 
against sensitive viruses compared to the other vaccination regimens.  
Results 
DNA prime-protein boost elicited high IgG binding titers in mice 
Five different immunization regimens were designed to study the impact of the 
delivery sequence of different immunogens on the humoral response upon in mice (Fig. 
4.1). Either DNA encoding JR-FL Env gp120 protein or matched JR-FL Env gp120 
protein were used as vaccines. Immunizations were given twice at four weeks apart, and 
either DNA or protein vaccines were injected intramuscularly (5 mice per group). The 
first group received 100µg DNA prime followed by 5µg protein boost, where the protein 
immunization was formulated with the adjuvant, alum. The second group received  
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Figure 4.1.Study design and immunization schedule for mice receiving JR-FL 
gp120-based immunizations. Mice were intramuscularly immunized with one of six 
vaccine regimens: A) once 100µg DNA prime plus once 5µg gp120 protein boost; B) 
twice simultaneous delivery of 50µg DNA and 2.5µg protein formulated with alum; C) 
twice simultaneous delivery of 50µg DNA and 5µg protein formulated with alum; D) 
twice 100µg DNA encoding Env gp120 protein; E) twice 5µg protein formulated with 
alum. “Priming” immunizations were administered at week 0, “boosting” immunizations 
were given at week 4. 
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simultaneous immunization of 50µg DNA and 2.5µg protein adjuvanted with alum twice. 
To prevent a chemical interaction between DNA and protein, we specifically injected the 
two vaccines into different legs of the animal. These two groups allowed for a direct 
comparison of humoral immune responses given the same vaccine dose during the 
immunization course. The third group received simultaneous delivery of 50µg DNA and 
2.5µg protein but without adjuvant twice. This helps address the question of whether 
DNA alone could function as adjuvant of protein. The other two control groups were 
twice 100µg DNA immunization and twice 5µg protein adjuvanted with alum, which 
were also used as controls in previous studies from our lab (95, 96). Blood was collected 
and the humoral immune responses were assessed at two and four weeks after the final 
immunization.  
At two weeks after the final immunization, the DNA prime-protein boost group 
(group A) showed higher titers compared to the protein alone group and the DNA- 
protein co-immunization without adjuvant group (Fig. 4.2A) (p=0.029 and p=0.032, 
respectively); however, the DNA prime-protein boost group showed a similar magnitude 
of binding as the co-delivery of DNA and protein with alum group, suggesting a critical 
role for adjuvant in the protein-based vaccine. Interestingly, DNA alone generated 
significantly higher antibody responses compared to protein/alum alone (p=0.044), 
suggesting that the DNA vaccine is highly immunogenic in mice. The humoral immune 
responses were further analyzed at week 8, 4 weeks post final immunization (Fig. 4.2B). 
Interestingly, each immunization regimen produced a unique antibody response profile. 
Three immunization groups, including the DNA prime-protein boost group, the  
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Figure 4.2. Env-specific binding titers in mice elicited by different vaccine regimens. 
(A) JR-FL gp120-specific binding IgG titer of rabbit sera collected 2 weeks after the final 
boost titer was measured by ELISA. (B) JR-FL gp120-specific binding IgG titer of rabbit 
sera collected 4 weeks post final boost were measured by ELISA. Statistical differences 
were determined using Student’s t test (*: p<0.05).  
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simultaneous delivery of DNA and protein adjuvanted with alum group, and the DNA 
alone group, showed a slightly decreased antibody titer  (0.94-, 0.65-, and 0.88-fold 
decrease, respectively) at week 8 compared to week 6. However, the protein/alum 
immunization group had a 1.65-fold increase in Env-specific humoral immune response 
at week 8 compared to that observed at week 6 and simultaneous delivery of DNA and 
protein without alum resulted in a 1.7-fold higher antibody response. DNA prime-protein 
boost had a significantly higher antibody response compared to DNA and protein/alum 
co-immunization (p=0.030) and compared to protein/alum alone (p=0.016).  
DNA prime-protein boost elicited comparable magnitudes of IgG binding titer in 
rabbit 
We further tested the impact of delivery sequence of DNA and protein-based vaccines on 
the humoral immune response of rabbits. To be consistent, JR-FL gp120 protein was used 
as the model antigen. In this rabbit study, five groups were included: A) twice 100µg 
protein prime followed by three times 200µg DNA boost; B) three times 200µg DNA 
protein prime twice 100µg protein boost; C) five times simultaneous immunization of 
120µg DNA and 40µg protein/alum; D) five times simultaneous immunization of 120µg 
empty DNA vector and 40µg protein/alum; E) five times simultaneous immunization of 
200µg DNA vector and 100µg protein/alum (Fig. 4.3). Of note, for immunization groups 
A-D, the same amount of protein and DNA encoding JR-FL gp120 protein or empty 
DNA vector was given during the entire immunization period. Consistent with our 
previous study in mice, DNA and protein were intramuscularly injected at two different 
muscle sites. Group E was included as control to compare with previously published 
results.  
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Figure 4.3. Study design and immunization schedule for rabbit receiving JR-FL 
gp120-based immunizations. Rabbit were immunized with one of four vaccine 
regimens: A) Twice 100µg protein, followed by three times 200µg DNA encoding gp120 
protein boost; B) Three times 200µg DNA encoding Env gp120 protein prime, followed 
by 100µg gp120 protein; C) five times simultaneous delivery of 120µg DNA and 40µg 
protein; D) five times simultaneous delivery of 120µg empty DNA vector and 40µg 
protein; E）five times simultaneous delivery of 200ug DNA and 100ug protein. 
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Peak immunogenicity antibody responses for individual rabbits were examined 
(Fig. 4.4). Specifically, geometric mean Env-binding titers for rabbits receiving protein 
prime-DNA boost had the lowest endpoint binding IgG titer (1:209499); while DNA 
prime-protein boost and co-delivery of DNA and protein had geometric mean Env-
specific IgG titers of 1: 452029. For co-delivery of empty vector and protein and co-
delivery of a double dose of DNA and protein, similar geometric mean Env-specific 
antibody titers were observed (1: 362863). This suggests that protein prime-DNA boost 
only induced transient high-titer antibody responses, which quickly diminished. 
Furthermore, DNA prime-protein boost was able to induce a similar magnitude of Env-
specific binding titers as co-delivery of DNA and protein/adjuvant when given the same 
antigen amount. Interestingly, increasing the amount of antigen given during co-delivery 
of DNA and protein impaired Env-specific antibody titers, suggesting that an optimal 
amount of antigen is critical to eliciting high magnitude of antibody titers.  
Longevity of HIV Env-specific humoral responses in rabbits 
We monitored the humoral immune response for an additional 12 weeks after the 
last vaccination. We observed persistent, high-level Env-specific antibody responses even 
after a long rest period after the last immunization. The DNA prime-protein boost group 
maintained high-level Env-specific binding geometric titers (1: 103849), which were 
significantly higher than observed in the co-delivery of DNA and protein group (1:52195) 
and the co-delivery of double dose DNA and protein group (1:52195) (Fig. 4.5). Further, 
we determined differences in the longevity of the Env responses among the groups by 
comparing the decline of the antibody titers from week 2 to week 14 after the final 
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immunization. Humoral immune responses from the DNA prime-protein boost group 
showed only a 0.64 log reduction; co-delivery of vector and protein showed a similar 
level of decline  (0.75 log), while protein prime-DNA boost and co-delivery of DNA and 
protein had greater declines (0.89 log and 0.94 log, respectively) over a 12-week period.  
Avidity of elicited antibody responses 
Avidity is an important property of an immune response to evaluate antibody 
quality. Non-neutralizing antibodies with high avidity contribute to protective efficacy 
against SHIV challenge in a non-human primate challenge study (219, 220). In the 
current study, the avidity of rabbit immune sera elicited by each immunization group was 
measured by how tightly the serum could bind the gp120 antigen in an ELISA assay (95). 
We found that serum avidity differed greatly between immunization regimens (Fig. 4.6). 
In the ELISA, we ran bound IgG from our test animals against an IgG standard and were 
able to calculate the amount of IgG displaced by increasing concentrations of sodium 
thiocynate (NaSCN). NaSCN most easily displaced sera from animals that received co-
delivery of vector and protein. Half of all bound IgG was displaced with an average of 
2.4M solution of NaSCN. When co-delivery of vector or protein was given, 50% of 
bound sera remained bound to the plate in 3.1M solution of NaSCN. Serum avidity 
increased further with the administration of co-delivery of DNA and protein 
immunization with 50% of sera remaining bound at a concentration of 3.8M NaSCN. 
Interestingly, co-delivery of a double dose of DNA-prime protein boost induced antibody 
with less avidity (3.0M NaSCN). The use of a DNA prime-protein boost approach 
improved this further to an average of 50% displacement at 4.8M NaSCN. Although a 
similar level of antibody quantity was detected, the quality of antibody responses varied.  
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Figure 4.6 Measurement of serum avidity elicited by varying order of DNA and 
protein-based immunizations. Sera were evaluated for their ability to be displaced from 
gp120 protein by increased molar concentration of sodium thiocynate (NaSCN). The 
minimal concentration of NaSCN to displace 50% of bound IgG was determined. 
Statistical differences were determined using Student’s t test (*: p<0.05).  
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The heterologous prime-boost strategy appears to induce Env-specific humoral responses 
with higher avidity.   
Epitope mapping of polyclonal sera using linear overlapping peptides  
To determine different antibody specificities among groups receiving different HIV-1 
vaccines, linear 15-mer peptides with an 11-residue overlap derived from clade B 
consensus gp120 sequence were used. Fig. 4.7A shows a heatmap of binding intensities 
against gp120 peptides for serum obtained at 2 weeks after the final immunization. 
Among them, V3 loop, C1 and C5 region of gp120 are the major targets for IgG 
responses in immunized animals. Interestingly, these three regions were also observed as 
the dominant response sites in the RV144 trial (23). Further, the DNA prime-protein 
boost group exhibited unique positive binding against the N terminal of C2, a site that 
was poorly recognized by the other three immunization groups (Fig.4.7B). In addition, 
the DNA prime-protein boost group elicited a less dominant V3-specific response 
compared to the other three groups (Fig.4.7C), with a significant difference compared to 
the co-delivery of vector and protein group (p=0.044). Further, the DNA prime-protein 
boost group induced higher-level antibody responses against the C1/V1 conjunction 
region when compared to protein prime-DNA boost and co-delivery of double dose DNA 
and protein group (p=0.004 and p=0.004, respectively). To our surprise, co-delivery of 
double dose of DNA and protein induced the lowest level of IgG response against several 
linear peptides compared to the other groups, including C1, C2, and C5 region, 
suggesting that repeated boosting of large dose of antigens might prevent the elicitation 
of diverse immune repertoire. Overall, the DNA prime-protein boost regimen induced 
responses with diverse specificities. 
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Figure 4.7. Distinct epitope specificities of immune sera elicited by varying order of 
DNA and protein-based immunizations.  Rabbit sera collected two weeks after the 
final protein immunizations were tested for their epitope specificity, especially against 
linear epitope and the V1V2 region. (A) Maximum binding intensity of immune sera 
against single peptide within an epitope region from individual immune rabbit sera. 
Regions that were strongly recognized by immune sera are shown in red. (B) Quantitative 
comparisons of epitope specificities against C1, C1/V1, C2, V2 and C5 region using 
immune sera. (C) Quantitative comparisons of IgG against V3 region (D) IgG response 
against gp70-V1V2 and cyclic V2 region. Statistical differences were determined using 
Student’s t test (*: p<0.05 and **: p<0.005). 
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Strong V2-specific humoral responses observed with DNA prime-protein boost 
 
In the RV144 clinical vaccine trial, which showed modest protection efficacy, 
extensive analysis demonstrated a positive correlation of protection with the presence of 
serum IgG binding Ab to variable region 2 (V2) (88). Since limited linear V2-specific 
humoral responses were detected in our overlapping peptide assay, we reasoned that 
antibody might preferentially recognize the conformational V2 region presented on Env. 
Therefore, we included fusion protein JR-FL gp70-V1V2 and A244 cyclic V2 peptides to 
determine V2 reactivity in rabbit sera. gp70-V1V2 is the scaffold protein carrying the 
first and second variable regions of the HIV Env glycoprotein fused with murine 
leukemia virus (MLV) glycoprotein 70 (gp70) (221), which helps to present V1V2 in its 
native conformation. Cyclic V2 is derived from isolate Case A2, a subtype B strain, 
which was used for the RV144 immune correlation analysis (222). As seen in Fig. 4.7D, 
the DNA prime-protein boost group generated the highest gp70-V1V2 IgG titer 
compared to the other four groups, significantly compared to protein prime-DNA boost 
(p=0.01) and the co-delivery of double dose DNA and protein (p=0.02). Further, both co-
delivery of DNA and protein and co-delivery of vector and protein induced significantly 
higher gp70-V1V2-specific antibody responses compared to protein prime-DNA boos 
immunization (p=0.006 and p=0.03 respectively).  
Neutralization activities of primary HIV isolates 
             To evaluate the neutralization activities of rabbit sera elicited by different vaccine 
regimens, rabbit sera was sent to Comprehensive Antibody Vaccine Immune Monitoring 
Consortium (CAVIMC), part of the Collaboration for AIDS Vaccine Discovery (CAVD) 
program supported by the Bill & Melinda Gates Foundation. The rabbit sera was tested 
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against a panel of 15 well-characterized pseudotyped viruses expressing Env from a wide 
range of primary HIV-1 isolates, including SF162.LS (Clade B), MW965.26 (Clade C), 
BaL.26 (Clade B), Bx08.16 (Clade B), DJ263.8 (Clade AG), and ss1196 (Clade B) for 
Tier 1 HIV viruses as well as TRO.11 (Clade B), AC10.0.29 (Clade B), Du422.1 (Clade 
C), ZM53M.PB12 (Clade C), 0260.v5.c36 (Clade A), A259.d22.17 (Clade A), and JR-FL 
(Clade B) for tier 2 viruses (Fig.4.8). For Tier 1a SF162.LS, DNA prime-protein boost 
had a geometric mean neutralization titer of 1:395; co-delivery of DNA and protein 
elicited an average neutralization titer of 1:308; the geometric mean NAb titer for co-
delivery of double dose DNA and protein was 1:195; while the other two immunization 
regimens, co-delivery of empty DNA vector and protein and protein prime-DNA boost 
induced neutralization titers of 1:128.4 and 1:155.2, respectively.  For another tier 1a 
virus, MW965.26 from Clade C, DNA prime-protein boost still had the highest 
neutralization titer (1:726.6) followed by co-delivery of double dose DNA and protein 
(1:639.2). This suggests that both DNA prime-protein boost and co-delivery of double 
dose DNA and protein were able to induce effective humoral responses against sensitive 
tier1a viruses.  
For Tier 1b viruses, sporadic neutralization activities against Clade B viruses 
Bal.26 and Bx08.16 were observed. For Bal.26, DNA prime-protein boost still induced 
the highest mean neutralizing titer (1:72.4) among the groups; while co-delivery of DNA 
and protein, co-delivery of vector and protein, and protein prime-DNA boost had 
neutralizing titers of 1:40, 1:56 and 1:29.8, respectively. Only 1 out of 5 rabbits from the 
co-delivery of double dose DNA and protein group was able to neutralize the Bal.26 
virus. For Bx08.16, protein prime-DNA boost elicited a significantly higher neutralizing 
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titer (1:76.4) compared to co-delivery of DNA and protein (1:10.6). DNA prime-protein 
boost and co-delivery of vector and protein had average neutralizing titers of 1:26.6 and 
1:28.8, respectively. Again, only 1 rabbit from the co-delivery of double dose DNA and 
protein group was able to neutralize Bx08.16. This suggests that co-delivery of double 
dose DNA and protein failed to generate effective humoral responses against relatively 
difficult to neutralize viruses. Previously observed high titer neutralizing activities 
against SF162 and MW965.26 may be mostly mediated by V3-specific antibodies. Only 
1 rabbit from the DNA prime-protein boost group and 1 from the protein prime-DNA 
boost group elicited weak neutralizing titers against virus DJ263.8 from Clade AG (1:21 
and 1:21, respectively). For ss1196, only weak neutralization activities were observed 
from 2 rabbits sera from the DNA prime -rotein boost group and 1 rabbit from the co-
delivery of double dose DNA and protein group.  
Among 8 tier 1 viruses, DNA prime-protein boost neutralized 75% of tier 1 
viruses, more compared to any other group. Both protein prime-DNA boost and double 
dose of DNA and protein neutralized 67.5% of tier 1 viruses, and co-delivery of DNA 
and protein and co-delivery of empty DNA vector and protein neutralized 50% of tier 1  
viruses. This suggests that DNA prime-protein boost was able to induce broad 
neutralizing activities against tier 1 viruses.  
Little neutralization activity was detected against tier 2 viruses. Only 1 rabbit 
from the co-delivery of DNA and protein group was able to neutralize homologous virus 
JR-FL at very low titer (1:21) (data not shown). 
Discussion 
Outcome after vaccination is influenced by a variety of factors due to the  
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Figure 4.8. Neutralization activity of sera elicited by varying order of DNA and 
protein-based immunizations against sensitive HIV isolates. Rabbit sera collected two 
weeks after the final protein immunization were tested for their ability to neutralize HIV 
isolates in TZM-bl assay, performed by CAVD’s Seaman laboratory. Statistical 
differences were determined using Student’s t test (*: p<0.05 and **: p<0.005).   
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comprehensive interplay between host immunity and each vaccine inoculation. For 
example, the order of administration of heterologous vaccines has a great impact on 
quantity and quality of antibody generation. Indeed, heterologous prime-boost could be 
considered a cause of  “original antigen sin” (223).  The initial priming events elicited by 
a foreign antigen appear to be imprinted permanently on host immune system. As a 
priming immunogen, DNA vaccine transduces a low level of antigen into the host cell, 
which can present naïve B cells with more authentic epitope structure in vivo. Later 
protein immunization, due to its high immunogenicity, can robustly drive and expand 
pre-existing epitope-specific memory B cells, during which, somatic hypermutation and 
affinity maturation occur and high affinity of boosted antibody responses with efficient 
antiviral functions are induced. In contrast, protein prime can induce robust primary 
immune responses, while DNA vaccine as a boost component, did not have a sufficient 
amount of antigen and therefore, cannot stimulate pre-existing memory B cells. Therefore, 
the protein prime-DNA boost regimen appears courter-productive since it might inhibit 
the efficacy of a boost vaccine. Indeed, this hypothesis is quite compatible with what we 
observed. In mice, at 2 weeks after the final immunization, we did not see any 
improvement in terms of antibody quantity from co-administration of DNA and protein 
compared to the traditional DNA prime-protein boost approach. At 4 weeks post final 
immunization, we found that DNA prime-protein boost had even higher antibody 
responses compared co-delivery of DNA and protein. Analysis of rabbit immunized sera 
suggested that DNA prime-protein boost induced high quality Env-specific antibody 
responses. Although they all induced a similar magnitude of Env-specific binding titers, 
more sustainable humoral immunity was observed after DNA prime-protein boost 
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immunization compared to other vaccination regimens. Moreover, antibody responses 
with higher avidity were observed after DNA prime-protein boost immunization. Further, 
a diverse repertoire of linear epitopes was found in the DNA prime-protein boost group, 
including C1, C1/V1 junction, V2, C2, and V3 regions. Interestingly, the RV144 clinical 
trial also showed robust antibody responses against the above regions (23). In the protein 
prime-DNA boost group, twice protein immunizations induced transient high titer 
antibody responses; however, three times DNA boost failed to further improve the 
magnitude of antibody responses. Long-term humoral immunity also waned quickly 
probably due to the low affinity of the Env-generated antibody response. As expected, 
antibody specificity predominantly focused on the V3 region by protein prime DNA 
boost approach, as V3 loop is the most immunodominant region when protein only was 
used in the priming phase. There was no detectable cyclic V2 specific-antibody response; 
neutralization potency was also quite low. 
              We also looked at co-delivery of DNA and protein. Given the same amount of 
antigen, we found that, different from protein prime-DNA boost, this regimen was able to 
sustain high-level antibody responses throughout the immunization. It induced a similar 
magnitude of binding titer at peak immunogenicity as was observed in the DNA prime-
protein boost group; however, the binding titer quickly waned at 12 weeks after the final 
immunization and was significantly lower than that observed in the DNA prime-protein 
boost group. Co-delivery of DNA and protein elicited a similar epitope profile of 
antibody specificity as DNA prime-protein boost, but a lower level of C terminal of C1- 
and N terminal of C2-specific antibody responses were seen. Furthermore, this regimen 
elicited immune sera with limited breadth of neutralization. This further confirms that the 
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overwhelming robust immune response at the priming phase failed to generate a high-
quality antibody response.  
           DNA vaccine may have a dual role as both an adjuvant through innate immune 
pathways and as a vector to deliver a subunit antigen. Therefore, in this study, we also 
included co-delivery of empty DNA vector and protein, in comparison with co-delivery 
of DNA and protein. We showed that co-delivery of DNA vector and protein induced 
similar peak level antibody responses and long-term humoral responses. However, 
antibody avidity was significantly lower compared to DNA prime-protein boost and co-
delivery of DNA and protein. Co-delivery of DNA vector and protein could only 
neutralize 50% tier 1 viruses, suggesting that an empty DNA empty could not improve 
the quality of antibody response compared to DNA vaccine. 
          Antigen dose also impacted the immunogenicity of vaccine regimens. It was 
previously reported that high-dose priming antigen can hinder a response to the boost 
inoculation and further impair long-term T cell memory response (224, 225). This may 
also apply to humoral immune responses. Co-delivery of double dose of antigen did not 
further improve either the quality or quantity of antibody responses. Env-specific binding 
titers diminished quickly at week 4 post final immunization, and only neutralized 67% of 
tier 1 viruses, compared to 75% neutralizing breadth with co-delivery of DNA and 
protein. Furthermore, the antibody specificity mapped by linear peptide microarray also 
showed the minimum IgG titer against C1, C2 and C5 region, with the only exception of 
V3 region.  
         More importantly, we did not see any benefit for simultaneous delivery of DNA and 
protein, as reported by the Pavlakis group, which showed that co-immunization of DNA 
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and protein induced humoral immune responses with a higher magnitude and greater 
avidity and longevity compared to DNA prime-protein boost in mice and macaques (217, 
218). Several factors might be responsible these divergent results. First, intramuscular 
injection of DNA vaccine was used in our study, and previous studies used 
electroporation to deliver DNA vaccines. Electroporation allows for more direct delivery 
of DNA molecules to target tissues so as to improve the efficiency of the DNA vaccine. It 
is possible that electroporation delivery of DNA could synergistically improve the 
immunogenicity of the protein immunization.  Second, in our study, to prevent further 
chemical interference of DNA and adjuvanted protein, we injected DNA into one leg of 
the animal, and administered protein into the other leg. Pavlakis’ group administered two 
different vaccine components at the same injection site.  Whether this has any effect on 
the fate of the immune outcome is yet to be determined.  Third, in our study, the same 
amount of antigen was used for DNA prime-protein boost group and co-delivery of DNA 
and protein group. While in other study co-delivery of DNA and protein group, double 
dose antigen amount was used, which might be responsible for higher magnitude of 
antibody response. However, we also included double dose co-delivery group, and there 
was still no improvement in terms of both magnitude and quality of antibody response. 
Fourth, animal species might also make a difference. In this study, both mice and rabbit 
were used as animal model, while other groups used non-human primate as animal 
model. Whether different animal models will have any impact on antibody response is yet 
to be investigated.  
         Overall, among all vaccine regimens we tested here, we found that the DNA prime-
protein boost regimen induced the best quality antibody response, in terms of broad 
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antibody specificities, avidity, longevity, and neutralization activities. Indeed, we have 
found that DNA priming resulted in a markedly more robust germinal center (GC) 
reaction compared to priming with protein alone, and that DNA priming also increased 
the percentage of GC-derived memory B cells that have undergone sufficient affinity 
maturation and Ig isotype switching (97). Such an underlying mechanism may be 
responsible for superior humoral responses induced by the heterologous DNA prime-
protein boost regimen.  
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Chapter V 
 
Antigenicity and immunogenicity of gp120 and gp160 in the context 
of heterologous DNA prime-protein boost 
 
Introduction 
Optimal envelope glycoprotein form for induction of HIV-1-specific neutralizing 
antibodies (NAbs) and functional antibodies is still yet to be elucidated. A major 
objective in the HIV vaccine field has been to develop a trimer Env mimicking the nature 
Env on HIV-1 viral particles. The recently reported BG505 SOSIP trimer has been shown 
to mimic the native state of the Env spike, which has high reactivity with all Env- 
specific broadly neutralizing antibodies (bNAb) but no detectable binding with non-NAb 
against CD4bs, CD4i, or the gp41 region (24). However, there was a disconnection 
between antigenicity and immunogenicity as this perfect trimer failed to induce Nab 
against heterologous viruses, as it had transient, positive NAbs against autologous Tier 2 
but not other Tier 2 viruses. There are additional designs of novel and modified Env 
immunogens. A unique one is the “full length single chain gp120-CD4 complex” 
(FLSC)–which was designed based on the idea that a conformationally constrained and 
stabilized gp120 Env is capable induce immune response against highly conserved gp120 
epitopes (221-223). Currently this novel Env immunogen is moving forward to be tested 
in humans. 
Historically, there are three major Env forms being tested for HIV vaccine 
research. The first is monomeric gp120 protein, which was included as a critical 
component in the RV144 trial, the first HIV-1 efficacy trial with modest success. It is 
safe and relatively easy to manufacture compared to other Env forms. The second Env 
form often employed is the gp140, the ectodomain of entire Env. Previous studies have 
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shown that both the gp120 and gp140 forms of envelope proteins have comparable 
immunogenicity, but gp140 trimers failed to induce stronger NAb responses compared to 
monomeric gp120 (224, 225).  Lately, a gp140 trimer with C-terminal T4 bacteriophage 
fibritin trimerization domains and polyhistidine motifs was produced from insect cells 
(226). These stable, homogenous trimmers have antigenic properties markedly different 
from those of monomeric gp120s derived from the same sequences (227). It has been 
tested in small animals and will be included in formulations moving into human studies.  
However there is no convincing data to support that neutralizing antibodies elicited by 
this gp140 timer is significantly improved against sera elicited by gp120 immunogens, 
because there is no significant Nab against tier 2 viruses (87, 227). 
The third, gp160 protein, is the native form of Env on the HIV-1 viral spike. It is 
unstable and technically difficult to produce as a recombinant product. Dr. Shiu-lok Hu 
group used the recombinant vaccinia virus system to express and further purified full-
length, membrane bound gp160 protein with cleavage site intact (228-230). Substantial 
gp160-specific antibody titers and neutralization activities were observed from gp160-
immunized rabbit sera. Further, priming with vaccinia recombinant expressing HIV Env 
gp160 followed by gp160 protein boost induced both a high magnitude of humoral and 
cellular responses in human (231). However, how to further optimize the immunogenicity 
of gp160 in the context of DNA prime and protein boost is yet to be determined.  
This prompted us to compare the immunogenicity of gp120 and gp160 Env in the 
context of DNA-protein vaccination. gp160 protein was generously provided by Dr. 
Shiu-lok Hu group. In the present study, we sought to do a comparative immunogenicity 
study using gp120 and gp160 (in both DNA and protein forms) derived from the JR-FL 
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isolate alternatively either as the priming or boosting immunogen. We evaluated the 
quantity of binding antibody against Env protein as well as other functional subregions at 
2 weeks post DNA prime and 2 weeks post final protein boost. Further, the neutralizing 
antibody titers against a panel of Tier 1 and Tier 2 HIV-1 viruses were determined. To 
elucidate the serum specificity elicited by different vaccine regimens, linear overlapping 
epitope mapping, V3 peptide absorption as well as CD4 binding site mapping were 
performed. 
Results 
Antigenic properties of trimeric Env gp160 and monomeric gp120 protein  
              To determine any significant antigenic differences between gp160 and gp120 
proteins, glycan-specific mAbs, CD4 binding site (CD4bs)-specific mAbs, and rabbit 
mAbs targeting linear and conformational epitopes were employed in ELISA and 
ForteBio assay to test their binding to either gp120 or gp160 proteins.  First, glycan-
specific mAb 2G12 targets at a specific high mannose patch. ELISA showed stronger 
2G12 binding to gp160 compared to gp120 (Fig. 5.1A). BLI assay using ForteBio 
instrument showed that 2G12 bound to gp160 with an affinity of 0.029nM, while it bound 
to gp120 with an affinity of 0.53nM, 24-fold lower compared to that of gp160. PGT128 is 
another bNAb that was able to recognize and penetrate the V3 glycan shield. It bound to 
gp160 protein more potently compared to gp120 demonstrated by ELISA (Fig. 5.1A). 
Binding kinetics also showed that PGT128 bound to gp160 with an affinity of 0.0192 nM, 
and to gp120 with a 61-fold lower affinity (1.18nM) (Fig. 5.1B). Although gp120 and 
gp160 had similar level of association rate when bound to PGT128, a slower dissociation 
rate of gp160 with PGT128 was observed compared to that of gp120.  
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            CD4 binding site (CD4bs) is one of the most conformation-dependent regions of 
the Env protein, which is also a key neutralizing epitope for a vaccine target.  The first 
probe we used was fusion protein Ig-CD4, which consists of the first two N-terminal 
domains of the CD4 molecules and the Fc region of human IgG1. The second mAb probe 
was b12, a moderate neutralizing antibody that can neutralize 40% of global circulating 
viruses. The third probe was VRC01, a recently isolated CD4bs bNAb. ELISA showed 
that all three CD4bs probes were capable of binding to gp160 with greater affinity 
compared to gp120 (Fig. 5.1A). Compatible with this ELISA result, the ForteBio Qke 
assay suggested that the binding affinities of these CD4bs probes interacting with gp160 
were higher compared to that of gp120. Ig-CD4 bound gp160 protein with very high 
affinity of 0.56nM while Ig-CD4 interacted with gp120 protein with 13-fold lower 
affinity. b12 reacted with gp160 with a high affinity of 0.163 nM, while b12 binding to 
gp120 had a 32-fold lower affinity (5.63 nM). VRC01 bound to both gp160 and gp120 
tightly, with affinities of 4.56nM and 16nM, respectively. The high binding affinity of 
these CD4bs probes bound to gp160 results from the slower off-rate of the gp160-CD4bs 
interaction, which could due to the avidity effect of the gp160 trimer (Fig.5.1B). 
               We also looked at exposure of linear or conformational epitopes on either gp160 
or gp120 proteins. A panel of rabbit mAbs including V3 mAb R56, C4 mAb R53, 
conformational-dependent mAb R52, and C1-specific mAb R13 was used. ELISA 
showed that they could bind to both gp160 and gp120 proteins with equal strength.  
               Overall, we found that these mAb targeting key neutralizing epitopes bound to 
gp160 trimer with higher affinity compared to gp120, ranging from 3- to 61-fold higher.  
On the other hand, rabbit mAbs with low to no neutralizing activities reacted with both 
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gp160 and gp120 proteins equally well, no matter whether they target either linear or 
conformational epitopes.  
gp120 DNA priming induced higher binding and neutralizing titers compared to 
gp160 DNA primng. 
               To investigate the immunogenicity of gp120 and gp160 as DNA priming 
immunogens, New Zealand White rabbits were immunized 3 times with either gp120 or 
gp160 DNA vaccines via gene gun (Fig. 5.2).  Sera were collected 2 weeks after the third 
immunization to evaluate Env-specific IgG and NAb responses. Despite having 3 
immunizations, rabbits that received gp120 as a prime (group A and group B) had 
significantly higher endpoint titers against gp120 Env protein (p=0.001) and gp70-V1V2 
protein (p=0.031) compared to gp160 DNA prime (Fig. 5.3A and Fig. 5.3B). As expected, 
low-level gp41-specific binding titers were significantly higher in rabbits immunized 
with gp160 DNA vaccines compared to those who had only gp120 DNA priming 
(p=0.0001) (Fig. 5.3C). Further, we were able to detect modest neutralization activities 
against the sensitive virus, SF162, and the less sensitive virus, SS1196, suggesting that 
DNA priming is very effective (Fig. 5.3D). Interestingly, after only three DNA priming 
immunizations, gp120 DNA priming elicited significantly higher neutralization titers 
against SS1196 than  gp160 priming (p=0.049).  
gp120 DNA prime elicited higher endpoint binding titers against gp120-based Env 
protein compared to gp160 DNA prime  
               Following the completion of three DNA priming immunizations, rabbits were 
boosted twice by either gp120 or gp160 Env protein (Fig. 5.2). Here we compare the 
immunogenicity of different combinations of gp120 or gp160 either as priming or  
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Figure 5.1. Antigenicity of gp160 and gp120 probed by key human and rabbit mAbs. 
(A) Head-to-head comparison of a panel of mAbs binding to gp160 and gp120 by ELISA. 
The antibody panel includes glycan-specific mAbs (2G12 and PGT128), CD4bs-related 
human mAbs (Ig-CD4, b12, and VRC01), rabbit V3 mAb (R56), C4 mAb (R53), 
conformational mAb (R52) and C1 mAb (R13). (B) Binding affinity, Kon (equilibrium 
association constant) and Koff (dissociation constant) for key human mAbs binding to 
gp160 and gp120, determined by a ForteBio Octect QKe system.  
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boosting immunogens (Fig. 5.4). First, gp120 prime-gp120 boost and gp120 prime-gp160 
boost induced significantly higher endpoint titers against JR-FL gp160 Env protein 
compared to the other two groups (Fig.5.4A). Further, we analyzed antibody response 
specificity by dissecting the different regions on the gp160 Env protein. gp120 prime-
gp160 boost group elicited the highest gp120-specific endpoint binding titers when 
compared to all other groups (Fig.5.4B). Significantly higher gp120 core-specific 
antibody responses were observed in the gp120 prime-gp120 boost group and the gp120 
prime-gp160 boost group compared to the other two groups (Fig.5.4C). Similarly, gp120 
prime-gp160 boost induced higher V1V2-specific endpoint binding titers compared to the 
two groups that received a gp160 prime. Moreover, gp160 prime-gp160 boost generated 
the highest level of gp41-specific antibodies, followed by gp120 prime-gp160 boost and 
gp160 prime-gp120 boost group.  
gp120 DNA prime elicited higher neutralizing titers against gp120-based Env  
protein compared to gp160 DNA prime  
            To elucidate the capability of vaccines to elicit NAbs, neutralization assays with 
rabbit sera from 2 weeks post final protein immunization were conducted by the 
Comprehensive Antibody Vaccine Immune Monitoring Consortium (CAVIMC) of the 
Collaboration for AIDS Vaccine Discovery (CAVD) program supported by the Bill & 
Melinda Gates Foundation. A panel of 14 well-characterized pseudotyped viruses 
expressing Env from a wide range of primary HIV-1 isolates, including 6 Tier 1 viruses 
and 8 Tier 2 viruses (Fig. 5.5A). Both gp120 DNA primed groups followed either by 
gp120 protein boost or gp160 protein boost showed the broadest neutralization  
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Figure 5.2. Study design and immunization schedule for rabbits. Rabbits were 
immunized with one of four prime-boost regimens: 1) JR-FL gp120 DNA prime plus JR-
FL gp120 protein boost; 2) JR-FL gp160 DNA plus JR-FL gp120 protein boost; 3) JR-FL 
gp120 DNA prime plus JR-FL gp160 protein boost; and 4) JR-FL gp160 DNA prime 
followed by JR-FL gp160 protein boost. 
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Figure 5.3. gp120 DNA prime alone elicited higher endpoint binding titers and 
neutralization titers compared to gp160 DNA prime. Rabbit sera were collected at two 
weeks post three times DNA immunization. Endpoint binding IgG titers against gp120 
protein (A), V1V2 region (B), gp41 region (C) and neutralization titers against Tier 1a 
virus SF162 and Tier 1b virus ss1196 (D) were measured by ELISA.  Statistical 
differences between groups were determined by Student’s t-test (*p<0.05, **p<0.005).  
  
169 
 
 
 
 
Figure 5.4. Both gp120 DNA primes elicited higher binding titer compared to both 
gp160 DNA primes. Rabbit sera were collected at two weeks post final immunization. 
Endpoint binding IgG titers against gp160 protein, gp120 protein, JR-FL core, V1V2 
region, gp41 region were determined by ELISA. Statistical differences between groups 
were determined by Student’s t-test (*: p<0.05, **: p<0.005).  
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activities (57%), among which, they can neutralize all Tier 1-tested viruses, and 25% of 
Tier 2-tested viruses (Fig. 5.5B). gp160 DNA prime-gp160 protein boost was able to 
neutralized 50% of viruses, while gp160 DNA prime-gp120 protein boost only 
neutralized 35.7% of viruses (Fig. 5.5B).  
               Both groups receiving gp120 DNA prime followed by either gp120 protein 
boost or gp160 protein boost showed higher NAbs against Tier 1a virus, SF162, with 
geometric titer of 1:6199 and 1:13329, respectively, while gp160 DNA prime followed 
by gp120 protein boost or gp160 protein boost had a geometric neutralizing titer of 
1:2777 and 1:866, respectively. The four groups also showed a similar trend of sensitivity 
to SF162 and other Tier 1b viruses tested here, including SS1196.1, BZ167.12, Bx08.16, 
Bal.26, and 6535.3. Of note, the form of Env immunogen used in the priming stage 
appeared to determine the final outcome of neutralization. Interestingly, if the 
neutralization capabilities between groups receiving gp120 DNA prime (group A and B) 
and groups receiving gp160 DNA prime (group C and D) were further compared, 
significantly higher neutralizing titers were observed in the gp120 priming groups 
compared to the gp160 priming groups against most of the tested Tier 1 viruses except 
BZ167.12 (Fig. 5.5C). However, there was no significant difference between the groups 
receiving gp120 protein as boost (group A and C) and the groups boosted with gp160 
protein (group B and group D), in terms of neutralization ability of the Tier 1 viruses 
mentioned above.  
                 Further, only few rabbit sera showed low level neutralization activities against 
3 out of 8 Tier 2 viruses tested, including JR-FL, QH0692.42, and TRO.11, but not the  
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Figure 5.5. gp120 DNA prime elicited higher neutralizing titers compared to gp160 
DNA prime. Rabbit sera collected two weeks after the final boost immunization were 
tested for neutralization ability in TZM-bl assay system. (A) Neutralization activities of 
immunized sera were determined against a panel of 14 viruses covering Tier 1 and Tier 2 
(left panel). Right panel is an overview of the percentage of total neutralized viruses 
given the different immunization regimens. (B) Neutralization titers against specific 
viruses for groups receiving different immunization regimens. (C) Neutralization 
activities of groups receiving either gp120 prime or gp160 prime and groups receiving 
gp120 boost and gp160 boost. Statistical differences between groups were determined by 
Student’s t-test (*: p<0.05, **: p<0.005). 
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other viruses tested, including AC10.0.29, SC422661.8, RHPA4259.7, REJO4541.67, 
and CAAN5342.A2.  For homologous virus JR-FL, 4 out of 5 rabbit sera from the gp120  
prime-gp160 boost group had neutralization activities with average neutralizing titer of 
1:56.2; 2 out of 5 rabbits in the gp120 prime-gp120 boost group were able to neutralize 
JR-FL with an average neutralizing titer of 1:5.6. Between the two groups receiving 
gp160 DNA prime, only 1 out of 5 rabbit sera from the gp160 prime-gp160 boost group 
could neutralize JR-FL viruses while no rabbit sera from the gp160 prime-gp120 boost 
group could neutralize this virus. For QH0692.42, two rabbits from the gp120 prime-
gp120 boost group were able to neutralize this virus with a mean neutralizing titer of 1:13, 
while two rabbits from the gp160 prime-gp160 boost group were able to neutralize 
QH069.42 with a mean neutralizing titer of 1:3.6. Another Tier 2 virus, TRO.11, was 
neutralized by only 2 out of 5 rabbit sera from the gp120 prime-gp160 boost group, while 
remaining resistant to all other immunized sera.  
Epitope mapping of polyclonal sera using linear overlapping peptide microarrays  
              To understand the linear epitope specificities of immunized serum, peptide 
microarrays were performed. Each array contained 1431 overlapping 15 amino acid 
peptides representing Env gp160 sequences from clades A, B, C, D, M, CRF1, and CRF2 
consensus and vaccine strains, which include 1.A244, 1.TH023, B.MN, C.1086, C.TV1 
and C.ZM651. The highest binding intensity to a single peptide within a specific epitope 
region was used as maximum binding value of each region of Env protein.  
             First, all animals from all groups developed strong IgG responses to epitopes in 
the C1 and V3 regions of HIV-1 gp120 of the different clades tested (Fig. 5.7A). There 
was no difference in total gp160 IgG linear epitope binding (sum of maximum binding 
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intensity for all epitopes) responses among groups (data not shown). Second, as expected, 
we observed a different IgG response against the gp41 subregion. Kennedy sequence is a 
loop at the C-terminal tail of gp41, and an early study showed that an antibody response 
against this region was able to neutralize viruses (226). Here we saw that gp160 DNA 
prime-gp160 protein boost and gp120 DNA prime-gp160 protein boost had the higher 
IgG response against gp41 Kennedy Sequence (Fig.5.6), compared to gp120 DNA prime-
DNA boost and gp160 DNA prime-gp120 boost. Beyond the gp41 region, to our surprise, 
we also noticed that gp160 DNA prime-gp160 protein boost group induced highest IgG 
response against the conjunction of the V4-C5 region, especially compared to gp160 
DNA prime-gp120 protein boost and gp120 DNA prime-gp160 protein boost (p=0.032 
and p=0.018, respectively). Further, a decreased C5-specific IgG response was elicited in 
gp160 DNA prime gp160 protein boost group when compared to other groups.  
Interestingly, anti-C5 IgG responses and gp41 Kennedy Sequence-specific IgG responses 
were discordant (Fig. 5.6B). Of note, we did not detect any positive signals against the 
V2 region using the linear peptide microarray (Fig. 5.6A), but when gp70-V1V2 scaffold 
proteins were used, V1V2-specific antibody responses was detected in all four groups 
(Fig. 5.4D). This assay outcome difference could be due to preferential recognition of the 
conformational antigen by V2-specific antibodies.  
Effect of V3 peptide adsorption on serum neutralization  
         Linear peptide microarray demonstrated robust cross-reactive V3-specific antibody 
responses among four groups, and V3-specific antibodies that were sensitive to several 
Tier 1 viruses, such as SF162. Therefore, we decided to determine neutralization 
capabilities of rabbit sera mediated by non-V3-specific antibodies. We addressed this  
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Figure 5.6. Linear overlapping peptide mapping for immunized sera.  (A) 
Accumulative signal intensity against Clade A, B, C, D, and AE consensus Env for 
immunized sera in HxB2 alignment for immunized sera.  (B) Maximum binding intensity 
for IgG antibody responses against V4-C4, C5 and Kennedy sequence region.  Statistical 
differences between groups were determined by Student’s t-test (*: p<0.05, **: p<0.005). 
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question by absorbing the V3-specific antibodies by incubating sera with 15-mer clade B 
consensus peptides spanning the entire V3 region. V3 peptide absorption of this serum 
resulted in overall reduction in neutralization activities against SF162, a virus very 
sensitive to V3-mediated neutralization (Fig. 5.8). After V3 absorption, previously 
superior neutralization activities against SF162 in the gp120 prime-gp160 boost group 
disappeared compared to the other three groups. Only the gp120 prime-gp120 boost 
group showed higher neutralization titers against SF162 compared to the gp160 prime 
gp120-boost group, suggesting gp120 Env might have induced other neutralizing 
antibodies that were absent from the other three groups. We also repeated the V3 peptide 
absorption in an attempt to neutralize two other clade B primary isolates, SS1196, and 
NL4-3 (Fig 5.8). We still observed a substantial reduction in neutralization activities 
against SS1196 and NL4-3. Different from SF162, the overall trend of neutralization 
among four groups remained the same as was observed prior to V3 absorption. This 
indicates that in addition to V3-specific antibodies, there were other functional antibodies, 
such as CD4bs antibodies or other conformational antibodies, that play an important role 
in the neutralization of more resistant primary isolates.  
High prevalence of CD4 binding site antibodies with gp120 DNA prime 
                In our previous studies, we found that the DNA prime-protein boost regimen 
induced significant levels of CD4 binding domain-specific antibodies (95, 96). Here we 
used a similar pseudoviral-based competitive binding assay to determine the presence of 
CD4 binding site-specific antibodies, as previously reported.  When the neutralizing mAb, 
b12, was used as a competitive binding target, all five rabbits from the gp120 prime- 
gp120 boost group were able to outcompete binding to b12 with highest mean dilution 
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Figure 5.7. Neutralization of Tier 1 viruses with V3 absorption. Neutralization 
activities of rabbit immune sera with or without pooled V3 peptide incubation. Black bar 
showed in-house neutralization activities in TZM-bl system. White bar showed pooled 
V3 peptides were incubated with rabbit immune sera for 1 hour and neutralization 
activities were measured. 
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titer of 1:64, while animals in the other three groups (gp120 DNA prime gp160 protein 
boost, gp160 DNA prime gp120 protein boost, and gp160 DNA prime gp160 protein 
boost) only sporadically elicited antibodies targeted to the CD4 binding site with a low 
titer (Fig. 5.9A). Again, 3 out of 5 animals from the gp120 DNA prime-gp160 protein 
boost and gp160 DNA prime-gp120 protein boost groups could outcompete with b12 
with a mean titer of 1:27 and 1:17.8, respectively. Finally, 2 out of 5 rabbits from the 
gp160 prime-gp160 boost group outcompeted with b12 with a lowest titer of 1:13.6. 
               To further confirm the presence of CD4bs-specific antibodies in immunized 
sera, we determined binding titers using immunized sera against either resurfaced, 
stabilized core (RSC3) protein or delta RSC3 (dRSC3) protein by ELISA. dRSC3 is 
modified based on RSC3 protein with a mutation that eliminates CD4 binding 
(RSC3delta371I) (116).  This pair of reagents were used to identify the CD4bs broadly 
Nab VRC01.  Using sera collected at 2 weeks after three times DNA prime, there were no 
differences in terms of antibody binding titers against RSC3 or dRSC3. However, both 
gp120 priming followed by either gp120 protein or gp160 protein boost induced 
significantly higher binding titers against RSC3 compared to dRSC3 (Fig 5.9B). 
Specifically, gp120 prime-gp120 boost had 1.84-fold higher binding titers against RSC3 
compared to dRSC3 (p=0.037), while gp160 prime-gp120 boost elicited 1.54-fold higher 
binding titer against RSC3 compared to dRSC3 (p=0.019). There was no significant 
difference in binding to RSC3 or dRSC3 for the two gp160-primed groups. This suggests 
that gp120 DNA prime followed by protein boost (either gp120 or gp160) leads to a 
higher population of CD4bs-specific binding antibodies, which may further be 
responsible for the higher neutralizing titer.  
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Figure 5.8. High prevalence of CD4 binding site antibodies in gp120 DNA primed 
groups. (A) The ability of serially diluted rabbit immune serum to outcompete binding of 
CD4bs mAb b12 to a JR-FL and VSV-G pseudotyped virus was measured. Competition 
titer is the serum dilution preventing 50% of pseudoviral binding to b12. (B) Binding 
antibody titer against RSC3 and dRSC3, a CD4bs mutant. Statistical differences between 
groups were determined by Student’s t-test (*: p<0.05, **: p<0.005). 
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Discussion 
                In this study, we assessed the impact of HIV Env form, either gp160 or gp120, 
based upon viral isolate JR-FL, to elicit humoral responses in rabbits. We inoculated the 
rabbits with DNA expressing cleavage site intact, cell surface presented gp160 trimer via 
gene gun for priming. As a control, we also included DNA priming groups that encoded 
gp120 protein. First, the DNA vaccination approach was able to express in vivo 
genetically encoded membrane-anchored gp160 or secreted gp120 protein, which 
maintained the native conformation of sensitive Env proteins compared to recombinant 
Env proteins manufactured by the traditional in vitro production and purification process 
(227). Second, as one of our boost immunogens, we were able to express full-length, 
membrane-bound Env gp160 protein with natural cleavage site intact in recombinant 
vaccina virus-infected cells. This way, we were able to mimic the natural form of full-
length Env spike to a larger degree compared to using a gp140 protein. Indeed, uncleaved 
gp140 trimers have been shown to be less stable and display aberrant conformations 
compared to the newly cleaved BG505 SOSIP.664 gp140 trimer (28). Two weeks after 
the DNA prime, higher antibody titers against gp120 and V1V2 region were observed in 
the gp120 DNA priming group when compared to the gp160 DNA prime group. In 
addition to binding antibody, the gp120 DNA priming group also elicited higher NAb 
against SS1196. This is consistent with previous reports, when gp120, gp140, and gp160 
DNA vaccines were compared directly in a rabbit study, gp120 was the most 
immunogenic in eliciting antibodies against Env protein, gp140 was less effective, and 
gp160 was the least immunogenic (228). 
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                Further, we boosted the DNA-primed Env-specific antibody responses by two 
additional intramuscular inoculations of either gp120 or gp160 protein, formulated with 
Incomplete Freund’s adjuvant (IFA). Interestingly, the quantity and quality of humoral 
responses elicited by four different vaccination regimens depended upon the form of 
DNA used during the priming stage. Compared to the two gp160 DNA primed groups, 
both gp120 DNA primed groups, generated higher antibody response against gp160, 
gp120, gp120 core as well as the V1V2 region, independent of the form of Env 
immunogens they were later boosted with. Moreover, gp120 DNA prime groups elicited 
higher neutralizing titers against Tier 1 viruses, compared to gp160 DNA-primed groups. 
For the first time, this evidence suggests that when using a heterologous prime boost 
strategy, DNA encoding gp120 protein, instead of gp160 protein, at an early stage 
directly impacts the fate of the immune response. It could be that DNA priming is more 
effective in eliciting memory B cells targeting corresponding conformational epitopes of 
priming immunogens. This is similar to the observation of “original antigen sin”, in 
which the immune system preferentially utilizes immunological memory based on the 
priming immunogen when a second slightly different version of a boosting immunogen is 
encountered. 
               Our earlier study showed that DNA prime followed by protein boost induces 
high frequency of CD4bs-directed antibodies compared to protein alone (96). Here we 
also sought to determine epitope specificity within immunized sera that might contribute 
to superior neutralization capabilities of gp120 DNA prime compared to the gp160 DNA 
prime. First, epitope mapping by virus capture assay suggested that gp120 DNA prime-
gp120 protein boost selectively elicited b12 competing binding antibodies. This was 
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further verified by determining binding titers against RSC3 and dRSC3 using immunized 
sera.  The gp120 DNA-primed groups showed high RSC3 binding titers compared to 
dRSC3 binding titers, suggesting that CD4 binding site-specific antibodies were 
generated in gp120 DNA-primed groups but less so in gp160 DNA-primed groups. 
Interestingly, there is no detected difference for CD4 binding site-specific binding titers 
among groups at DNA priming phase, suggesting that protein boost is essential to 
amplify such CD4 binding site-directed binding antibody response.  
It is intriguing to see that DNA prime with gp160 immunogen expressed in vivo 
which should mimic an Env trimer, did not elicit superior NAbs, compared to DNA 
primed with gp120, a monomer. Meanwhile, several studies suggested that immunogens 
designed to expose conserved regions did not enhance generation of bNAbs compared to 
immunogens that failed to expose those regions.  For example, gp140 trimer used for 
solving trimer cystal structures is selectively recognized by bNAbs, but not by non-
broadly Nabs. However, it only induced transient, positive neutralization activities 
against autologous Tier 2 but not other Tier 2 viruses (29).  The RSC3 probe, which was 
specifically designed to fish out CD4bs-specific monoclonal antibodies, failed to detect 
CD4-binding site NAbs. Another study used two closely related Env antigens with 
different antigenic properties to compare their immunogenicity (213). The Env with low 
CD4 affinity turned out to elicit broader NAbs with higher titer compared to the Env with 
high CD4 affinity. Moreover, superior NAb abilities were pinpointed to limited residues 
within or flanking the CD4 binding site. Coincidentally, all these data suggest a 
disconnection between antigenicity and immunogenicity.  
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               To summarize, this study provides key information to guide the design of 
optimal form of Env in the context of DNA prime and protein boost. Our data 
demonstrate that DNA priming was a critical stage that determined the immunogenicity 
outcome. Furthermore, gp120 DNA priming was able to effectively induce a high 
quantity of binding antibodies that recognized diverse linear and conformational epitopes 
on HIV-1 Env, thus might contribute to superior neutralization activities.  
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Chapter VI 
Materials and Methods 
HIV-1 gp120 DNA vaccine   
Gene segment coding for the gp120 region of HIV-1 isolate JR-FL was produced 
by PCR from parental full length JR-FL env genes (229). JR-FL gp120 gene was then 
subcloned into the pJW4303 DNA vaccine vector for the DNA priming phase of the 
immunization, as previously reported (92).  JR-FL gp120 DNA plasmid was produced in 
the HB101 strain of E. coli then purified using the Qiagen Plasmid Mega Kit (cat.no. 
12183). 
HIV-1 gp120 protein vaccines  
Recombinant HIV-1 gp120 protein vaccine was produced from Chinese Hamster 
Ovary (CHO) cells.  Secreted gp120 proteins from stably transfected CHO cell lines were 
harvested and purified over a lectin column. 
Rabbit Immunizations  
New Zealand White rabbits (6-8 weeks of age) were purchased from Millbrook 
Farm (Amherst, MA) and housed in the animal facility managed by the Department of 
Animal Medicine at the University of Massachusetts Medical School.   
For Chapter II mAb project, each rabbit was immunized with three times gp120 
DNA vaccine via a Bio-Rad Helios gene gun to the shaved abdominal skin (36 
µg/immunization), followed by twice intramuscularly boosted with gp120 recombinant 
proteins formulated with incomplete Freund’s adjuvant (IFA). After a 4-month resting 
period post three times DNA prime-twice protein boost, one rabbit from the study group 
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was boosted again with the same JR-FL gp120 DNA vaccine at week 28, followed by an 
intravenous 400 µg JR-FL gp120 protein immunization at week 32.  
In Chapter III, the rabbits were intramuscularly immunized with four times JR-FL 
gp120 proteins formulated with ISCOMATRIXTM adjuvant (CSL Ltd.). In Chapter IV, 
the rabbits were either intramuscularly immunized with JR-FL gp120 DNA or gp120 
protein formulated with aluminum hydroxide. In Chapter V, the rabbits were immunized 
with three times either gp120 or gp160 JR-FL DNA vaccine via gene gun, and boosted 
with twice either gp120 or gp160 JR-FL protein formulated with IFA. The JR-FL gp160 
protein was generously provided by Dr. Shiu-lok Hu from University of Washington. The 
gp160 protein expression and purification was described previously (75, 230). 
Rabbit hybridoma production 
Spleens were collected from sacrificed rabbits 4 days after the final protein boost 
and sent to a subcontractor (Epitopmics) for the production of hybridoma cells, according 
to the company’s established procedure.   
Enzyme Linked Immunosorbent Assay (ELISA)   
Supernatant from hybridoma culture was sent back to UMMS for screening of 
gp120-specific antibodies.  ELISA was conducted in 96-well microtiter plates (Corning, 
NY), which were first incubated with concanavalin A (ConA) (5 µg per well in 100 µl of 
PBS, pH 7.2) for 1 hour then coated with 100 µl of gp120 antigen (1 µg/ml) from 
transiently transfected 293T cell supernatant.  Plates were washed five times with ELISA 
Washing Buffer (EWB, PBS containing 0.1% Triton-X), and blocked overnight at 4°C in 
PBS containing whey dilution buffer (4% whey by weight) and 5% powdered milk.  The 
following morning, plates were washed five times in EWB.  Hybridoma supernatants or 
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serially diluted rabbit monoclonal antibodies were added to the wells in a volume of 100 
µL.  Plates were washed five times in EWB and incubated with 100 µL of biotinylated 
anti-rabbit secondary antibody (Vector Labs BA-1000) at 1.5 µg/mL for 1 hr at room 
temperature.  Plates were washed five times with EWB and incubated with 100 µL of a 
streptavidin-conjugated horseradish peroxidase (Vector Labs, cat.no. SA-5004) at 500 
ng/mL.  Plates were washed five times with EWB and developed for 3 min in 100 µL of a 
3,3’5,5’-tetramethylbenzidine substrate solution (Sigma, cat.no. T3405). The reaction 
was stopped with 25 µL of 2N H2SO4.  
For the peptide epitope assay, 96-well microtiter plates were coated with 
overlapping peptides of HIV-1 consensus subtype B Env at 4 µg/mL for one hour and 
blocked overnight. Hybridoma supernatants (100 µl) were then added to the peptide wells. 
Bound antibody was detected using an anti-rabbit IgG secondary antibody, as described 
above. 
Western Blot 
The JR-FL gp120 antigen used in the Western blot analysis was obtained from 
293T cells transiently transfected with JR-FL gp120 expressing DNA vaccine, as 
previously reported (96).  The gp120 antigens were subjected to SDS-PAGE and blotted 
onto a PVDF membrane, as previously described (98). Blocking of the PVDF membrane 
was done with 0.1% I-Block (Tropix, Bedford, MA). The membranes were incubated 
with hybridoma supernatants at 1:100 dilution for 45 min and subsequently reacted with 
AP-conjugated goat anti-rabbit IgG (Tropix, Bedford, MA) at 1:5000 dilution for 30 min. 
Membranes were washed with blocking buffer after each step. Western-light substrate 
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was then applied to the membranes for 5 min. Once the membranes were dry, X-ray films 
were exposed to the membrane and developed using a Kodak processor.    
Cloning and Expression of rabbit mAb IgG genes  
Full length heavy chain and light chain gene transcripts of rabbit mAb were 
isolated by one-step RT-PCR amplification of hybridoma cell RNA using primers 
specific to conserved regions of rabbit IgG genes. Antibody heavy chain and light chain 
gene products were separately cloned into a mammalian expression vector, pJW4303.  
For expression, equal amounts of heavy- and light-chain plasmid DNAs were transfected 
with 293Fectin into Freestyle 293F cells (Invitrogen).  The cell culture supernatant 
containing the secreted rabbit IgG was harvested 2 days after transfection and purified 
using protein A-Sepharose columns (GE healthcare).  
Analysis of rabbit mAb heavy chain and light chain sequences 
The cloned full-length heavy chain and light chain DNA fragments were 
sequenced by Gene-Wiz, North Brunswick, NJ. Sequencing analysis was conducted with 
the rabbit heavy chain and light chain genes of rabbit mAb.  ClustalW was used and the 
multiple sequence alignments were done to construct phylogenetic trees using maximum 
likelihood methods. The trees were then graphically edited (231).  Antibody germline 
usage, mutation frequency, and CDR3 length were determined by means of IMGT/V-
QUEST (232).  
Neutralization Assays  
In-house neutralization assays were done as previously described (233). HIV 
pseudoviruses were first produced and titrated.  Briefly, equimolar quantities of a plasmid 
expressing gp160 from the HIV-1 Env of interest and the pSG3∆Env HIV backbone were 
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co-transfected into HEK 293T cells.  At 48 hours after transfection, supernatants were 
harvested and cleared of cell debris by low speed centrifugation.  Produced pseudoviruses 
were titrated on TZM-bl cells using a two-fold increase above background levels of 
luciferase activity as a positive cutoff.  
For in-house neutralization assay, 200 TCID50 of pseudovirus was incubated with 
the rabbit sera or rabbit mAb for 1 hr at 37°C.  The virus/mAb mix was then added to 105 
TZM-bl cells in a final concentration of 20 µg/mL DEAE Dextran.  Plates were incubated 
at 37°C for 48 hours and developed with luciferase assay reagent according to the 
manufacturer’s instruction (Promega).  Neutralization was calculated as the percent 
change in luciferase activity in the presence of preimmune sera versus that of luciferase 
activity in the presence of immune sera [(Preimmune RLUs – Immune 
RLUs)/(Preimmune RLUs)] X100. 
 Selected RmAbs were tested in a high throughput neutralization assay using the 
PhenoSense assay at Monogram Biosciences as previously reported (South San 
Francisco, CA) (96). 
Additional neutralization assays were conducted at Duke University, and Beth 
Israel Deaconess Medical Center, Harvard Medical School, according to their established 
protocols as described in previous reports (92).  
Binding kinetics of rabbit mAbs  
The binding kinetics of rabbit mAb to five representative gp120s from HIV-1 
clades A to E were studied using a ForteBio Octet QKe instrument based on the Biolayer 
Interferometry (BLI) measurement in a 96-well format following the manufacturer’s 
instructions. Protein A coated tips (ForteBio) were loaded with rabbit mAbs at 10 µg/ml 
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diluted in the buffer of PBS/0.1%BSA/0.002%Tween 20.  After capture, a 1-min wash in 
loading buffer removed excess unbound Ab to establish a new baseline signal. The 
biosensor tip was then put into wells containing the selected gp120 proteins at three-fold 
serially diluted concentrations from 100 to 11 nanomolar (nM), in loading buffer. 
Rabbit mAb-gp120 association on-rate was measured given a 3-min interval, 
followed by putting the sensor in wells containing regenerating buffer (500mM 
phosphoric acid) to measure dissociation rate (off-rate) over a 10-min interval.  KD values 
were calculated as the ratio of off-rate/on-rate. The sensorgrams were corrected with the 
blank reference and fit with the software ForteBio Data Analysis package 7.0 using a 1:1 
binding model with the global fitting function (grouped by color, Rmax). 
Competitive binding assays 
The sheep gp120 C5-specific mAb, D3742 (Aalto Bio Reagents), was used at 2 µg/ml to 
coat ELISA plates. The plates were washed for five times and blocked with PBS 
containing 4% whey and 5% powdered milk, and gp120 proteins were then added to 
these pre-coated plates. After a five-time wash, the competitor rabbit mAbs or sCD4 were 
diluted in the blocking buffer and plated at 3-fold serial dilutions, starting at 500 µg/ml. 
After a 30-min incubation, 10 µl Ig-CD4 at 0.1 µg/ml was added to wells. Bound Ig-CD4 
was performed as ELISA assay described above. 
Virus capture competition.  
Virus Capture competition assay was performed as previously described (Vaine et 
al, Vaccine, 2010). Pseudovirions bearing the JR-FL Env and vesicular stomatitis virus 
(VSV) glycoprotein were produced with the pSG3∆Env backbone in 293T cells. 
Microtiter plates were coated with 50µl of monoclonal antibodies b12, 3074 and 2G12 at 
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5 µg/ml for 1 h at room temperature. Plates were then blocked in PBS with 3% bovine 
serum albumin overnight at 4°C. Rabbit hybridoma supernatants were incubated with 
pseudovirus correlating to 2.5 ng of p24/well for 1 h prior to the addition to the virus-sera 
mixture to the ELISA wells. The pseudovirus-sera mixture was then incubated in the 
ELISA wells for 3 h at room temperature. Plates were washed 5 times with sterile PBS 
and overlaid with 10,000 TZM-bl cells per well. Plates were then incubated for 48 h at 
37°C. Luciferase activity was determined per the manufacturer’s instructions (Promega). 
The percentage inhibition is reported when compared to PBS as negative control.  
The ability of rabbit sera to inhibit the capture of pseudovirions by CD4bs 
specific monoclonal antibody (mAb) b12 was investigated as described above. The 
capture of pseudovirions by HIV-1 monoclonal antibodies will be blocked if there is a 
competing antibody in the rabbit sera. Briefly, microwells were coated with mAb b12 (5 
µg/ml) overnight and were then washed and blocked with 3% bovine serum albumin in 
PBS. Graded dilutions of rabbit sera were added to the virus, and the virus-serum 
mixtures were then added to b12-coated ELISA wells for 3 h, followed by washing with 
TMZ-BL cells were overlaid, and 2 days later infection was measured by assaying 
luciferase. The reciprocal serum dilution that inhibited b12-mediated virus capture by 50% 
was recorded.  
NaSCN Displacement  
JR-FL gp120 was coated onto 96 well microtiter plates (Costar) at 1 µg/mL in 
100 µL of PBS for 1 hr at room temperature. Plates were then washed 5 times in PBS 
containing 0.1% Triton-X (EWB) and blocked overnight at 4°C in PBS containing 4% by 
weight whey (whey dilution buffer) and 5% powdered milk. Rabbit sera were then added 
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to the plate at either a 1:30,000 or 1:100,000 dilution and incubated at room temperature 
for 1 hr. Plates were then washed 5 times in EWB. NaSCN was then added at various (0, 
1, 2, 3, 4, 5 M) concentrations in PBS for 15 min followed by 5 washes in EWB. Bound 
IgG was detected as described above. Determination of IgG quantity remaining on the 
plates was done using linear regression analysis of a standard IgG curve (Southern 
Biotech). Data is reported as the NaSCN concentration required to displace 50% of IgG 
initially bound on the plate. 
Fab production and purification 
             Details of the rabbit mAb R53 productions and antigenicity characterizations 
have been published (191). The Fab fragment of R53 was prepared by papain digestion as 
described previously (234). Briefly, the IgG molecule was mixed with papain 
(Worthington) at a 20:1 ratio and 100 mM Tris (pH 6.8) with 1 mM cysteine 
hydrochloride and 4 mM EDTA. The mixtures were incubated for 1 hour at 37°C and the 
reaction was stopped by adding 10 mM iodoacetamide. The Fab fragment was separated 
from Fc and the undigested IgG by a protein A column and further purified by size 
exclusion chromatography. The concentration of the Fab fragment for crystallization is 
about 10 mg/ml. 
Crystallization, data collection, structure determination and refinement 
                 The C4 peptide was synthesized by Biomatik (Wilmington, DE) and dissolved 
in water to a concentration of 10 mg/ml. Preliminary crystals of Fab in complex 
with/without peptide were obtained by robot screening using the vapor diffusion hanging 
drop method. Well-diffracted crystals of R53 Fab in complex with peptide were obtained 
in a solution of 24% polyethylene glycol 6000, 0.1 M citric acid pH 5.0, and 0.02% NaN3. 
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Crystals of R53 Fab alone were obtained in a solution of 14% polyethylene glycol 8000, 
0.1 M HEPES pH 7.5, and 8% ethylene glycol. Crystals of Fab R53/epitope complex and 
Fab R53 alone were first soaked in the mother liquor with additional 20% glycerol (v/v) 
and 20% ethylene glycol, respectively, before placed in the X-ray beam. X-ray diffraction 
data of the crystals of Fab R53/epitope complex were collected at beam line X6A, 
National Synchrotron Light Source (NSLS), Brookhaven National Laboratory. Data of 
the crystals of R53 Fab alone were collected at the synchrotron beamline GM/CA CAT at 
the Advanced Photo Source (APS), Argonne National Laboratory. All data sets were 
processed using the HKL 2000 package (235), and structures were determined by 
molecular replacement, using as the starting model the structure of another rabbit mAb 
R56 we previously determined (PDB ID 4JO1). Cycles of refinement for each model 
were carried out in COOT and Phenix (236, 237). Contact areas were calculated by ICM 
(238). Final structural analysis was carried out using ICM and figures were generated 
using Pymol (239) and ICM. 
Linear peptide microarray 
               Peptide microarray was performed at Duke University according to their 
established protocols as described in previous reports (23, 240). Peptide libraries 
(designed by Dr. Bette Korber) consist of 15-mers overlapped by 12 amino acids were 
printed on glass slides, covering the full length of consensus gp160 Env from clade A, B, 
C, D, M, CRF01_AE, and CRF02_AE as well as gp120 derived from vaccine strain, 
including 1. A244, 1.TH023, MN, C.1086, C.TV1, and C.ZM651. Briefly, the peptide 
microarray was performed using a Tecan HS4000 Hybridization WorkStation.  All arrays 
were blocked with Superblock T20 PBS blocking buffer for 0.5 hour at 30°C with heat 
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inactivated plasma diluted 1:100 in SuperBlock T20. The arrays were incubated for 45 
minutes at 30°C with anti-IgG Cy5 secondary antibody (1.5ug/ml final concentration). 
PBS containing 0.1% Tween was used for each washes between all steps. Arrays were 
scanned at 635 nm using an Axon Genepix 4300 Scanner (Molecular Devices, 
Sunnyvale, CA, USA) at a PMT setting of 600, 50% laser power. Images were analyzed 
using Genepix Pro 7 software (Molecular Device). 
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Chapter VII 
Final comments and Conclusions 
 An effective prophylactic AIDS vaccine is still urgently needed to control the 
current HIV pandemic. The unprecedented, albeit modest, protection elicited in the 
RV144 trial suggested that substantial effort is still necessary to improve the vaccine 
efficacy. However, it remains unknown what are the desirable immune responses capable 
of providing protection against virus acquisition. Evidence from the recent immune 
correlate study of RV144 trial not only confirmed the importance of antibody responses, 
but also suggested that a successful HIV vaccine should induce a broad repertoire of 
HIV-1 epitope specificity and antibody subclasses with a wide range of antiviral 
mechanisms. Therefore, well-characterized vaccine-elicited antibody response in terms of 
magnitude and quality will be essential for rational design of HIV vaccines. 
I started to characterize the antibody response by isolation of vaccine elicited 
Env-specific rabbit monoclonal antibodies (RmAbs). Two dozens of RmAbs were 
isolated from immunized rabbits primed with DNA vaccines expressing gp120 protein 
following recombinant gp120 protein boost. They showed a broad diversity of Env 
epitopes focusing on C1, V3, C4, C5 and unknown conformational regions. Overall, 
these RmAbs showed high binding affinities, and a majority of them could cross-react 
with multiple clades of gp120 antigens, and several had quite potent and broad 
neutralizing activities against Tier 1 sensitive viruses. Specifically, RmAb R56 
recognized the immunodominant region in V3 crown, the epitope previously identified in 
HIV infected individuals. R16 shared a similar antigen-binding region of R56, with 
merely one amino acid shift from charged to hydrophobic residue. However, such 
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structural shift led to great improvement in neutralization activities in both potency and 
breadth. R20 targeted at C-terminal region of V3 region that overlaps the epitope of 
human broadly neutralizing Ab PGT128. The epitope of R53 within C4 region is a 
representative of CD4 blocking mAbs identified in mouse model during early HIV 
research. Overall, the rabbit mAb platform has provided us a great tool to dissect the 
specificity, biochemical and biological function of vaccine-induced antibody response at 
molecular level.  
The traditional hybridoma fusion technology was used to isolate antigen-specific 
rabbit monoclonal antibodies. This protocol requires around 3 month, and I only obtained 
two dozens of gp120-specific rabbit hybridoma cell lines. With current advancement of 
single B cell labeling and cloning technology, in future florescence labeled protein or 
peptide probes could be used to isolate the antigen-specific B cells by flow cytometry and 
the immunoglobulin genes could be cloned in a high throughput manner. These cloned 
mAbs will be further carefully characterized for their biochemical and biophysical 
properties and anti-viral functions. Further, development of next generation sequencing 
(NGS) technology also allows monitoring the selection, enrichment and maturation of 
immunoglobulin genes with sequences that have been identified as potentially yielding 
anti-viral functions. Such combination of single B cell identification as well as NGS of 
antigen-specific B cell heavy chain and light chain genes will provide valuable 
information about the quality of antibody response driven by vaccine. Moreover, if 
longitudinal samples at key time points post each immunization are collected, this will 
help understand the molecular pathway of affinity maturation of antigen-specific B cells. 
Such information will be highly useful to further guide us in designing better 
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immunogens and an optimal immunization schedule. 
In addition, with a variety of assay systems to evaluate the magnitude and quality 
of antibody response within polyclonal sera, we attempted to evaluate novel immungens 
or immunization regimens. Since heavily glycosylated gp120 Env protein is one of the 
critical components in HIV vaccine, we want to determine the impact of glycan shield of 
HIV Env on antibody responses. Six Env proteins modified with homogenous population 
of distinct glycoforms were produced from humanized glycoengineered yeast cell lines. 
The selective glycoforms are as follows: Man3, Man5, Man8/9, terminal galactose, and 
2,6 sialic acid. Antigenicity analysis showed that glycoforms did impact the exposure of 
key neutralizing epitope on these glycan modified Envs if compared to Env protein 
produced from traditional Chinese Hamster Ovary (CHO) cells. Specifically, glycan-
specific mAb 2G12 could not recognize Man3 and Man5-modified Env proteins, but the 
binding affinity of 2G12 to Man8/9 Env was improved compared to that of Env from 
CHO cells. CD4bs related mAbs also has decreased binding affinity with most of these 
glycan-modified Envs compared to CHO-derived Envs. Rabbit studies tested the 
immunogenicity of that these novel immunogens and Env protein produced from 
traditional CHO cells was used as control. The glycan-modified Envs are highly 
immunogenic and elicited gp120-specific antibody response. Most significantly, sera 
elicited by glycan modified gp120 protein immunogens revealed better neutralizing 
activities and an increased diversity of epitopes than sera elicited by traditional gp120 
produced in CHO cells. 
It is intriguing to observe that relative homogenous glycan modification on Env 
can improve the immunogenicity of Env. The mechanism of how N-glycans manipulate 
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the immune system and generate high quality of antibody response is yet to be 
determined. First, a comparison needs to be performed regarding glycan site occupancies 
for Envs produced from CHO cells and from glycoengineered yeast cells. If fewer glycan 
occupancy sites were observed from GlycoFi Envs, this might expose more critical 
epitopes, such as V1/V2 region, to immune system. Further, a dense shield of the uniform 
N-glycans might be capable of inducing antibody responses against the particular 
glycoform, as we observed from Man8/9 Env immune sera. It is not known that whether 
these glycan-specific antibodies contributed to better neutralization activities. It will be 
helpful if we can identify and further characterize the biological function of gp120-
specific monoclonal antibodies that involve glycan recognition. 
In present study, all the Envs modified with different glycans were based on JR-
FL gp120 backbone. To verify my findings, Env from other isolates could also be tested 
to see whether Env produced from glyco-engineered yeast cell strains still have a superior 
immunogenicity compared Envs produced from CHO cells. Further, several glycoforms 
of interest were identified, such as Man8/9 and 2,6 sialic acid. They both induce 
significantly higher neutralization activities and V1/V2-specific antibody response. It will 
be interesting to test the immunogenicity of a polyvalent vaccine consisting of several 
GlycoFi Envs modified with different glycoforms. I would expect that such a polyvalent 
vaccine might have synergistic effects to further improve humoral response compared to 
monovalent GlycoFi Env vaccine.   
RV144 trial has demonstrated the improved vaccine efficacy by the combination 
of two vaccines via distinct mechanisms. We aimed to define the impact of the varying 
delivery order of DNA and protein-based vaccine on the antibody response. In particular, 
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DNA prime-protein boost, co-delivery of DNA and protein, and protein prime-DNA 
boost were analyzed. In murine model, we showed that DNA prime protein boost was 
able to elicit highest level of Env-specific binding Abs compared to co-delivery DNA and 
protein. The immune rabbit sera further suggested the presence of quality differences of 
antibody response among groups. DNA prime protein boost group induced Env-specific 
persistent antibody response with high avidity and a broad repertoire of specificity. 
Although immunized group induced comparable level of neutralizing antibodies, DNA 
prime protein boost neutralized the most viruses compared to other group. All of these 
parameters indicated that DNA prime-protein boost regimen is a promising strategy for 
future vaccine development. 
While we have demonstrated that sequential delivery of DNA and protein-based 
vaccine generated the most effective antibody response, the optimal form of HIV-1 Env, 
either gp120 or gp160, at the prime and boost phase is still not clear.  Our data confirmed 
that at prime stage, DNA vaccine expressing gp120 protein was more immunogenic and 
induce higher magnitude of neutralizing antibodies against ss1196. This further directly 
determined the final immune outcome. At the peak immunogenicity point after final 
boost, both groups receiving gp120 DNA vaccines showed higher level of binding 
antibody against gp160 Env, gp120 Env, V1V2 region and CD4 binding site than gp160 
DNA primed groups. Further, gp120 DNA primed groups showed C4, C5, and V5 
focused humoral response, which is lacking in the sera from gp160 DNA primed and 
gp160 protein boost group. Moreover, both gp120 DNA primed groups showed broader 
and more potent neutralizing activities compared to gp160 DNA primed groups. Indeed, a 
collaboration study with us showed that DNA prime was able to re-orchestrate germinal 
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center response by rapidly developing T follicular helper cells and further recruit B cells 
into germinal center, a crucial process for antibody somatic mutation and affinity 
maturation (97). These results suggested that appropriate stimulation of immune cells at 
the early immunization event is essential and pivotal to generate high quality of antibody 
responses. 
While we have learned the uniqueness of DNA vaccine in induction of high 
quality of antibody response from this thesis work, the mechanisms of DNA vaccine 
priming immune system are not well understood. Indeed, priming with DNA activates 
more CD4+ T cells into T follicular helper (Tfh) cells and directs more germinal center 
(GC) B cells into memory cells, if compared to priming with protein-based immunization 
(97). This might be due to several reasons. First, similar to viral vector-based vaccine, 
DNA vaccine transfected into host cell, producing endogenous antigens which could be 
effectively presented to immune system by MHC class I and class II pathway. This will 
effectively induce both CD4+ and CD8+ T cell responses. Second, DNA vaccination also 
activates innate signaling pathways to regulate the antigen-specific adaptive immune 
responses, including AIM2 (absent in melanoma 2) inflammasome, a DNA sensor 
responsible for maturation of IL-1 and IL18 (241). Therefore, DNA vaccine is capable of 
providing a favorable microenvironment with sufficient Tfh cells and inflammatory 
cytokines, thus facilitating the affinity maturation of B cells. Future work should further 
understand how DNA vaccine orchestrates high frequency of Tfh cells and GC B cells, 
whether this process involves any well-characterized innate signaling pathways and the 
serum cytokine profile after DNA immunization.  
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In conclusion, in my thesis I characterized the quality of antibody response 
induced by different immunogens and immunization schedules, in the context of either 
mAbs or polyclonal sera. Through DNA prime-protein boost vaccination, a panel of 
antibody repertoire with diverse specificities and anti-viral function is observed. Further, 
I found that glycan modification on HIV-1 Env protein and appropriately priming the 
immune system have a great impact on the quality of antibody responses. The data 
presented here will be the guideline for rational design of next generation HIV-1 vaccine.  
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Preface to Appendix I 
Appendix I were taken from the following publication: 
Ruimin Pan, Jared M Sampson, Yuxin Chen, Michael Vaine, Shixia Wang, Shan Lu, 
Xiang-Peng Kong. Rabbit anti-HIV-1 monoclonal antibodies raised by immunization can 
mimic the antigen-binding modes of antibodies derived from HIV-1 infected humans. 
J.Virol. 2013, 87(18):10221. 
 
In this collaboration study, we provided the reagents rabbit monoclonal antibodies R56 
and R20. Dr. Ruimin Pan and Dr. Xiang-Peng Kong conducted the rabbit mAb structural 
analysis.
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Appendix I 
 
Rabbit anti-Env monoclonal antibodies raised by immunization can mimic the 
antigen-binding modes of antibodies derived from HIV-1-Infected humans 
Introduction 
Here we present structural analyses of two rabbit monoclonal antibodies (mAbs) 
against the third variable region (V3) of HIV-1 gp120. V3 plays a key role in virus entry 
into the host cell, participating in the binding of the CCR5 or CXCR4 co-receptor (14, 
242). V3 is about 35 amino acids in length, and the structure of full-length V3 in the 
context of the gp120 core showed that it can be divided into three regions, the base in the 
gp120 core (residues 296 to 300 and 326 to 331), the flexible stem (residues 301 to 303 
and 319 to 325), and the crown at the distal apex (304 to 318) (25, 172). The V3 crown 
can be further divided into three smaller regions, the arch of the beta hairpin of the V3 
crown (consisting of residues 312 to 315), the band (residues 304 to 305 and 317 to 318), 
and the circlet between the arch and the band, which is more genetically diverse than the 
other two regions (172). The amino acid sequence of the arch is often GPGR in clade B 
strains and GPGQ in non-clade B strains. 
               There are many anti-V3 mAbs derived from human patients, as well as from 
animal models other than the rabbit (243, 244). Most of the known anti-V3 mAbs are 
against the V3 crown; only a few of them target the C-terminal region, including a mouse 
mAb raised by immunization with a synthetic peptide (245). Several recently described 
highly potent human mAbs, including PGT128, are also against the C-terminal region of 
V3, as well as its associated glycans (118). Many of the anti-V3 mAbs are characterized 
by structural methods, including protein crystallography and the nuclear magnetic 
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resonance (NMR) method (118, 172, 246, 247). These structural studies of mAbs against 
the V3 crown showed that they have, in general, two antigen-binding modes. (i) In the 
“ladle” mode, the antibodies have a long CDR H3 (the handle of the ladle) interacting 
with the main chain of the N-terminal beta strand of the V3 crown and a pocket at the 
base of the CDR H3 (the bowl of the ladle) interacting with the apex beta turn of the V3 
crown. (ii) In the “cradle” mode, the antigen lies along a long binding groove resembling 
a cradle (172, 248, 249). The former is represented by human mAb 447-52D, and the 
latter is represented by several human mAbs, including mAb 2557, encoded by germline 
IGHV5-51 (172). 
                 We present here several Fab/epitope complex structures of rabbit anti-V3 
mAbs R56 and R20 that had been raised by immunization with gp120 of clade B strain 
JR-FL by using the DNA prime-protein boost regimen. The epitopes of R56 and R20 
have been mapped to the V3 crown and the V3 C-terminal region, respectively. By 
analyzing the antigen-antibody interactions of these mAbs and comparing them with 
those of human and mouse anti-V3 antibodies, we showed that immunization of rabbits 
with HIV-1 gp120 can elicit anti-V3 crown antibodies with a binding mode similar to that 
of human IGHV5-51 antibodies and that this immunization can also produce rabbit 
antibodies that target an epitope in the C-terminal region that overlaps the epitope of 
human mAb PGT128. 
Results 
Determination of the structures of Fabs R56 and R20.  
                We first determined the crystal structures of Fab R56 in complex with its  
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Figure AI.1 Structure of Fab R56 in complex with V3JR-FL. (A) Ribbon representation 
of a front view of the Fab R56/V3JR-FL complex with the light and heavy chains and the 
V3 epitope colored cyan, green, and magenta, respectively (a coloring scheme kept 
throughout this report, except where indicated otherwise). Disulfide bonds are shown by 
side chain sticks. (B) Side view of the complex. (C) Top view of the complex looking at 
the antigen-binding site of Fab R56. The CDRs are labeled and colored differently from 
the rest of the Fab. (D) Surface representation of Fab R56 colored according to its 
electrostatic surface potentials, with the negatively charged region in red and the 
positively charged region in blue. V3 is shown as a ribbon. The inset is the sequence of 
the peptide used for crystallization, and the magenta residues are those visualized in the 
crystal structure. 
  
205 
Table AI.1 Crystallization data collection and refinement statistics 
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epitope, which was mapped to the crown region of V3 (Fig. AI.1 and Table AI.1). We 
crystallized Fab R56 in complex with two different V3 peptides, NNTRKSIHIG 
PGRAFYTTGE IIG (V3JR-FL), derived from the clade B strain JR-FL, and NNTRKSIRIG 
PGQAFY ATGD IIG (V3conA), derived from the consensus A sequence of gp120. These 
two peptides were selected because JR-FL gp120 was the one used to immunize the 
rabbit and the consensus A sequence has a GPGQ motif in the crown arch, representing 
non- clade B HIV-1 strains. We determined the Fab R56/V3JR-FL and Fab R56/V3conA 
complex structures by molecular replacement and refined them to 2.0 Å and 2.5 Å 
resolutions, respectively (Fig.AI.1; Table AI.1). The crystals of both complexes belong to 
monoclinic space group P21 with essentially the same unit cell parameters. The two 
Fab/V3 complexes in the asymmetry unit are highly similar (for example, the root mean 
square deviation [RMSD] for super- imposition of all of the C-α atoms is 0.16 Å in the 
R56/V3JR-FL complex). We therefore, for simplicity, refer to only one of the complexes. 
We assigned the chain identities (IDs) L, H, and P, respectively, to the light and heavy 
chains and the epitope of the first Fab/V3 complex in the asymmetric unit. We numbered 
the residues of the light and heavy chains by following the Kabat and Wu convention, 
applied to the coordinates with the Abnum server (250), and the residues of V3 in the 
HXB2 numbering scheme (251). A residue is referred to by its number preceded by its 
chain ID, for example, Arg
P315 refers to arginine residue 315 of the V3 epitope. Although 
23-mer peptides were used for crystallization, only 10 residues, from Thr
P303 to Gly
P314 of 
the V3 crown region, with the sequence TRKSIHIGPG for V3JR-FL or TRKSIRIGPG for 
V3conA, were observed in the electron densities and have thus been built into the final 
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structures (Fig. AI.1). Since the R56/V3conA structure has a slightly twinned data set with 
a lower resolution (Table AI.1) and is essentially the same as that of Fab R56/V3JR-FL, 
we have not included it here but the atomic coordinates have been deposited in the PDB. 
                  We then determined the crystal structure of Fab R20 in complex with its 
epitope, which was mapped to the C-terminal region of V3 (Fig. AI.2 and Table AI.1). 
We crystallized the Fab fragment of R20 in complex with a 15-mer V3 peptide of the 
consensus B sequence, TTGEIIGDIRQAHCN (V3conB). The complex structure was de- 
termined by molecular replacement and refined to 2.6 Å resolution (Fig. AI.1 and Table 
AI.1). The crystals belong to the orthorhombic space group P212121 with two Fab/V3 
complexes in the asymmetric unit. Again we refer to only one of the complexes in this 
report, as the structures of the two complexes are highly similar (RMSD of 
superimposition of all C-α 0.55 Å). We have numbered the residues of the Fab R20/V3 
complex in the same way as those of the R56/V3 complex. Although a 15-mer peptide 
was used for crystallization, only nine residues, Glu
P322 to Ala
P329 of the V3 C-terminal 
region, with the sequence EIIGDIRQA, were observed.  
Antigen-binding mode of R56 
The structures of R56/V3 complexes showed that R56 binds the V3 crown by using the 
cradle-binding mode (Fig. AI.1 and Fig.AI.3), similar to that of the human anti-V3 
IGHV5-51 mAbs (172, 249). Its antigen-binding site is shaped like a cradle between the 
light and heavy chains ∼14 Å deep and ∼10 Å wide with CDR L3 at one end of the cradle 
and CDR H3 at the other end (Fig. AI.1C and Fig.AI.5A). Similar to that of the human 
anti-V3 crown mAbs, the antigen-binding site of R56 has a negative charge contributed  
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Figure AI.2 Structure of Fab R20 in complex with V3conB. (A) Ribbon representation 
of a front view the Fab R20/V3conB complex. (B) Side view of the complex. (C) Top 
view of the complex looking at the antigen-binding site of Fab R20 with the CDRs 
labeled and colored differently from the rest of the Fab. (D) Surface representation of Fab 
R20 colored according to its electrostatic surface potentials. The inset is the sequence of 
the peptide used for crystallization, and the magenta residues are those visualized in the 
crystal structure. 
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Figure AI.3 Antigen-antibody interactions in the Fab R56/V3JR-FL complex. (A) Stereo 
view of the antigen-binding site. Side chains are displayed for key residues involved in 
the hydrogen bonding and van der Waals interactions (with contact areas greater than 10 
Å2). For simplicity, the chain IDs are not shown in residue labels because the chains are 
already indicated by the coloring scheme. (B) Schematic illustration of antigen-antibody 
interactions. Hydrogen-binding interactions are indicated by dashed lines between the 
residues, while van der Waals contacts are indicated by eyelashes. Residues in solid ovals 
contribute to the interactions by their main chain atoms, and those in dashed ovals 
contribute by their side chain atoms. 
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in part by three CDR residues from the light chain (Asp
L50
, Asp
L93
, and Asp
L95C
) and 
three CDR residues from the heavy chain (Asp
H34
, Glu
H52
, and Asp
H101
), all located at the 
periphery of the cradle. The bottom of the cradle is very hydrophobic and is formed by 
residues Ala
L34
, Leu
L49
, Leu
L89
, Cys
L94
, Cys
L95D
, and Ala
L96 
from the light chain and 
residues Cys
H50 and Phe
H96 from the heavy chain (Fig.AI.3). The aforementioned two 
noncanonical disulfide bonds (Cys
H35A
-Cys
H50 and Cys
L94
-Cys
L95D
) in the CDRs both 
contribute to this hydrophobic base. Interestingly, the epitope of R56 superimposed well 
on that of mAb 447-52D (RMSD ∼0.75 Å with the superimposed C-α atoms of eight 
residues [P305 to P314]), even though the latter belongs to the ladle V3-binding mode. 
                 Our Fab R56/V3 complex structures showed that the epitope recognized by 
R56 consists of 10 amino acids (P303 to P314) in the N-terminal half of the V3 crown 
(Fig. AI.1 and Fig.AI.3). The N terminus of the epitope harbors two highly conserved 
positively charged band residues (Arg
P304 and Lys
P305
), and the C terminus ends with the 
highly conserved Gly
P312 Pro
P313 Gly
P314 sequence of the crown arch. The epitope lies 
along the cradle with its N terminus sitting on top of the disulfide bond (Cys
L94
-Cys
L95D
) 
of CDR L3 and its C terminus extending toward CDR H3. The antigen-antibody 
interactions buried a total surface area of 750 Å
2 with 356 Å
2 from the antibody and 394 
Å
2 from the epitope. There are three key components of the antigen-antibody interactions 
(Fig.AI.3). The first is a salt bridge between band residue Arg
P304 of the epitope and 
Asp
H34 of CDR H1. Negatively charged Glu
H52 sits on the top of Arg
P304
, leaving the salt 
bridge largely buried. The second is the hydrophobic interactions between highly  
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Figure AI.4. Antigen-antibody interactions in the Fab R20/V3conB complex. (A) Stereo 
view of the antigen-binding site. Side chains are displayed for key residues. (B) 
Schematic illustration of the antigen-antibody interactions. The short beta strand in the 
epitope is indicated by a pink arrow, and the short 310 G turn is indicated by a pink shed. 
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conserved circlet residues Ile
P307 and Ile
P309 of the epitope and the hydrophobic base of 
the antigen-binding site, burying these two isoleucines in the center of the cradle. The 
third is Pro
P313 at the GPG beta turn stacking with the side chain of Tyr
L49 in CDR L2. 
Interestingly, the side chain of circlet residue His
P308 (Arg
P308 in V3conA) in the center of 
the epitope points away from the antibody toward the solvent; thus, it does not contribute 
to the antigen-antibody interaction. Therefore, R56 does not distinguish the sequence 
difference between JR-FL and consensus A (data not shown). There are at least two facts 
explaining the broad reactivity of R56. (i) The interacting residues in the three key 
components are highly conserved among HIV-1 strains, and (ii) the side chain of variable 
residue His
P308
/Arg
P308 is not involved in the antigen-antibody interaction. It is also clear 
from the structures that R56 will not be able to bind gp120 of 92UG021, a clade D strain 
with the sequence VSYRTPIGVG (from 303 to 314) in the epitope region of R56. In 
particular, the region of the antigen-binding site that fits Ser
P306 in JR-FL will not be able 
to accommodate the long side chain of an Arg in the case of 92UG021. Similarly, R56 
will not bind gp120 of the MN strain, which also has an Arg at position P306. In addition, 
R56 does not neutralize commonly used strain IIIB because it has a QR insertion in the 
V3 crown just before the GPG turn, and Gln has a large side chain, which does not fit the 
space that is occupied by Gly
P312 in the JR-FL/conA complex structures. 
Antigen-binding mode of R20 
                 R20 has a long CDR H3 of 21 amino acids, unlike R56, which has a short 
CDR H3 of only 4 amino acids (Kabat definition). CDR H3 of R20 forms a beta hairpin 
standing tall at the center of its antigen-binding site (Fig. AI.2). This conformation is  
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FIG AI.5. Structural comparison of R56 with mouse and human anti-V3 mAbs. (A) 
Superimposition of the Fv region of R56 on that of mouse anti-V3 mAb 50.1. The RMSD 
of the superimposed C-α  is 0.73 Å. (B) Superimposition of the V3JR-FL epitope bound 
to R56 (magenta) with that bound to mouse mAb 50.1 (salmon). The RMSD of the 
superimposed C-α of the eight atoms (P305 to P314) is 0.57 Å. (C) Superimposition of 
V3JR-FL (magenta) bound to R56 with V3NY5 (orange) bound to human mAb 2557. The 
RMSD of the superim- posed 10 C-α atoms (P303 to P314) is 1.7 Å. The antigen-binding 
modes of mAb R56 and human IGHV5-51 mAb 2557 are shown in panels D and E, 
respectively. 
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similar to that of several human and rhesus mAbs, such as quaternary neutralizing epitope 
mAbs 2909 and 2.5B (252). Residues at the top of the other CDR loops form a pedestal-
like structure. This pedestal is roughly 30 Å long and 10 Å wide and is contributed about 
equally by the light chain at one end and the heavy chain at the other end. The antigen-
binding site of R20 runs across the light chain and heavy chain; this is again different 
from that of R56, whose antigen-binding site groove is the chasm between the light and 
heavy chains. 
                Our Fab R20/V3conB complex structure showed that the epitope recognized by 
R20 consists of nine amino acids (P322 to P329, including a numbering insertion for 
IleP322A in the HXB2 scheme) of the C-terminal region of V3 (Fig. AI.2 and Fig. AI.4). 
This epitope is shaped like a fishhook lying on the top of the pedestal of the antigen-
binding site. A short two-residue beta strand (Gly
P324 and Asp
P326
) in the N-terminal half 
of the epitope—the shank of the fishhook—forms a parallel beta sheet with the C-
terminal strand of the CDR H3 hairpin. This beta-sheet-type interaction is similar to the 
ladle antigen-binding mode described for anti-V3 mAbs 447-52D and 537 (248). 
Following the beta strand, a short 310 G helical turn (Ile
P326
, Arg
P327
,and Gln
P328
)—the 
bend of the fish hook—extends toward the light-chain side of the pedestal. Interestingly, 
it was previously predicted by sequence analysis that the C-terminal region of V3 has a 
tendency to form a short alpha helix (253), and it was reported that the V3 C-terminal 
strand could form a helical conformation in an NMR study of a cyclic V3 peptide (254). 
However, this region of the full-length V3 structures in the context of the gp120 core 
does not contain any helical conformation (24, 25). Taken together, these data suggest 
that this region of V3 is very flexible and it can have many different conformations. 
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                  The antigen-antibody interactions buried a total of 804 Å
2 of surface area with 
344 Å
2 from the antibody and 460 Å
2 from the epitope. Tyr
H100G on the C-terminal strand 
of the CDR H3 hairpin bisects the antigen-antibody interactions (Fig. AI.4). The antigen- 
antibody interactions at the N terminus of the epitope have two components centered at 
residues Glu
P322 and Ile
P322A
, respectively (Fig. AI.4). First, negatively charged residue 
Glu
P322 interacts with Arg
H54
, forming a hydrogen bond with its amide group. Second, the 
side chain of hydrophobic residue Ile
P322A is buried by the side chains of Tyr
H52 
and Ile
H56 
on one side and by the backbones of Tyr
H100G and Ser
H100H on the other side. The antigen-
antibody interactions at the C terminus of the epitope have three components centered at 
residues Asp
P325
, Ile
P326
, and Arg
P327
, respectively (Fig. AI.4). First, Asp
P325 near the 
middle of the epitope is buried in the center of the antigen-binding site and its side chain 
can form hydrogen bonds with the side chains of Ser
L92 and Tyr
H100K and the backbone 
amide of Ile
L94
. Second, the side chain of hydrophobic Ile
P326 is buried by the side chain 
of Tyr
L92 on the one side and by the side chains of Val
H100 and Tyr
H100G on the other side. 
Third, positively charged Arg
P327 (shaped like the bait on the fishhook) forms a salt 
bridge with Asp
L1
, the first residue of the light chain. Three negatively charged residues 
in the light chain, Asp
L1
, Glu
L27
, and Asp
L95A
, encircle the side chain of Arg
P327
, holding 
it at the center of this highly negatively charged environment. 
Comparison with the binding modes of mouse and human anti-V3 mAbs.  
               By comparing the antigen-binding mode of R56 with those of all of the 
available complex structures of anti-V3 mAbs, we found that the antigen-binding mode 
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of mouse mAb 50.1 (IgG2a) is the most similar one (Fig. AI.5). Mouse mAb 50.1, 
although also produced by immunization, was induced by using the disulfide-linked 40-
mer cyclic peptide RP70 (INCTRPNYNKRKRIHIGPGRAFYTTKNIIGTIRQAHCNIS), 
which contains the V3 sequence of strain MN of HIV-1 gp120 (243). The complex 
structure of mAb 50.1 was resolved to 2.8 Å resolution by co-crystallizing its Fab with 
another cyclic peptide, MP1 (CKRIHIGPGRAFYTTC) (246). The N-terminal nine 
amino acids of the peptide were observed in the structure, including the first Cys, a non- 
HIV-1 amino acid. Only the N-terminal half of the crown hairpin was observed in the 
50.1 complex structure, as in the case of R56, although a cyclic peptide was used. 
Notably, the sequences of the epitopes of mAbs 50.1 and R56 are derived from the same 
region of the V3 crown, and the structures of the epitopes have the same 3D shape (Fig. 
AI.5B), with an RMSD of 0.57 Å for superimposition of the C-α atoms of P305 to P314. 
The Fv domains of mAbs 50.1 and R56 also superimpose well, with an RMSD of 0.73 Å 
for the C-α atoms. The details of the antigen-antibody interactions of the two mAbs have 
several similarities. First, both mAbs have an antigen-binding site shaped like a cradle 
running along the interface between the light and heavy chains (Fig. AI.5A). Second, 
both antigen-binding sites have a hydrophobic base, burying highly conserved Ile
P307 and 
Ile
P309
. Third, mAb 50.1 also harbors Tyr
L49 in its CDR L2 and stacks Pro
P313 in the same 
manner as that of mAb R56. 
                 Some human anti-V3 mAbs also have a binding mode similar to that of R56. 
The best example is the family of anti-V3 mAbs encoded by IGHV5-51 germ line genes, 
including mAbs 1006, 2219, 2557, 2558, and 4025 (249, 255). The binding mode of this 
human mAb family has a couple of similarities to that of R56 and 50.1. First, all of these 
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mAbs have a cradle-shaped antigen-binding site with a hydrophobic base that binds 
conserved N-terminal circlet residues Ile
P307 and Ile
P309 of the V3 crown. Structure 
superimposition showed that the epitope of R56 and the N termini of the epitopes of 
IGHV5-51 anti-V3 mAbs are very similar; e.g., the structure superimposition of V3JR-
FL bound to R56 with the N terminus of V3NY5 bound to human mAb 2557 has an 
RMSD of 1.7 Å (Fig. AI.5C). Second, Pro
P313 in the GPG turn of the V3 epitopes bound 
by the IGHV5-51 anti-V3 mAbs is stacked by a van der Waals interaction against the 
side chain of a tyrosine (Tyr
L32
) from the CDR L1 region (172), although in the case of 
R56, Pro
P313 
is packed against a tyrosine from the CDR L2 region, Tyr
L49
. How- ever, the 
binding mode of the human IGHV5-51 anti-V3 mAbs also has a couple of differences 
from that of mAbs R56 and 50.1. First, the whole beta hairpin of the V3 crown is visible 
in all of the Fab/epitope complex structures of human IGHV5-51 mAbs, while only the 
N-terminal half of the V3 crown hairpin could be observed in the complex structures of 
R56 and 50.1. The C-terminal half of the V3 crown hairpin was also observed in the 
complex structure of mouse mAb 0.5β determined by an NMR study (256). Interestingly 
mAb 0.5β was raised by immunization of IIIB gp120, which is different from mouse 
mAb 50.1, which was raised by a cyclic peptide. Thus, gp120 itself may be able to elicit 
in mice antibody responses with a more complex epitope. Second, the orientation of the 
antigen-binding cradle of the IGHV5-51 mAbs is perpendicular to that of R56 and 50.1. 
In the human case, the epitope bridges the two chains, with the arch of the V3 crown 
binding the light chain and the band binding the heavy chain (Fig. AI.5D and E). 
                 The recently identified highly potent human mAb PGT128 has an epitope 
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region that overlaps that of R20. PGT128 binds the mannose glycans harbored by two 
glycosylation sites (Asn
P301 and Asn
P332
) at the base of V3 (127). It also engages amino 
acids in the C-terminal region of V3 through its CDR H3 by a beta-sheet-type interaction. 
The key interacting V3 amino acids are residues P323 to P327 (IGDIR), which are at the 
core of the R20 epitope. Nevertheless, the conformation of the PGT128 epitope is rather 
different from that of the R20 epitope, reflecting the flexibility of the V3 stem. 
Interestingly, PGT128 also has a noncanonical disulfide bond between CDRs H1 and H2 
that plays a critical role in antigen binding; removing it will make PGT128 lose its 
gp120-binding activity (127). 
Discussion 
               We present Fab/epitope complex structures of two rabbit mAbs, R56 and R20, 
raised by immunization with gp120 of HIV-1 clade B strain JR-FL with a DNA prime-
protein boost regimen. These structures show that they recognize two V3 regions known 
to be immunogenic in humans—the crown located at the apex and the C-terminal region, 
including residues from both the V3 stem and base regions (257, 258). R56 has a cradle 
antigen-binding mode similar to that of a panel of human anti-V3 antibodies encoded by 
IGHV5-51 germ line genes. Antibodies with this binding mode focus their antigen 
binding on the highly conserved residues at the N terminus of the V3 crown, consistent 
with their broad antigen-binding activities. Our analyses further support the notion that 
the V3 crown has a shape that naturally fits the cradle-binding mode of antibodies. 
Antibodies with this binding mode are preferentially encoded in humans by the IGHV5-
51 germ line genes, making it possible to design a vaccine that elicits antibodies encoded 
by a specific germ line to target the highly immunogenic V3 crown. 
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               R20 recognizes an epitope consisting of amino acids P322 to P329, just 
preceding the disulfide bond at the V3 base (Cys
P296
- Cys
P331
). This region is spatially 
close to the two highly conserved glycosylation sites (Asn
P301 and Asn
P332
) near the V3 
base. The glycans harbored by these two sites have been shown to be part of the epitope 
of hyperpotent human mAb PGT128 and related mAbs (118). Unlike PGT128, which has 
broadly potent neutralization activity, R20 does not neutralize the strains tested. There are 
several potential reasons for this difference. First, the epitope of R20 has a shape very 
different from that of the V3 region bound by PGT128. Superimposition of the two 
epitopes showed that only the last five residues of the R20 epitope adopt a conformation 
similar to that of the PGT128 epitope. Second, the epitope of PGT128 consists mainly of 
glycans harbored by N301 and N332 while our mutagenesis study suggested that R20 
does not need glycan for binding (data not shown). Third, R20 approaches the V3 base 
from an angle tilted about 20° from that of PGT128; this lower approach angle likely 
hinders its ability to bind gp120 in the trimeric conformation. Nevertheless, the 
overlapping of the epitopes of mAbs R20, IIIB-V3-01, and PGT128 suggests that this V3 
C-terminal region is immunogenic and a target of first immune responses (257). 
Structurally designed immunogens that target this V3 C-terminal region may induce 
precursor antibodies with a potential to mature into antibodies that can recognize the 
glycans at the V3 base in a way that mimics that of PGT128. 
                There are clearly differences between the epitopes recognized by the rabbit 
mAbs raised by immunization and those recognized by human mAbs derived from 
chronically infected patients. This can best be understood in the case of R56, as we have 
for comparison many structures of human anti-V3 mAbs with the same antigen-binding 
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mode. Previous structural data showed that the C- terminal residues of the V3 crown are 
visible in the complex structures of the human anti-V3 mAbs because these residues 
engage the antibody by specific interactions sufficient to stabilize the C terminus of the 
V3 crown (172, 249, 259). For rabbit antibody R56, on the contrary, only the N-terminal 
half of the V3 crown can be observed in the complex structures. Since the V3 crown 
tends to have a beta hairpin structure, its C-terminal half must be spatially close to the N-
terminal half. However, R56 did not develop contacts with the C terminus of the V3 
crown or the contacts were not sufficiently strong to stabilize the C-terminal half to be 
observable in the crystal structure. This is also the case for mouse mAb 50.1, which was 
raised by immunization as well. Thus, we hypothesize that, because of the limited time 
intervals and insufficient antigen stimulation in immunization, the immunization-derived 
antibodies do not have the necessary affinity maturation to develop strong contacts with 
the C terminus of the V3 crown. 
             Our structural analyses of R56 and R20 show from several aspects the suitability 
of using the rabbit as an animal model for AIDS vaccine development. First, the rabbit 
immune system is able to respond to gp120 immunogens and recognizes immunogenic 
regions similar to those recognized by the human immune system, such as the crown and 
C-terminal regions of V3. Second, antibodies elicited by gp120 immunogens in rabbits 
can mimic the binding modes of human antibodies. This is most clear in the case of 
antibodies that target the V3 crown. Third, rabbits can produce antibodies with CDR H3s 
with a wide length range, including antibodies with very long CDR H3s, a hallmark 
increasingly found in potent human mAbs. Fourth, the long CDR H3s of rabbit antibodies 
can engage antigen through a beta-sheet-type interaction, a feature often observed in 
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human mAbs with long CDR H3s. Taken together, our data show that the rabbit is a 
useful animal model in which to test immunogens and immunization regimens in AIDS 
vaccine development. 
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